Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • C—CHEMISTRY; METALLURGY
  • C40—COMBINATORIAL TECHNOLOGY
  • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
  • C40B80/00—Linkers or spacers specially adapted for combinatorial chemistry or libraries, e.g. traceless linkers or safety-catch linkers
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00277—Apparatus
  • B01J2219/00497—Features relating to the solid phase supports
  • B01J2219/00513—Essentially linear supports
  • B01J2219/00524—Essentially linear supports in the shape of fiber bundles
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00277—Apparatus
  • B01J2219/00497—Features relating to the solid phase supports
  • B01J2219/00527—Sheets
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00277—Apparatus
  • B01J2219/0054—Means for coding or tagging the apparatus or the reagents
  • B01J2219/00572—Chemical means
  • B01J2219/00576—Chemical means fluorophore
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00583—Features relative to the processes being carried out
  • B01J2219/00603—Making arrays on substantially continuous surfaces
  • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00583—Features relative to the processes being carried out
  • B01J2219/00603—Making arrays on substantially continuous surfaces
  • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
  • B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00583—Features relative to the processes being carried out
  • B01J2219/00603—Making arrays on substantially continuous surfaces
  • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
  • B01J2219/00623—Immobilisation or binding
  • B01J2219/00626—Covalent
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00583—Features relative to the processes being carried out
  • B01J2219/00603—Making arrays on substantially continuous surfaces
  • B01J2219/00659—Two-dimensional arrays
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/0068—Means for controlling the apparatus of the process
  • B01J2219/00702—Processes involving means for analysing and characterising the products
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00718—Type of compounds synthesised
  • B01J2219/0072—Organic compounds
  • B01J2219/00722—Nucleotides
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00718—Type of compounds synthesised
  • B01J2219/0072—Organic compounds
  • B01J2219/00725—Peptides
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00718—Type of compounds synthesised
  • B01J2219/0072—Organic compounds
  • B01J2219/00731—Saccharides
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
  • B01J2219/00718—Type of compounds synthesised
  • B01J2219/0072—Organic compounds
  • B01J2219/00738—Organic catalysts

Definitions

• the present invention relates to artificial receptors, arrays or microarrays of artificial receptors or candidate artificial receptors, and methods of making them.
• Each member of the array includes a plurality of building block compounds, typically immobilized in a spot on a support.
• the present invention also includes the building blocks, combinations of building blocks, arrays of building blocks, and receptors constructed of these building blocks together with a support.
• the present invention also includes methods of using these arrays and receptors.
• the present invention relates to building blocks for making or forming candidate artificial receptors.
• a building block can provide one or more structural characteristics such as positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, ⁇ electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• a building block can be bulky or it can be small.
• the building block can include one or more carboxyl, amine, hydroxyl, phenol, carbonyl, and thiol groups, which can be a recognition moiety.
• the building block can include one or more moieties with positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, ⁇ electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• Figure 1 schematically illustrates two dimensional representations of an embodiment of a receptor according to the present invention that employs 4 different building blocks to make a ligand binding site.
• Figure 2 schematically illustrates two and three dimensional representations of an embodiment of a molecular configuration of 4 building blocks, each building block including a recognition element, a framework, and a linker coupled to a support (immobilization/anchor).
• Figure 3 schematically illustrates an embodiment of the present methods and artificial receptors employing shuffling and exchanging building blocks.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand, such as a molecule or cell.
• Figure 5 schematically illustrates an embodiment of the present method employing an array of candidate artificial receptors.
• Figure 6 schematically illustrates certain binding patterns on an array of working artificial receptors.
• Figure 7 schematically illustrates an embodiment of a method for developing a method and system for detecting a test ligand.
• Figure 8 schematically illustrates an embodiment of a method for detecting an agent that disrupts a binding interaction of a target molecule.
• Figure 9 schematically illustrates an embodiment of a method for detecting an agent that disrupts a binding interaction of a complex including a target molecule.
• Figure 10 schematically illustrates a candidate disruptor disrupting a proteimprotein complex.
• Figure 11 schematically illustrates an embodiment of a method of employing the present artificial receptors to produce or as an affinity support.
• Figures 12A-B schematically illustrates evaluating an array of candidate artificial receptors for binding of a test ligand and selecting one or more working artificial receptors for binding or operating on a test ligand.
• Figure 13 schematically illustrates identification of a lead artificial receptor from among candidate artificial receptors.
• Figure 14 schematically illustrates a false color fluorescence image of a labeled microarray according to an embodiment of the present invention.
• Figure 15 schematically illustrates a two dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding phycoerythrin.
• Figure 16 schematically illustrates a three dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding phycoerythrin.
• Figure 17 schematically illustrates a two dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding a fluorescent derivative of ovalbumin.
• Figure 18 schematically illustrates a three dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding a fluorescent derivative of ovalbumin.
• Figure 19 schematically illustrates a two dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding a fluorescent derivative of bovine serum albumin.
• Figure 20 schematically illustrates a three dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding a fluorescent derivative of bovine serum albumin.
• Figure 21 schematically illustrates a two dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding an acetylated horseradish peroxidase.
• Figure 22 schematically illustrates a three dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding an acetylated horseradish peroxidase.
• Figure 23 schematically illustrates a two dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding a TCDD derivative of horseradish peroxidase.
• Figures 24 schematically illustrates a three dimensional plot of data obtained for candidate artificial receptors contacted with and/or binding a TCDD derivative of horseradish peroxidase.
• Figure 25 schematically illustrates a subset of the data illustrated in Figure
• Figure 26 schematically illustrates a subset of the data illustrated in Figure
• Figure 27 schematically illustrates a subset of the data illustrated in Figure 16.
• Figure 28 schematically illustrates a correlation of binding data for phycoerythrin against logP for the building blocks making up the artificial receptor.
• Figure 29 schematically illustrates a correlation of binding data for phycoerythrin against logP for the building blocks making up the artificial receptor.
• Figure 30 schematically illustrates a two dimensional plot comparing data obtained for candidate artificial receptors contacted with and/or binding phycoerythrin to data obtained for candidate artificial receptors contacted with and/or binding a fluorescent derivative of bovine serum albumin.
• Figures 31, 32, and 33 schematically illustrate subsets of data from Figures 16, 20, and 18, respectively, and demonstrate that the array of artificial receptors according to the present invention yields receptors distinguished between three analytes, phycoerythrin, bovine serum albumin, and ovalbumin.
• Figure 34 schematically illustrates a gray scale image of the fluorescence signal from a scan of a control plate which was prepared by washing off the building blocks with organic solvent before incubation with the test ligand.
• Figure 35 schematically illustrates a gray scale image of the fluorescence signal from a scan of an experimental plate which was incubated with 1.0 ⁇ g/ml Cholera Toxin B at 23 °C.
• Figure 36 schematically illustrates a gray scale image of the fluorescence signal from a scan of an experimental plate which was incubated with 1.0 ⁇ g/ml Cholera Toxin B at 3 °C.
• Figure 37 schematically illustrates a gray scale image of the fluorescence signal from a scan of an experimental plate which was incubated with 1.0 ⁇ g/ml Cholera Toxin B at 43 °C.
• Figures 38-40 schematically illustrate plots of the fluorescence signals obtained from the candidate artificial receptors illustrated in Figures 35-37.
• Figure 41 schematically illustrate plots of the fluorescence signals obtained from the combinations of building blocks employed in the present studies, when those building blocks are covalently linked to the support. Binding was conducted at 23 °C.
• Figure 42 schematically illustrates the changes in fluorescence signal from individual combinations of covalently immobilized building blocks at 4 °C, 23 °C, or 44 °C.
• Figure 43 schematically illustrates a graph of the changes in fluorescence signal from individual combinations of building blocks at 4 °C, 23 °C, or 44 °C.
• Figure 44 schematically illustrates the data presented in Figure 42 (lines marked A) and the data presented in Figure 43 (lines marked B).
• Figure 45 schematically illustrates a graph of the fluorescence signal at 44 °C divided by the signal at 23 °C against the fluorescence signal obtained from binding at 23 °C for the artificial receptors with reversibly immobilized receptors.
• Figure 46 illustrates fluorescence signals produced by binding of cholera toxin to a microarray of the present candidate artificial receptors followed by washing with buffer in an experiment reported in Example 4.
• Figure 47 illustrates the fluorescence signals due to cholera toxin binding that were detected upon competition with GMl OS (0.34 ⁇ M) in an experiment reported in Example 4.
• Figure 48 illustrates the ratio of the amount bound in the absence of GMl OS to the amount bound in competition with GMl OS(0.34 ⁇ M) in an experiment reported in Example 4.
• Figure 49 illustrates fluorescence signals produced by binding of cholera toxin to a microarray of the present candidate artificial receptors followed by washing with buffer in an experiment reported in Example 4 and for comparison with competition experiments using 5.1 ⁇ M GMl OS.
• Figure 50 illustrates the fluorescence signals due to cholera toxin binding that were detected upon competition with GMl OS (5.1 ⁇ M) in an experiment reported in Example 4.
• Figure 51 illustrates the ratio of the amount bound in the absence of GMl OS to the amount bound in competition with GMl OS(5.1 ⁇ M) in an experiment reported in Example 4.
• Figure 52 illustrates the fluorescence signals produced by binding of cholera toxin to the microarray of candidate artificial receptors alone and in competition with each of the three concentrations of GMl in the experiment reported in Example 5.
• Figure 53 illustrates the ratio of the amount bound in the absence of GMl OS to the amount bound upon competition with GMl for the low concentration of GMl employed in Example 5.
• Figure 54 illustrates the fluorescence signals produced by binding of cholera toxin to the microarray of candidate artificial receptors without pretreatment with GMl in the experiment reported in Example 6.
• Figures 55-57 illustrate the fluorescence signals produced by binding of cholera toxin to the microarray of candidate artificial receptors with pretreatment with GMl (100 ⁇ g/ml, 10 ⁇ g/ml, and 1 ⁇ g/ml GMl, respectively) in the experiment reported in Example 6.
• Figure 58 illustrates the ratio of the amount bound in the presence of 1 ⁇ g/ml GMl to the amount bound in the absence of GMl in the experiment reported in Example 6.
• proteome refers to the expression profile of the proteins of an organism, tissue, organ, or cell. The proteome can be specific to a particular status (e.g., development, health, etc.) of the organism, tissue, organ, or cell.
• Reversibly immobilizing building blocks on a support couples the building blocks to the support through a mechanism that allows the building blocks to be uncoupled from the support without destroying or unacceptably degrading the building block or the support. That is, immobilization can be reversed without destroying or unacceptably degrading the building block or the support. In an embodiment, immobilization can be reversed with only negligible or ineffective levels of degradation of the building block or the support.
• Reversible immobilization can employ readily reversible covalent bonding or noncovalent interactions. Suitable noncovalent interactions include interactions between ions, hydrogen bonding, van der Waals interactions, and the like.
• Readily reversible covalent bonding refers to covalent bonds that can be formed and broken under conditions that do not destroy or unacceptably degrade the building block or the support.
• a combination of building blocks immobilized on, for example, a support can be a candidate artificial receptor, a lead artificial receptor, or a working artificial receptor. That is, a heterogeneous building block spot on a slide or a plurality of building blocks coated on a tube or well can be a candidate artificial receptor, a lead artificial receptor, or a working artificial receptor.
• a candidate artificial receptor can become a lead artificial receptor, which can become a working artificial receptor.
• the phrase "candidate artificial receptor” refers to an immobilized combination of building blocks that can be tested to determine whether or not a particular test ligand binds to that combination.
• the combination includes one or more reversibly immobilized building blocks.
• the candidate artificial receptor can be a heterogeneous building block spot on a slide or a plurality of building blocks coated on a tube or well.
• the phrase "lead artificial receptor” refers to an immobilized combination of building blocks that binds a test ligand at a predetermined concentration of test ligand, for example at 10, 1, 0.1, or 0.01 ⁇ g/ml, or at 1, 0.1, or 0.01 ng/ml.
• the combination includes one or more reversibly immobilized building blocks.
• the lead artificial receptor can be a heterogeneous building block spot on a slide or a plurality of building blocks coated on a tube or well.
• working artificial receptor refers to a combination of building blocks that binds a test ligand with a selectivity and/or sensitivity effective for categorizing or identifying the test ligand. That is, binding to that combination of building blocks describes the test ligand as belonging to a category of test ligands or as being a particular test ligand.
• a working artificial receptor can, for example, bind the ligand at a concentration of, for example, 100, 10, 1, 0.1, 0.01, or 0.001 ng/ml.
• the combination includes one or more reversibly immobilized building blocks.
• the working artificial receptor can be a heterogeneous building block spot on a slide or a plurality of building blocks coated on a tube, well, slide, or other support or on a scaffold.
• the phrase "working artificial receptor complex" refers to a plurality of artificial receptors, each a combination of building blocks, that binds a test ligand with a pattern of selectivity and/or sensitivity effective for categorizing or identifying the test ligand.
• binding to the several receptors of the complex describes the test ligand as belonging to a category of test ligands or as being a particular test ligand.
• the individual receptors in the complex can each bind the ligand at different concentrations or with different affinities.
• the individual receptors in the complex each bind the ligand at concentrations of 100, 10, 1, 0.1, 0.01 or 0.001 ng/ml.
• the combination includes one or more reversibly immobilized building blocks.
• the working artificial receptor complex can be a plurality of heterogeneous building block spots or regions on a slide; a plurality of wells, each coated with a different combination of building blocks; or a plurality of tubes, each coated with a different combination of building blocks.
• the phrase "significant number of candidate artificial receptors" refers to sufficient candidate artificial receptors to provide an opportunity to find a working artificial receptor, working artificial receptor complex, or lead artificial receptor. As few as about 100 to about 200 candidate artificial receptors can be a significant number for finding working artificial receptor complexes suitable for distinguishing two proteins (e.g., cholera toxin and phycoerythrin).
• a significant number of candidate artificial receptors can include about 1,000 candidate artificial receptors, about 10,000 candidate artificial receptors, about 100,000 candidate artificial receptors, or more. Although not limiting to the present invention, it is believed that the significant number of candidate artificial receptors required to provide an opportunity to find a working artificial receptor may be larger than the significant number required to find a working artificial receptor complex. Although not limiting to the present invention, it is believed that the significant number of candidate artificial receptors required to provide an opportunity to find a lead artificial receptor may be larger than the significant number required to find a working artificial receptor.
• the term "building block" refers to a molecular component of an artificial receptor including portions that can be envisioned as or that include one or more linkers, one or more frameworks, and one or more recognition elements.
• the building block includes a linker, a framework, and one or more recognition elements.
• the linker includes a moiety suitable for reversibly immobilizing the building block, for example, on a support, surface or lawn. The building block interacts with the ligand.
• linker refers to a portion of or functional group on a building block that can be employed to or that does (e.g., reversibly) couple the building block to a support, for example, through covalent link, ionic interaction, electrostatic interaction, or hydrophobic interaction.
• frame refers to a portion of a building block including the linker or to which the linker is coupled and to which one or more recognition elements are coupled.
• recognition element refers to a portion of a building block coupled to the framework but not covalently coupled to the support.
• the recognition element can provide or form one or more groups, surfaces, or spaces for interacting with the ligand.
• the phrase "plurality of building blocks” refers to two or more building blocks of different structure in a mixture, in a kit, or on a support or scaffold. Each building block has a particular structure, and use of building blocks in the plural, or of a plurality of building blocks, refers to more than one of these particular structures. Building blocks or plurality of building blocks does not refer to a plurality of molecules each having the same structure.
• the phrase “combination of building blocks” refers to a plurality of building blocks that together are in a spot, region, or a candidate, lead, or working artificial receptor.
• a combination of building blocks can be a subset of a set of building blocks.
• the phrases "homogenous immobilized building block” and “homogenous immobilized building blocks” refer to a support or spot having immobilized on or within it only a single building block.
• activated building block refers to a building block activated to make it ready to form a covalent bond to a functional group, for example, on a support.
• a building block including a carboxyl group can be converted to a building block including an activated ester group, which is an activated building block.
• An activated building block including an activated ester group can react, for example, with an amine to form a covalent bond.
• the term "na ⁇ ve" used with respect to one or more building blocks refers to a building block that has not previously been determined or known to bind to a test ligand of interest.
• the recognition element(s) on a na ⁇ ve building block has not previously been determined or known to bind to a test ligand of interest.
• a building block that is or includes a known ligand (e.g., GMl) for a particular protein (test ligand) of interest (e.g., cholera toxin) is not na ⁇ ve with respect to that protein (test ligand).
• a known ligand e.g., GMl
• test ligand e.g., cholera toxin
• immobilized used with respect to building blocks coupled to a support refers to building blocks being stably oriented on the support so that they do not migrate on the support or release from the support.
• Building blocks can be immobilized by covalent coupling, by ionic interactions, by electrostatic interactions, such as ion pairing, or by hydrophobic interactions, such as van der Waals interactions.
• a "region" of a support, tube, well, or surface refers to a contiguous portion of the support, tube, well, or surface. Building blocks coupled to a region can refer to building blocks in proximity to one another in that region.
• a "bulky” group on a molecule is larger than a moiety including 7 or 8 carbon atoms.
• a "small” group on a molecule is hydrogen, methyl, or another group smaller than a moiety including 4 carbon atoms.
• the term "lawn" refers to a layer, spot, or region of functional groups on a support, for example, at a density sufficient to place coupled building blocks in proximity to one another.
• the functional groups can include groups capable of forming covalent, ionic, electrostatic, or hydrophobic interactions with building blocks.
• alkyl refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
• a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C 12 for straight chain, C ⁇ -C 6 for branched chain).
• cycloalkyls can have from 3-10 carbon atoms in their ring structure, for example, 5, 6 or 7 carbons in the ring structure.
• alkyl refers to both "unsubstituted alkyls" and
• substituted alkyls refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
• substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an ester, a formyl, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfon
• the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
• the substituents of a substituted alkyl can include substituted and unsubstituted forms of the groups listed above.
• aryl alkyl refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
• alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and optional substitution to the alkyls groups described above, but that contain at least one double or triple bond respectively.
• aryl as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
• Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or "heteroaromatics”.
• the aromatic ring can be substituted at one or more ring positions with such substituents such as those described above for alkyl groups.
• aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic ring(s) can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
• heterocycle or “heterocyclic group” refer to 3- to 12-membered ring structures, e.g., 3- to 7-membered rings, whose ring structures include one to four heteroatoms.
• Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, o
• heterocyclic ring can be substituted at one or more positions with such substituents such as those described for alkyl groups.
• heteroatom as used herein means an atom of any element other than carbon or hydrogen, such as nitrogen, oxygen, sulfur and phosphorous.
• FIG. 1 schematically illustrates an embodiment employing 4 distinct building blocks in a spot on a microarray to make a ligand binding site.
• This Figure illustrates a group of 4 building blocks at the corners of a square forming a unit cell.
• a group of four building blocks can be envisioned as the vertices on any quadrilateral.
• Figure 1 illustrates that spots or regions of building blocks can be envisioned as multiple unit cells, in this illustration square unit cells. Groups of unit cells of four building blocks in the shape of other quadrilaterals can also be formed on a support.
• Each immobilized building block molecule can provide one or more "arms" extending from a "framework” and each can include groups that interact with a ligand or with portions of another immobilized building block.
• Figure 2 illustrates that combinations of four building blocks, each including a framework with two arms (called “recognition elements"), provides a molecular configuration of building blocks that form a site for binding a ligand.
• Such a site formed by building blocks such as those exemplified below can bind a small molecule, such as a drug, metabolite, pollutant, or the like, and/or can bind a larger ligand such as a macromolecule or microbe.
• the present artificial receptors can include building blocks reversibly immobilized on a support or surface.
• Reversing immobilization of the building blocks can allow movement of building blocks to a different location on the support or surface, or exchange of building blocks onto and off of the surface.
• the combinations of building blocks can bind a ligand when reversibly coupled to or immobilized on the support. Reversing the coupling or immobilization of the building blocks provides opportunity for rearranging the building blocks, which can improve binding of the ligand.
• the present invention can allow for adding additional or different building blocks, which can further improve binding of a ligand.
• Figure 3 schematically illustrates an embodiment employing an initial artificial receptor surface (A) with four different building blocks on the surface, which are represented by shaded shapes.
• This initial artificial receptor surface (A) undergoes (1) binding of a ligand to an artificial receptor and (2) shuffling the building blocks on the receptor surface to yield a lead artificial receptor (B).
• Shuffling refers to reversing the coupling or immobilization of the building blocks and allowing their rearrangement on the receptor surface.
• additional building blocks can be (3) exchanged onto and/or off of the receptor surface (C). Exchanging refers to building blocks leaving the surface and entering a solution contacting the surface and/or building blocks leaving a solution contacting the surface and becoming part of the artificial receptor.
• the additional building blocks can be selected for structural diversity (e.g., randomly) or selected based on the structure of the building blocks in the lead artificial receptor to provide additional avenues for improving binding.
• the original and additional building blocks can then be (4) shuffled and exchanged to provide higher affinity artificial receptors on the surface (D).
• a description of general and specific features and functions of a variety of such artificial receptors can be found in copending U.S. Patent Application Serial No. 10/244,727, filed September 16, 2002, and Application No. PCT/US03/05328, filed February 19, 2003, each entitled "ARTIFICIAL RECEPTORS, BUILDING BLOCKS, AND METHODS", U.S. Provisional Patent Application Serial No. 60/500,081, also entitled “ARTIFICIAL RECEPTORS, BUILDING BLOCKS, AND METHODS", filed September 3, 2003, and U.S. Provisional Patent Application Serial No. 60/499,975, entitled 'ARTIFICIAL RECEPTORS INCLUDING REVERSIBLY IMMOBILIZED BUILDING BLOCKS AND METHODS" also filed September 3, 2003.
• Building Blocks The present invention relates to building blocks for making or forming candidate artificial receptors.
• Building blocks can be designed, made, and selected to provide a variety of structural characteristics among a small number of compounds.
• the present building blocks also include a functional group or structural feature or moiety that allows them to be immobilized (e.g., reversibly) on a support, which can occur by way of a lawn.
• a building block can provide one or more structural characteristics such as positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, 7T electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• a building block can be bulky or it can be small.
• a building block can be visualized as including several components, such as one or more frameworks, one or more linkers, and/or one or more recognition elements.
• the framework can be covalently coupled to each of the other building block components.
• the recognition element can be covalently coupled to the framework.
• the linker can be covalently coupled to the framework and coupled (e.g., reversibly) to a support or to a lawn molecule.
• a building block includes a framework, a linker, and a recognition element.
• a building block includes a framework, a linker, and two recognition elements.
• the building block can include one or more functional groups, structural features, or moieties that form the recognition moiety.
• the building block can include one or more carboxyl, amine, hydroxyl, phenol, carbonyl, and thiol groups, which can be a recognition moiety.
• the building block can include one or more moieties with positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, ⁇ electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• the building block can include two, three, or four such functional groups, structural features, or moieties.
• the building block can include one or more functional groups, structural features, or moieties that form all or part of the linking moiety.
• the building block can include one or more carboxyl, amine, hydroxyl, phenol, carbonyl, and thiol groups, which can be a linking moiety.
• the building block can include one or more moieties with positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, ⁇ electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• the linking moiety is configured for coupling (e.g., reversibly) to the support.
• a building block can be or can include any of a variety of compounds or substructures.
• a building block can be or include an amino acid (natural or synthetic), a dipeptide, a monosaccharide, a disaccharide, another carbohydrate, a mixture or combination thereof, or the like; a catalytic moiety such as a coenzyme, a metal, a metal complex, or the like; a polymer of up to 2000 carbon atoms (e.g., up to 48 carbon atoms), e.g., a polyether, polyethyleneimine, a polyacrylamide, or like polymer; an ⁇ -hydroxy acid, a thioic acid; an enzyme inhibitor (e.g., a protease inhibitor (such as pepstatin), a statin, or the like), a receptor antagonist (e.g., a benzodiazepine), a receptor agonist, a pharmaceutical, a peptide hormone; a natural product, a starting material, intermediate, or end product of a metabolic pathway (e.g., glycolysis, the citric acid
• a building block can be a naturally occurring or synthetic compound; can be racemic, optically active, or achiral; can include positional isomers of any specifically described structure; or can include conformationally restricted functional groups.
• the building block is or includes a monosaccharide. Any of a variety of naturally occurring or synthetic monosaccharides can be employed as a building block.
• Suitable monosaccharides include pyranoses and furanoses, such as glucose, fructose, ribulose, allose, altrose, mannose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, or the like; erythrose, threose, or the like; inositol, or the like; amino sugars, such as rhammose, fucose, glucosamine, galactosamine, or the like; aldonic and uronic acids, such as gluconic acid, glucuronic acid, glucaric acid, or the like; glycosides including these monosaccharides; disaccharides or oligosaccharides including these monosaccharides, such as sucrose, raffinose, gentianose, cellobiose, maltose, lactose, trehalose, gentio
• the building block is or includes a disaccharide. Any of a variety of naturally occurring or synthetic disaccharides can be employed as a building block. Suitable disaccharides include disaccharides or oligosaccharides including the monosaccharides listed above. Such disaccharides include sucrose, raffinose, gentianose, cellobiose, maltose, lactose, trehalose, gentiobiose, meliobiose, or the like; a mixture or combination thereof, or the like. In an embodiment, the building block is or includes a carbohydrate. Any of a variety of naturally occurring or synthetic carbohydrates can be employed as a building block.
• Suitable carbohydrates include cellulose, chitin, starch, glycogen, hyaluronic acid, chondroitin sulfates, keratosulfate, heparin, glycoproteins, or the like; a mixture or combination thereof, or the like.
• the building block is or includes a catalytic moiety. Any of a variety of naturally occurring or synthetic catalytic moieties can be employed as or can be a moiety on a building block. Suitable catalytic moieties include coenzymes, metals, metal complexes, pronucleophiles, proelectrophiles, proreducing agents, prooxidizing agents, general acid catalysts, general base catalysts, a mixture or combination thereof, or the like.
• the building block is or includes a metal binding or complexing moiety.
• a metal binding or complexing moiety Any of a variety of naturally occurring or synthetic metal binding or complexing moieties can be employed as or can be a moiety on a building block.
• Suitable metal binding or complexing moieties include synthetic and naturally occurring po ⁇ hyrin (e.g., etiopo ⁇ hyrin, mesopo ⁇ hyrin, protopo ⁇ hyrin (e.g., heme or hematin), copropo ⁇ hyrin, tetraphenylpo ⁇ hyrin, octaethylpo ⁇ hyrin, or the like), a cobamide coenzyme (e.g., coenzyme B 12 , a cobalamin such as methyl- cobalamin, or the like), selenocysteine, selenomethionine, ferritin; naturally occurring or synthetic complexes of magnesium
• the building block is or includes a coenzyme (which can also be called a prosthetic group or cofactor).
• a coenzyme which can also be called a prosthetic group or cofactor.
• Any of a variety of naturally occurring or synthetic coenzymes can be employed as or can be a moiety on a building block.
• Suitable coenzymes include a nicotinamide coenzyme (e.g., NAD, NADH, NADP, NADPH, and the like), a flavin compound (e.g., FAD, FADH 2 , FMN, FMNH 2 ), a lipoic acid (e.g., oxidized or reduced lipoic acid), a glutathione (e.g., oxidized or reduced glutathione), an ascorbic acid, a quinone (e.g., ubiquinone, vitamins K, or the like), a po ⁇ hyrin (e.g., etiopo ⁇ hyrin,
• the building block is or includes a polymer of up to 2000 carbon atoms (e.g., up to 48 carbon atoms). Such a polymer can be naturally occurring or synthetic. Suitable polymers include a polyether or like polymer, such as a PEG, a polyethyleneimine, polyacrylate (e.g., substituted polyacrylates), salt thereof, a mixture or combination thereof, or the like. Suitable PEGs include PEG 1500 up to PEG 20,000, for example, PEG 1450, PEG 3350, PEG 4500, PEG 8000, PEG 20,000, and the like. In an embodiment, the present building block can be or include a lipophilic moiety.
• Suitable lipophilic moieties include one or more branched or straight chain C 6-36 alkyl, C 8 . 2 alkyl, C 12-24 alkyl, C 12-18 alkyl, or the like; C 6-36 alkenyl, C 8-24 alkenyl, C 12- 4 alkenyl, C 12-18 alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8-24 alkynyl, C 12 _ 24 alkynyl, C 12-18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or substituted aryl moieties (e.g., phenyl or naphthyl moieties at the end or middle of a chain); polyaromatic hydrocarbon moieties; cycloalkane or substituted alkane moieties with numbers of carbons as described for chains; combinations or mixtures thereof; or the like.
• the alkyl, alkenyl, or alkynyl group can include branching; within chain functionality like an ether group; terminal functionality like alcohol, amide, carboxylate or the like; or the like.
• Suitable building blocks include carboxylic acids (e.g., mono and di- carboxylates) with the carboxylate appended to a lipophilic moiety, such as one or more branched or straight chain C 6-36 alkyl, C 8-24 alkyl, C 12-24 alkyl, C 1 - ⁇ 8 alkyl, or the like; C 6-36 alkenyl, C 8-24 alkenyl, C 12-24 alkenyl, C 12-18 alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8- 4 alkynyl, C 12- 4 alkynyl, C 1 -18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or
• Such carboxylic acids include arachidonic acid, linoleic acid, linolenic acid, oleic acid, and the like. Such carboxylic acids can be immobilized on a support through covalent bonding or electrostatic interaction between Suitable building blocks include carboxylic acids (e.g., mono and di- carboxylates) with the carboxylate appended to a an organic radical, such as one or more branched or straight chain C 2-8 alkyl, arylalkyl, alkenyl, alkynyl, or the like. These carboxylic acids can include substituted aryl moieties (e.g., phenyl or naphthyl moieties).
• aryl moieties e.g., phenyl or naphthyl moieties
• Such carboxylic acids include acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, benzoic acid, and the like.
• Such carboxylic acids can be immobilized on a support through covalent bonding or electrostatic interaction between the carboxyl(ate) and the support or lawn.
• the building block is or includes an amino acid. Suitable amino acids include a natural or synthetic amino acid. Amino acids include carboxyl and amine functional groups.
• amino acids can also include a moiety with one or more of positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, it electrons, charge polarization, hydrophilicity, or hydrophobicity.
• Suitable amino acids include those with a functional group on the side chain.
• the side chain functional group can include, for natural amino acids, an amine (e.g., alkyl amine, heteroaryl amine), hydroxyl, phenol, carboxyl, thiol, thioether, or amidino group. Any of the natural amino acids can be employed as a building block.
• the natural amino acids include aliphatic amino acids (e.g., alanine, valine, leucine, and isoleucine), hydroxyamino acids (e.g., serine, threonine, and tyrosine), dicarboxylic acids (e.g., glutamic acid and aspartic acid), amides (e.g., glutamine and asparagine), amino acids with basic sidechains (e.g., lysine, hydroxylysine, histidine, and arginine), aromatic amino acids (e.g., histidine, phenylalanine, tyrosine, tryptophan, and thyroxine), sulfur containing amino acids (e.g., cysteine, cystine, and methionine), imino acids (e.g., proline and hydroxyproline).
• aliphatic amino acids e.g., alanine, valine, leucine, and isoleucine
• Natural amino acids suitable for use as building blocks include, for example, serine, threonine, tyrosine, aspartic acid, glutamic acid, asparagine, glutamine, cysteine, lysine, arginine, histidine.
• Synthetic amino acids can include the naturally occurring side chain functional groups or synthetic side chain functional groups which modify or extend the natural amino acids with alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, and like moieties and with carboxyl, amine, hydroxyl, phenol, carbonyl, or thiol functional groups.
• Suitable synthetic amino acids include N-substituted glycine and oligomers of N-substituted glycines. Suitable synthetic amino acids include jS-amino acids and homo or ⁇ analogs of natural amino acids.
• the building block is or includes a dipeptide. Any of the 400 dipeptides including the 20 natural amino acids in any order can be employed as building blocks. Suitable dipeptides include muramyl dipeptide or the like. In an embodiment the building block can be or include a therapeutic or pharmacologically active agent.
• Suitable therapeutic or pharmacologically active agents include a nitrate, nitric oxide, a nitric oxide promoter, nitric oxide donors, dipyridamole, or another vasodilator; HYTRIN® or another antihypertensive agent; a glycoprotein Ilb/IIIa inhibitor (abciximab) or another inhibitor of surface glycoprotein receptors; aspirin, ticlopidine, clopidogrel or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor; a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; methotrexate or another antimetabolite or antiproliferative agent; tamoxifen citrate, TAXOL®, paclitaxel, or derivatives thereof, rapamycin, vinblastine, vincristine, vinorelbine, etoposide, tenopiside, dactinomycin (actinomycin
• the building block can be or can include an antibiotic.
• antibiotics include penicillin, tetracycline, chloramphenicol, minocycline, doxycycline, vancomycin, bacitracin, kanamycin, neomycin, gentamycin, erythromycin and cephalosporins.
• cephalosporins examples include cephalothin, cephapirin, cefazolin, cephalexin, cephradine, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefonicid, ceforanide, cefotaxime, moxalactam, ceftizoxime, ceftriaxone, and cefoperazone.
• the building block can be or can include an enzyme inhibitor.
• Suitable enzyme inhibitors include edrophonium chloride, N- methylphysostigmine, neostigmine bromide, physostigmine sulfate, tacrine HCL, tacrine, 1-hydroxy maleate, iodotubercidin, p-bromotetramisole, 10-( ⁇ - diethylaminopropionyl)-phenothiazine hydrochloride, calmidazolium chloride, hemicholinium-3,3,5-dinitrocatecho-l, diacylglycerol kinase inhibitor I, diacylglycerol kinase inhibitor II, 3-phenylpropargylaminie, N-monomethyl-L- arginine acetate, carbidopa, 3-hydroxybenzylhydrazine HCI, hydralazine HCI, clorgyline HCI, deprenyl HCI L(-), deprenyl HCI D(+),
• the building block is or includes a signal element that produces a detectable signal when a test ligand is bound to the receptor.
• the signal element can produce an optical signal or a electrochemical signal. Suitable optical signals include chemiluminescence or fluorescence.
• the signal element can be a fluorescent moiety.
• the fluorescent molecule can be one that is quenched by binding to the artificial receptor.
• the signal element can be a molecule that fluoresces only when binding occurs.
• Suitable electrochemical signal elements include those that give rise to current or a potential.
• Suitable electrochemical signal elements include phenols and anilines, such as those with substitutents oriented ortho or para to one another, polynuclear aromatic hydrocarbons, sulfide-disulfide, sulfide-sulfoxide-sulfone, polyenes, polyeneynes, and the like.
• Suitable electrochemical signal elements include quinones and ferrocenes.
• the building block includes or is substituted with a moiety providing a positive charge (e.g., at neutral pH in aqueous compositions).
• Suitable positively charged moieties include one or more groups such as amines, quaternary ammonium moieties, sulfonium, phosphonium, ferrocene, and the like.
• Suitable amines include alkyl amines, alkyl diamines, heteroalkyl amines, aryl amines, heteroaryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, hydrazines, and the like.
• Alkyl amines generally have 1 to 12 carbons, preferably 1-8, rings can have 3-12 carbons, preferably 3-8. Any of the amines can be employed as a quaternary ammonium compound.
• quaternary ammonium moieties include trimethyl alkyl quaternary ammonium moieties, dimethyl ethyl alkyl quaternary ammonium moieties, dimethyl alkyl quaternary ammonium moieties, aryl alkyl quaternary ammonium moieties, pyridinium quaternary ammonium moieties, and the like.
• the building block includes or is substituted with a moiety providing a negative charge (e.g., at neutral pH in aqueous compositions).
• Suitable negatively charged moieties include one or more groups such as carboxylates, phenols substituted with strongly electron withdrawing groups (e.g., substituted tetrachlorophenols), phosphates, phosphonates, phosphinates, sulphates, sulphonates, thiocarboxylates, and hydroxamic acids.
• Suitable carboxylates include alkyl carboxylates, aryl carboxylates, and aryl alkyl carboxylates.
• Suitable phosphates include phosphate mono-, di-, and tri- esters, and phosphate mono-, di-, and tri- amides.
• Suitable phosphonates include phosphonate mono- and di- esters, and phosphonate mono- and di- amides (e.g., phosphonamides).
• Suitable phosphinates include phosphinate esters and amides.
• the building block includes or is substituted with a moiety providing a negative charge and a positive charge (at neutral pH in aqueous compositions), such as sulfoxides, betaines, and amine oxides.
• the building block includes or is substituted with an acidic moiety.
• Suitable acidic moieties include one or more groups such as carboxylates, phosphates, sulphates, and phenols.
• Suitable acidic carboxylates include thiocarboxylates.
• Suitable acidic phosphates include the phosphates listed hereinabove.
• the building block includes or is substituted with a basic moiety. Suitable basic moieties include one or more groups such as amines. Suitable basic amines include alkyl amines, aryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, and any additional amines listed hereinabove.
• the building block includes or is substituted with a hydrogen bond donor.
• Suitable hydrogen bond donors include one or more groups such as amines, amides, carboxyls, protonated phosphates, protonated phosphonates, protonated phosphinates, protonated sulphates, protonated sulphinates, alcohols, and thiols.
• Suitable amines include alkyl amines, aryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, ureas, and any other amines listed hereinabove.
• Suitable protonated carboxylates, protonated phosphates include those listed hereinabove.
• Suitable alcohols include primary alcohols, secondary alcohols, tertiary alcohols, and aromatic alcohols (e.g., phenols).
• the building block includes or is substituted with a hydrogen bond acceptor or a moiety with one or more free electron pairs.
• Suitable groups can include one or more groups such as amines, amides, carboxylates, carboxyl groups, phosphates, phosphonates, phosphinates, sulphates, sulphonates, alcohols, ethers, thiols, and thioethers.
• Suitable amines include alkyl amines, aryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, ureas, and amines as listed hereinabove.
• Suitable carboxylates include those listed hereinabove.
• Suitable phosphates, phosphonates and phosphinates include those listed hereinabove.
• Suitable alcohols include primary alcohols, secondary alcohols, tertiary alcohols, aromatic alcohols, and those listed hereinabove.
• Suitable ethers include alkyl ethers, aryl alkyl ethers.
• the building block includes or is substituted with a an uncharged polar or hydrophilic group.
• Suitable groups include one or more groups such as amides, alcohols, ethers, thiols, thioethers, esters, thio esters, boranes, borates, and metal complexes.
• Suitable alcohols include primary alcohols, secondary alcohols, tertiary alcohols, aromatic alcohols, and those listed hereinabove.
• Suitable ethers include those listed hereinabove.
• the building block includes or is substituted with an uncharged hydrophobic group.
• Suitable groups include one or more groups such as alkyl (substituted and unsubstituted), alkene (conjugated and unconjugated), alkyne (conjugated and unconjugated), aromatic.
• Suitable alkyl groups include lower alkyl, substituted alkyl, cycloalkyl, aryl alkyl, and heteroaryl alkyl.
• Suitable alkene groups include lower alkene and aryl alkene.
• Suitable aromatic groups include unsubstituted aryl, heteroaryl, substituted aryl, aryl alkyl, heteroaryl alkyl, alkyl substituted aryl, and polyaromatic hydrocarbons.
• the building block includes or is substituted with a spacer (e.g., small) moiety, such as hydrogen, methyl, ethyl, and the like.
• a spacer e.g., small
• spacer such as hydrogen, methyl, ethyl, and the like.
• the framework can be selected for functional groups that provide for coupling to the recognition moiety and for coupling to or being the linking moiety.
• the framework can include multiple reaction sites with orthogonal and reliable functional groups and with controlled stereochemistry.
• a variety of compounds fit the schemes and formulas describing the framework including amino acids, and naturally occurring or synthetic compounds including, for example, oxygen and sulfur functional groups.
• Suitable molecules for use as a framework include a natural or synthetic amino acid, e.g., an amino acid with a functional group (e.g., third functional group) on its side chain.
• Amino acids include carboxyl and amine functional groups.
• a framework can be or can include any of a variety of compounds or substructures.
• a framework can be or include an amino acid (natural or synthetic), a dipeptide, a monosaccharide, a disaccharide, another carbohydrate, a mixture or combination thereof, or the like; a catalytic moiety such as a coenzyme, a metal, a metal complex, or the like; a polymer of up to 2000 carbon atoms (e.g., up to 48 carbon atoms), e.g., a polyether, polyethyleneimine, a polyacrylamide, or like polymer; an ⁇ -hydroxy acid, a thioic acid; an enzyme inhibitor (e.g., a protease inhibitor (such as pepstatin), a statin, or the like), a receptor antagonist (e.g., a benzodiazepine), a receptor agonist, a pharmaceutical, a peptide hormone; a natural product, a starting material, intermediate, or end product of a metabolic pathway (e.g., glycolysis, the citric acid cycle
• a framework can be a naturally occurring or synthetic compound; can be racemic, optically active, or achiral; can include positional isomers of any specifically described structure; or can include conformationally restricted functional groups.
• the framework is or includes a monosaccharide. Any of a variety of naturally occurring or synthetic monosaccharides can be employed as a framework.
• Suitable monosaccharides include pyranoses and furanoses, such as glucose, fructose, ribulose, allose, altrose, mannose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, or the like; erythrose, threose, or the like; inositol, or the like; amino sugars, such as rhammose, fucose, glucosamine, galactosamine, or the like; aldonic and uronic acids, such as gluconic acid, glucuronic acid, glucaric acid, or the like; glycosides including these monosaccharides; a mixture or combination thereof, or the like.
• pyranoses and furanoses such as glucose, fructose, ribulose, allose, altrose, mannose, gulose, idose, galactose, ta
• the framework is or includes a disaccharide. Any of a variety of naturally occurring or synthetic disaccharides can be employed as a framework. Suitable disaccharides include disaccharides or oligosaccharides including the monosaccharides listed above. Such disaccharides include sucrose, raffinose, gentianose, cellobiose, maltose, lactose, trehalose, gentiobiose, meliobiose, a mixture or combination thereof, or the like. In an embodiment, the framework is or includes a carbohydrate. Any of a variety of naturally occurring or synthetic carbohydrates can be employed as a framework.
• Suitable carbohydrates include cellulose, chitin, starch, glycogen, hyaluronic acid, chondroitin sulfates, keratosulfate, heparin, glycoproteins, or the like; a mixture or combination thereof, or the like.
• the framework is or includes a catalytic moiety. Any of a variety of naturally occurring or synthetic catalytic moieties can be employed as or can be a moiety on a framework. Suitable catalytic moieties include coenzymes, metals, metal complexes, pronucleophiles, proelectrophiles, proreducing agents, prooxidizing agents, general acid catalysts, general base catalysts, a mixture or combination thereof, or the like.
• the framework is or includes a metal binding or complexing moiety.
• metal binding or complexing moieties include synthetic and naturally occurring po ⁇ hyrin (e.g., etiopo ⁇ hyrin, mesopo ⁇ hyrin, protopo ⁇ hyrin (e.g., heme or hematin), copropo ⁇ hyrin, tetraphenylpo ⁇ hyrin, octaethylpo ⁇ hyrin, or the like), a cobamide coenzyme (e.g., coenzyme B 12 , a cobalamin such as methyl- cobalamin, or the like), selenocysteine, selenomethionine, ferritin; naturally occurring or synthetic complexes of magnesium, zinc, copper, chromium, iron,
• Suitable coenzymes include a nicotinamide coenzyme (e.g., NAD, NADH, NADP, NADPH, and the like), a flavin compound (e.g., FAD, FADH 2 , FMN, FMNH 2 ), a lipoic acid (e.g., oxidized or reduced lipoic acid), a glutathione (e.g., oxidized or reduced glutathione), an ascorbic acid, a quinone (e.g., ubiquinone, vitamins K, or the like), a po ⁇ hyrin (e.g., etiopo ⁇ hyrin, mesopo ⁇ hyrin, protopo ⁇ hyrin (e.g., heme or hematin), copropo ⁇ hyrin, or the like), a nucleoside (e.g., adenine, guanine, cytosine, thymine, uracil),
• the framework is or includes a polymer of up to 2000 carbon atoms (e.g., up to 48 carbon atoms). Such a polymer can be naturally occurring or synthetic. Such a polymer can be naturally occurring or synthetic. Suitable polymers include a polyether or like polymer, such as a PEG, a polyethyleneimine, polyacrylate (e.g., substituted polyacrylates), salt thereof, a mixture or combination thereof, or the like. Suitable PEGs include PEG 1500 up to PEG 20,000, for example, PEG 1450, PEG 3350, PEG 4500, PEG 8000, PEG 20,000, and the like. In an embodiment, the building block is or includes a dipeptide.
• Suitable dipeptides include muramyl dipeptide or the like.
• the framework can be or include a therapeutic or pharmacologically active agent.
• Suitable therapeutic or pharmacologically active agents include a nitrate, nitric oxide, a nitric oxide promoter, nitric oxide donors, dipyridamole, or another vasodilator; HYTRIN® or another antihypertensive agent; a glycoprotein Ilb/IIIa inhibitor (abciximab) or another inhibitor of surface glycoprotein receptors; aspirin, ticlopidine, clopidogrel or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor; a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; methotrexate or another antimetabolite or antiproliferative agent; tamoxifen
• the framework can be or can include an antibiotic.
• antibiotics include penicillin, tetracycline, chloramphenicol, minocycline, doxycycline, vancomycin, bacitracin, kanamycin, neomycin, gentamycin, erythromycin and cephalosporins.
• cephalosporins include cephalothin, cephapirin, cefazolin, cephalexin, cephradine, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefonicid, ceforanide, cefotaxime, moxalactam, ceftizoxime, ceftriaxone, and cefoperazone.
• the framework can be or can include an enzyme inhibitor.
• Suitable enzyme inhibitors include edrophonium chloride, N-methylphysostigmine, neostigmine bromide, physostigmine sulfate, tacrine HCL, tacrine, 1-hydroxy maleate, iodotubercidin, p-bromotetramisole, l ⁇ -( ⁇ -diethylaminopropionyl)- phenothiazine hydrochloride, calmidazolium chloride, hemicholinium-3,3,5- dinitrocatecho-1, diacylglycerol kinase inhibitor I, diacylglycerol kinase inhibitor II, 3-phenylpropargylaminie, N-monomethyl-L-arginine acetate, carbidopa, 3- hydroxybenzylhydrazine HCI, hydralazine HCI, clorgyline HCI, deprenyl HCI L(-), deprenyl HCI D(+),
• the framework is or includes a signal element that produces a detectable signal when a test ligand is bound to the receptor.
• the signal element can produce an optical signal or a electrochemical signal. Suitable optical signals include chemiluminescence or fluorescence.
• the signal element can be a fluorescent moiety.
• the fluorescent molecule can be one that is quenched by binding to the artificial receptor.
• the signal element can be a molecule that fluoresces only when binding occurs.
• Suitable electrochemical signal elements include those that give rise to current or a potential.
• Suitable electrochemical signal elements include phenols and anilines, such as those with substitutents oriented ortho or para to one another, polynuclear aromatic hydrocarbons, sulfide-disulfide, sulfide-sulfoxide-sulfone, polyenes, polyeneynes, and the like.
• Suitable electrochemical signal elements include quinones and ferrocenes.
• the framework includes multiple reaction sites with orthogonal and reliable functional groups and with controlled stereochemistry. Suitable functional groups with orthogonal and reliable chemistries include, for example, carboxyl, amine, hydroxyl, phenol, carbonyl, and thiol groups, which can be individually protected, deprotected, and derivatized.
• the framework has two, three, or four functional groups with orthogonal and reliable chemistries.
• the framework has three functional groups. In such an embodiment, the three functional groups can be independently selected, for example, from carboxyl, amine, hydroxyl, phenol, carbonyl, or thiol group.
• the framework can include alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, and like moieties.
• a general structure for a framework with three functional groups can be represented by Formula la: F 2 Fi-Ri- F 3
• a general structure for a framework with four functional groups can be represented by Formula lb: F 2 F1-R1- F 3 F 4
• R ! can be a 1-12, a 1-6, or a 1-4 carbon alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, or like group; and Fi, F , F 3 , or F can independently be a carboxyl, amine, hydroxyl, phenol, carbonyl, or thiol group.
• F ls F 2 , F 3 , or F 4 can independently be a 1-12, a 1-6, a 1-4 carbon alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, or inorganic group substituted with carboxyl, amine, hydroxyl, phenol, carbonyl, or thiol group.
• F 3 and/or F 4 can be absent.
• frameworks suitable for reactions for coupling to recognition element(s) and/or linkers can be purchased or made by known methods (see, e.g., Green, TW; Wuts, PGM (1999), Protective Groups in Organic Synthesis Third Edition, Wiley-Interscience, New York, 779 pp.; Bodanszky, M.; Bodanszky, A. (1994), The Practice of Peptide Synthesis Second Edition, Springer-Verlag, New York, 217 pp.).
• the recognition element can be selected to provide one or more structural characteristics to the building block.
• the framework and/or recognition element can interact with the ligand as part of the artificial receptor.
• the recognition element can provide one or more structural characteristics such as positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, 7T electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• a recognition element can be a small group or it can be bulky.
• the recognition element can be a 1-12, e.g., 1-6, e.g., 1-4 carbon alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, or like group.
• the recognition element can be substituted with a group that includes or imparts positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, TT electrons, charge polarization, hydrophilicity, hydrophobicity, and the like.
• a recognition element can be or can include any of a variety of compounds or substructures.
• a recognition element can be or include an amino acid (natural or synthetic), a dipeptide, a monosaccharide, a disaccharide, another carbohydrate, a mixture or combination thereof, or the like; a catalytic moiety such as a coenzyme, a metal, a metal complex, or the like; a polymer of up to 2000 carbon atoms (e.g., up to 48 carbon atoms), e.g., a polyether, polyethyleneimine, a polyacrylamide, or like polymer; an c-hydroxy acid, a thioic acid; an enzyme inhibitor (e.g., a protease inhibitor (such as pepstatin), a statin, or the like), a receptor antagonist (e.g., a benzodiazepine), a receptor agonist, a pharmaceutical, a peptide hormone; a natural product, a starting material, intermediate, or end product of a metabolic pathway (e.g., glycolysis, the citric acid
• a building block can be a naturally occurring or synthetic compound; can be racemic, optically active, or achiral; can include positional isomers of any specifically described structure; or can include conformationally restricted functional groups.
• the recognition element is or includes a monosaccharide.
• Suitable monosaccharides include pyranoses and furanoses, such as glucose, fructose, ribulose, allose, altrose, mannose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, or the like; erythrose, threose, or the like; inositol, or the like; amino sugars, such as rhammose, fucose, glucosamine, galactosamine, or the like; aldonic and uronic acids, such as gluconic acid, glucuronic acid, glucaric acid, or the like; glycosides including these monosaccharides; a mixture or combination thereof, or the like.
• the recognition element is or includes a disaccharide. Any of a variety of naturally occurring or synthetic disaccharides can be employed as a building block. Suitable disaccharides include disaccharides or oligosaccharides including the monosaccharides listed above. Such disaccharides include sucrose, raffinose, gentianose, cellobiose, maltose, lactose, trehalose, gentiobiose, meliobiose, a mixture or combination thereof, or the like. In an embodiment, the recognition element is or includes a carbohydrate. Any of a variety of naturally occurring or synthetic carbohydrates can be employed as a recognition element.
• Suitable carbohydrates include cellulose, chitin, starch, glycogen, hyaluronic acid, chondroitin sulfates, keratosulfate, heparin, glycoproteins, or the like; a mixture or combination thereof, or the like.
• the recognition element is or includes a catalytic moiety. Any of a variety of naturally occurring or synthetic catalytic moieties can be employed as or can be a moiety on a recognition element. Suitable catalytic moieties include coenzymes, metals, metal complexes, pronucleophiles, proelectrophiles, proreducing agents, prooxidizing agents, general acid catalysts, general base catalysts, a mixture or combination thereof, or the like.
• the recognition element is or includes a metal binding or complexing moiety.
• a metal binding or complexing moiety Any of a variety of naturally occurring or synthetic metal binding or complexing moieties can be employed as or can be a moiety on a recognition element.
• Suitable metal binding or complexing moieties include synthetic and naturally occurring po ⁇ hyrin (e.g., etiopo ⁇ hyrin, mesopo ⁇ hyrin, protopo ⁇ hyrin (e.g., heme or hematin), copropo ⁇ hyrin, tetraphenylpo ⁇ hyrin, octaethylpo ⁇ hyrin, or the like), a cobamide coenzyme (e.g., coenzyme B 12 , a cobalamin such as methyl-cobalamin, or the like), selenocysteine, selenomethionine, ferritin; naturally occurring or synthetic complexes of magnesium
• the recognition element is or includes a coenzyme (which can also be called a prosthetic group or cofactor).
• a coenzyme which can also be called a prosthetic group or cofactor.
• Any of a variety of naturally occurring or synthetic coenzymes can be employed as or can be a moiety on a recognition element.
• Suitable coenzymes include a nicotinamide coenzyme (e.g., NAD, NADH, NADP, NADPH, and the like), a flavin compound (e.g., FAD, FADH 2 , FMN, FMNH 2 ), a lipoic acid (e.g., oxidized or reduced lipoic acid), a glutathione (e.g., oxidized or reduced glutathione), an ascorbic acid, a quinone (e.g., ubiquinone, vitamins K, or the like), a po ⁇ hyrin (e.g., etiopo ⁇ hyrin,
• the present recognition element can be or include a lipophilic moiety.
• Suitable lipophilic moieties include one or more branched or straight chain C 6-36 alkyl, C 8-24 alkyl, C 12-24 alkyl, C 12-18 alkyl, or the like; C 6-36 alkenyl, C 8-24 alkenyl, C 12- 4 alkenyl, Cn-is alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8-24 alkynyl, C 12-24 alkynyl, C 12-18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or substituted aryl moieties (e.g., phenyl or naphthyl moieties at the end or middle of a chain); polyaromatic hydrocarbon moieties; cycloalkane or substituted alkane moieties with numbers of carbons as described for chains
• the alkyl, alkenyl, or alkynyl group can include branching; within chain functionality like an ether group; terminal functionality like alcohol, amide, carboxylate or the like; or the like.
• Suitable recognition elements include carboxylic acids (e.g., mono and di- carboxylates) with the carboxylate appended to a lipophilic moiety, such as one or more branched or straight chain C 6-36 alkyl, C 8-2 alkyl, C ⁇ 2-24 alkyl, C 12-18 alkyl, or the like; C 6-36 alkenyl, C 8-24 alkenyl, C 12-24 alkenyl, C 12-18 alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8-24 alkynyl, C 1 -24 alkynyl, C 1 -18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or substituted
• Such carboxylic acids include arachidonic acid, linoleic acid, linolenic acid, oleic acid, and the like. Such carboxylic acids can be immobilized on a support through covalent bonding or electrostatic interaction between Suitable recognition elements include carboxylic acids (e.g., mono and di- carboxylates) with the carboxylate appended to a an organic radical, such as one or more branched or straight chain C 2-8 alkyl, arylalkyl, alkenyl, alkynyl, or the like. These carboxylic acids can include substituted aryl moieties (e.g., phenyl or naphthyl moieties).
• aryl moieties e.g., phenyl or naphthyl moieties
• Such carboxylic acids include acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, benzoic acid, and the like.
• Such carboxylic acids can be immobilized on a support through covalent bonding or electrostatic interaction between the carboxyl(ate) and the support or lawn.
• the recognition element is or includes an amino acid. Suitable amino acids include a natural or synthetic amino acid. Amino acids include carboxyl and amine functional groups.
• amino acids can also include a moiety with one or more of positive charge, negative charge, acid, base, electron acceptor, electron donor, hydrogen bond donor, hydrogen bond acceptor, free electron pair, ⁇ electrons, charge polarization, hydrophilicity, or hydrophobicity.
• Suitable amino acids include those with a functional group on the side chain.
• the side chain functional group can include, for natural amino acids, an amine (e.g., alkyl amine, heteroaryl amine), hydroxyl, phenol, carboxyl, thiol, thioether, or amidino group. Any of the natural amino acids can be employed as a recognition element.
• the natural amino acids include aliphatic amino acids (e.g., alanine, valine, leucine, and isoleucine), hydroxyamino acids (e.g., serine, threonine, and tyrosine), dicarboxylic acids (e.g., glutamic acid and aspartic acid), amides (e.g., glutamine and asparagine), amino acids with basic sidechains (e.g., lysine, hydroxylysine, histidine, and arginine), aromatic amino acids (e.g., histidine, phenylalanine, tyrosine, tryptophan, and thyroxine), sulfur containing amino acids (e.g., cysteine, cystine, and methionine), imino acids (e.g., proline and hydroxyproline).
• aliphatic amino acids e.g., alanine, valine, leucine, and isoleucine
• Natural amino acids suitable for use as recognition elements include, for example, serine, threonine, tyrosine, aspartic acid, glutamic acid, asparagine, glutamine, cysteine, lysine, arginine, histidine.
• Synthetic amino acids can include the naturally occurring side chain functional groups or synthetic side chain functional groups which modify or extend the natural amino acids with alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, and like moieties as framework and with carboxyl, amine, hydroxyl, phenol, carbonyl, or thiol functional groups.
• Preferred synthetic amino acids include jS-amino acids and homo or ⁇ analogs of natural amino acids.
• the building block is or includes a dipeptide. Any of the 400 dipeptides including the 20 natural amino acids in any order can be employed as building blocks. Suitable dipeptides include muramyl dipeptide or the like.
• the recognition element can be or include a therapeutic or pharmacologically active agent.
• Suitable therapeutic or pharmacologically active agents include a nitrate, nitric oxide, a nitric oxide promoter, nitric oxide donors, dipyridamole, or another vasodilator; HYTPJN® or another antihypertensive agent; a glycoprotein Ilb/IIIa inhibitor (abciximab) or another inhibitor of surface glycoprotein receptors; aspirin, ticlopidine, clopidogrel or another antiplatelet agent; colchicine or another antimitotic, or another microtubule inhibitor; a retinoid or another antisecretory agent; cytochalasin or another actin inhibitor; methotrexate or another antimetabolite or antiproliferative agent; tamoxifen citrate, TAXOL®, paclitaxel, or derivatives thereof, rapamycin, vinblastine, vincristine, vinorelbine, etoposide, tenopiside, dactinomycin (actino
• the recognition element can be or can include an antibiotic.
• antibiotics include penicillin, tetracycline, chloramphenicol, minocycline, doxycycline, vancomycin, bacitracin, kanamycin, neomycin, gentamycin, erythromycin and cephalosporins.
• cephalosporins examples include cephalothin, cephapirin, cefazolin, cephalexin, cephradine, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefonicid, ceforanide, cefotaxime, moxalactam, ceftizoxime, ceftriaxone, and cefoperazone.
• the recognition element can be or can include an enzyme inhibitor.
• Suitable enzyme inhibitors include edrophonium chloride, N- methylphysostigmine, neostigmine bromide, physostigmine sulfate, tacrine HCL, tacrine, 1-hydroxymaleate, iodotubercidin, p-bromotetramisole, 10-( ⁇ - diethylaminopropionyl)-phenothiazine hydrochloride, calmidazolium chloride, hemicholinium-3,3,5-dinitrocatecho-l, diacylglycerol kinase inhibitor I, diacylglycerol kinase inhibitor II, 3-phenylpropargylaminie, N-monomethyl-L- arginine acetate, carbidopa, 3-hydroxybenzylhydrazine HCI, hydralazine HCI, clorgyline HCI, deprenyl HCI L(-), deprenyl HCI D(+),
• the recognition element is or includes a signal element that produces a detectable signal when a test ligand is bound to the receptor.
• the signal element can produce an optical signal or a electrochemical signal. Suitable optical signals include chemiluminescence or fluorescence.
• the signal element can be a fluorescent moiety.
• the fluorescent molecule can be one that is quenched by binding to the artificial receptor.
• the signal element can be a molecule that fluoresces only when binding occurs.
• Suitable electrochemical signal elements include those that give rise to current or a potential.
• Suitable electrochemical signal elements include phenols and anilines, such as those with substitutents oriented ortho or para to one another, polynuclear aromatic hydrocarbons, sulfide-disulfide, sulfide-sulfoxide-sulfone, polyenes, polyeneynes, and the like.
• Suitable electrochemical signal elements include quinones and ferrocenes.
• a recognition element can be coupled to the building block, e.g., to the framework, through any of a variety of interactions.
• the recognition element can be reversibly coupled to the framework.
• Reversibly coupling a recognition element to a framework employs a mechanism that allows the recognition element to be uncoupled from the framework without destroying or unacceptably degrading the recognition element, the framework, other parts of the building block, or other parts of the artificial receptor. That is, coupling can be reversed without destroying or unacceptably degrading the recognition element or the framework. In an embodiment, coupling can be reversed with only negligible or ineffective levels of degradation of the recognition element or the framework.
• Reversible coupling can employ readily reversible covalent bonding or noncovalent interactions. Suitable noncovalent interactions include interactions between ions, hydrogen bonding, van der Waals interactions, and the like. Readily reversible covalent bonding refers to covalent bonds that can be formed and broken under conditions that do not destroy or unacceptably degrade the recognition element or the framework.
• reversible coupling of a recognition element employs a framework including moieties on the framework that can engage in a reversible interaction with the recognition element.
• the framework can include moieties that can engage in reversible covalent bonding, moieties that can engage in noncovalent interactions, a mixture of these moieties, or the like.
• the present invention can employ any of a variety of the numerous known functional groups, reagents, and reactions for forming reversible covalent bonds.
• Suitable reagents for forming reversible covalent bonds include those described in Green, TW; Wuts, PGM (1999), Protective Groups in Organic Synthesis Third Edition. Wiley-Interscience, New York, 779 pp.
• the framework can include functional groups such as a carbonyl group, a carboxyl group, a silane group, boric acid or ester, an amine group (e.g., a primary, secondary, or tertiary amine, a hydroxylamine, a hydrazine, or the like), a thiol group, an alcohol group (e.g., primary, secondary, or tertiary alcohol), a diol group (e.g., a 1,2 diol or a 1,3 diol), a phenol group, a catechol group, or the like.
• functional groups such as a carbonyl group, a carboxyl group, a silane group, boric acid or ester, an amine group (e.g., a primary, secondary, or tertiary amine, a hydroxylamine, a hydrazine, or the like), a thiol group, an alcohol group (e.g., primary, secondary, or tert
• These functional groups can form groups with reversible covalent bonds, such as ether (e.g., alkyl ether, silyl ether, thioether, or the like), ester (e.g., alkyl ester, phenol ester, cyclic ester, thioester, or the like), acetal (e.g., cyclic acetal), ketal (e.g., cyclic ketal), silyl derivative (e.g., silyl ether), boronate (e.g., cyclic boronate), amide, hydrazide, imine, carbamate, or the like.
• ether e.g., alkyl ether, silyl ether, thioether, or the like
• ester e.g., alkyl ester, phenol ester, cyclic ester, thioester, or the like
• acetal e.g., cyclic acetal
• Such a functional group can be referred to as a covalent bonding moiety, e.g., a first covalent bonding moiety.
• a carbonyl group on the framework and an amine group on a recognition element can form an imine or Schiff s base. The same is true of an amine group on the framework and a carbonyl group on a recognition element.
• the imine or Schiff s base can be formed and cleaved under conditions that do not destroy or unacceptably degrade either the framework or the recognition element.
• a carbonyl group on the framework and an alcohol group on a recognition element can form an acetal or ketal. The same is true of an alcohol group on the framework and a carbonyl group on a recognition element.
• the acetal or ketal can be formed and cleaved under conditions that do not destroy or unacceptably degrade either the framework or the recognition element.
• a thiol (e.g., a first thiol) on the framework and a thiol (e.g., a second thiol) on the recognition element can form a disulfide.
• the disulfide bond can be formed and cleaved under conditions that do not destroy or unacceptably degrade either the framework or the recognition element.
• a carboxyl group on the framework and an alcohol group on a recognition element can form an ester. The same is true of an alcohol group on the framework and a carboxyl group on a recognition element.
• esters that provide covalent bonding that can be reversed in the context of the present invention.
• readily reversible ester linkages can be formed from alcohols such as phenols with electron withdrawing groups on the aryl ring, other alcohols with electron withdrawing groups acting on the hydroxyl-bearing carbon, other alcohols, or the like; and/or carboxyl groups such as those with electron withdrawing groups acting on the acyl carbon (e.g., nitrobenzylic acid, R-CF 2 -COOH, R-CCl 2 -COOH, and the like), other carboxylic acids, or the like.
• Reversible ester linkages can be formed and cleaved under conditions that do not destroy or unacceptably degrade either the framework, the lawn, or the recognition element.
• the framework and the recognition element can be functionalized with moieties that can engage in noncovalent interactions.
• the framework can include functional groups such as an ionic group, a group that can hydrogen bond, or a group that can engage in van der Waals or other hydrophobic interactions.
• the recognition element can include a complementary group for such an interaction.
• Such functional groups can include cationic groups, anionic groups, lipophilic groups, amphiphilic groups, and the like.
• a cationic group on the framework and an anionic group on a recognition element can form an ionic bond under conditions that do not destroy or unacceptably degrade either the framework or the recognition element.
• an anionic group on the framework and a cationic group on a recognition element can engage in a lipophilic interaction under conditions that do not destroy or unacceptably degrade either the framework or the recognition element.
• the present methods and compositions can employ a framework including a charged moiety (e.g., a first charged moiety) and a recognition element including an oppositely charged moiety (e.g., a second charged moiety).
• Suitable charged moieties include positively charged moieties and negatively charged moieties.
• Suitable positively charged moieties include amines, quaternary ammonium moieties, sulfonium, phosphonium, ferrocene, or the like.
• a positively charged moiety, such as a quaternary ammonium moiety, can also include one or more lipophilic moieties.
• Suitable negatively charged moieties include carboxylates, alkoxylates, phenols substituted with strongly electron withdrawing groups (e.g., tetrachlorophenols), phosphates, phosphonates, phosphinates, sulphates, sulphonates, thiocarboxylates, hydroxamic acids, or the like.
• the present methods and compositions can employ a framework including groups that can hydrogen bond (e.g., a first hydrogen bonding group), either as donors or acceptors.
• the framework can include a hydrogen bond donor and the recognition element can include a hydrogen bond acceptor (or vice versa).
• Suitable hydrogen bonding groups include carboxyl groups, amine groups, hydroxyl groups, carbonyl groups, or the like. Ionic groups can also participate in hydrogen bonding.
• the present methods and compositions can employ a framework and a recognition element each independently including a lipophilic moiety (e.g., a first lipophilic moiety and a second lipophilic moiety).
• Suitable lipophilic moieties include branched or straight chain C 6-36 alkyl, C 8- 4 alkyl, C 12-24 alkyl, C 12-18 alkyl, or the like; C 6-36 alkenyl, Cg-24 alkenyl, C 12-24 alkenyl, C 12- ⁇ s alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8-24 alkynyl, C 12-24 alkynyl, C 12-18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or substituted aryl moieties (e.g., phenyl or naphthyl moieties at the end or middle of a chain); polyaromatic hydrocarbon moieties; cycloalkane or substituted alkane moieties with numbers of carbons as described for chains; combinations or mixtures thereof; or the like.
• the alkyl, alkenyl, or alkynyl group can include branching; within chain functionality like an ether group; terminal functionality like alcohol, amide, carboxylate or the like; or the like.
• a lipophilic moiety like a quaternary ammonium lipophilic moiety can also include a positive charge.
• the present building blocks or mixtures of building blocks include reversibly and irreversibly coupled recognition elements.
• such an irreversibly coupled recognition element can be coupled through a covalent bond that cannot be broken without destroying or unacceptably degrading the recognition element or the framework.
• irreversible coupling employs a covalent bond that is stable under conditions used to reverse the reversible covalent bond.
• an amide bond irreversibly couples a recognition element to a framework.
• a recognition element reversibly coupled to a framework can be irreversibly coupled to the framework.
• the present method can include converting a reversible covalent bond that links a recognition element to a lawn or framework into an irreversible bond.
• Such conversions include converting a disulfide link to an irreversible link by, for example, methods including reducing and/or oxidizing the disulfide to an irreversible bond.
• Such a conversion can include reducing an imine to an amine.
• Embodiments of Recognition Elements include amines, quaternary ammonium moieties, sulfonium, phosphonium, ferrocene, and the like.
• Suitable amines include alkyl amines, alkyl diamines, heteroalkyl amines, aryl amines, heteroaryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, hydrazines, and the like.
• Alkyl amines generally have 1 to 12 carbons, e.g., 1-8, and rings can have 3-12 carbons, e.g., 3-8.
• Suitable alkyl amines include that of formula B9.
• Suitable heterocyclic or alkyl heterocyclic amines include that of formula A9.
• Suitable pyridines include those of formulas A5 and B5. Any of the amines can be employed as a quaternary ammonium compound.
• Additional suitable quaternary ammonium moieties include trimethyl alkyl quaternary ammonium moieties, dimethyl ethyl alkyl quaternary ammonium moieties, dimethyl alkyl quaternary ammonium moieties, aryl alkyl quaternary ammonium moieties, pyridinium quaternary ammonium moieties, and the like.
• Basic recognition elements include amines. Suitable basic amines include alkyl amines, aryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, and any additional amines listed hereinabove.
• Suitable alkyl amines include that of formula B9.
• Suitable heterocyclic or alkyl heterocyclic amines include that of formula A9.
• Suitable pyridines include those of formulas A5 and B5.
• Recognition elements including a hydrogen bond donor include amines, amides, carboxyls, protonated phosphates, protonated phosphonates, protonated phosphinates, protonated sulphates, protonated sulphinates, alcohols, and thiols.
• Suitable amines include alkyl amines, aryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, ureas, and any other amines listed hereinabove.
• Suitable alkyl amines include that of formula B9.
• Suitable heterocyclic or alkyl heterocyclic amines include that of formula A9.
• Suitable pyridines include those of formulas A5 and B5.
• Suitable protonated carboxylates, protonated phosphates include those listed hereinabove.
• Suitable amides include those of formulas A8 and B8.
• Suitable alcohols include primary alcohols, secondary alcohols, tertiary alcohols, and aromatic alcohols (e.g., phenols). Suitable alcohols include those of formulas A7 (a primary alcohol) and B7 (a secondary alcohol). Recognition elements including a hydrogen bond acceptor or one or more free electron pairs include amines, amides, carboxylates, carboxyl groups, phosphates, phosphonates, phosphinates, sulphates, sulphonates, alcohols, ethers, thiols, and thioethers.
• Suitable amines include alkyl amines, aryl amines, aryl alkyl amines, pyridines, heterocyclic amines (saturated or unsaturated, the nitrogen in the ring or not), amidines, ureas, and amines as listed hereinabove.
• Suitable alkyl amines include that of formula B9.
• Suitable heterocyclic or alkyl heterocyclic amines include that of formula A9.
• Suitable pyridines include those of formulas A5 and B5.
• Suitable carboxylates include those listed hereinabove.
• Suitable amides include those of formulas A8 and B8.
• Suitable phosphates, phosphonates and phosphinates include those listed hereinabove.
• Suitable alcohols include primary alcohols, secondary alcohols, tertiary alcohols, aromatic alcohols, and those listed hereinabove. Suitable alcohols include those of formulas A7 (a primary alcohol) and B7 (a secondary alcohol).
• Suitable ethers include alkyl ethers, aryl alkyl ethers. Suitable alkyl ethers include that of formula A6. Suitable aryl alkyl ethers include that of formula A4. Suitable thioethers include that of formula B6.
• Recognition elements including uncharged polar or hydrophilic groups include amides, alcohols, ethers, thiols, thioethers, esters, thio esters, boranes, borates, and metal complexes.
• Suitable amides include those of formulas A8 and B8.
• Suitable alcohols include primary alcohols, secondary alcohols, tertiary alcohols, aromatic alcohols, and those listed hereinabove.
• Suitable alcohols include those of formulas A7 (a primary alcohol) and B7 (a secondary alcohol).
• Suitable ethers include those listed hereinabove.
• Suitable ethers include that of formula A6.
• Suitable aryl alkyl ethers include that of formula A4.
• Recognition elements including uncharged hydrophobic groups include alkyl
• Suitable alkyl groups include lower alkyl, substituted alkyl, cycloalkyl, aryl alkyl, and heteroaryl alkyl.
• Suitable lower alkyl groups include those of formulas Al, A3, A3a, and Bl.
• Suitable aryl alkyl groups include those of formulas A3, A3a, A4, B3, B3a, and B4.
• Suitable alkyl cycloalkyl groups include that of formula B2.
• Suitable alkene groups include lower alkene and aryl alkene.
• Suitable aryl alkene groups include that of formula B4.
• Suitable aromatic groups include unsubstituted aryl, heteroaryl, substituted aryl, aryl alkyl, heteroaryl alkyl, alkyl substituted aryl, and polyaromatic hydrocarbons.
• Suitable aryl alkyl groups include those of formulas A3, A3a and B4.
• Suitable alkyl heteroaryl groups include those of formulas A5 and B5.
• Spacer (e.g., small) recognition elements include hydrogen, methyl, ethyl, and the like. Bulky recognition elements include 7 or more carbon or hetero atoms.
• Formulas A1-A9 and B1-B9 are:
• a and B recognition elements can be called derivatives of, according to a standard reference: Al, ethylamine; A2, isobutylamine; A3, phenethylamine; A4, 4-methoxyphenethylamine; A5, 2-(2-aminoethyl)pyridine; A6, 2- methoxyethylamine; A7, ethanolamine; A8, N-acetylethylenediamine; A9, l-(2- aminoethyl)pyrrolidine; Bl, acetic acid, B2, cyclopentylpropionic acid; B3, 3- chlorophenylacetic acid; B4, cinnamic acid; B5, 3-pyridinepropionic acid; B6, (methylthio)acetic acid; B7, 3-hydroxybutyric acid; B8, succinamic acid; and B9, 4- (dimethylamino)butyric acid.
• the recognition elements include one or more of the structures represented by formulas Al, A2, A3, A3a, A4, A5, A6, A7, A8, and/or A9 (the A recognition elements) and/or Bl, B2, B3, B3a, B4, B5, B6, B7, B8, and/or B9 (the B recognition elements).
• each building block includes an A recognition element and a B recognition element.
• a group of 81 such building blocks includes each of the 81 unique combinations of an A recognition element and a B recognition element.
• the A recognition elements are linked to a framework at a pendant position.
• the B recognition elements are linked to a framework at an equatorial position.
• the A recognition elements are linked to a framework at a pendant position and the B recognition elements are linked to the framework at an equatorial position.
• Reagents that form many of the recognition elements are commercially available.
• reagents for forming recognition elements Al, A2, A3, A3a, A4, A5, A6, A7, A8, A9 Bl, B2, B3, B3a, B4, B5, B6, B7, B8, and B9 are commercially available.
• the linker is selected to provide suitable immobilization of the building block on a support or lawn.
• the linker can interact with the ligand as part of the artificial receptor.
• the linker can also provide bulk, distance from the support, hydrophobicity, hydrophilicity, and like structural characteristics to the building block.
• the linker forms a covalent bond with a functional group on the framework.
• the linker includes a functional group that can reversibly interact with the support or lawn, e.g., through reversible covalent bonding or noncovalent interactions.
• the linker includes one or more moieties that can engage in reversible covalent bonding. Suitable groups for reversible covalent bonding include those described hereinabove.
• An artificial receptor can include building blocks reversibly immobilized on the lawn or support through, for example, imine, acetal, ketal, disulfide, ester, or like linkages.
• Such functional groups can engage in reversible covalent bonding.
• a functional group can be referred to as a covalent bonding moiety, e.g., a second covalent bonding moiety.
• the linker before attachment to the support the linker can include a functional group that can be activated to react with or that will react with a functional group on the support.
• the linker can form or can be visualized as forming a covalent bond with an alcohol, phenol, thiol, amine, carbonyl, or like group on the framework.
• the linker can include a carboxyl, alcohol, phenol, thiol, amine, carbonyl, maleimide, or like group that can react with or be activated to react with the support. Between the bond to the framework and the group formed by the attachment to the support, the linker can include an alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, ethoxy or propoxy oligomer, a glycoside, or like moiety.
• the linker can include a good leaving group bonded to, for example, an alkyl or aryl group.
• Such a linker can include a moiety represented by the formula: R-X, in which X is a leaving group such as halogen (e.g., -CI, -Br or -I), tosylate, mesylate, triflate, and R is alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, ethoxy or propoxy oligomer, a glycoside, or like moiety.
• halogen e.g., -CI, -Br or -I
• R is alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, ethoxy or propoxy oligomer, a glycoside, or like moiety.
• the linker can be functionalized with moieties that can engage in noncovalent interactions.
• the linker can include functional groups such as an ionic group, a group that can hydrogen bond, or a group that can engage in van der Waals or other hydrophobic interactions.
• Such functional groups can include cationic groups, anionic groups, lipophilic groups, amphiphilic groups, and the like.
• the present methods and compositions can employ a linker including a charged moiety (e.g., a second charged moiety). Suitable charged moieties include positively charged moieties and negatively charged moieties.
• Suitable positively charged moieties include amines, quaternary ammonium moieties, sulfonium, phosphonium, ferrocene, and the like.
• Suitable negatively charged moieties include carboxylates, phenols substituted with strongly electron withdrawing groups (e.g., tetrachlorophenols), phosphates, phosphonates, phosphinates, sulphates, sulphonates, thiocarboxylates, and hydroxamic acids.
• the present methods and compositions can employ a linker including a group that can hydrogen bond, either as donor or acceptor (e.g., a second hydrogen bonding group).
• the linker can include one or more carboxyl groups, amine groups, hydroxyl groups, carbonyl groups, or the like. Ionic groups can also participate in hydrogen bonding.
• the present methods and compositions can employ a linker including a lipophilic moiety (e.g., a second lipophilic moiety).
• Suitable lipophilic moieties include one or more branched or straight chain C 6-36 alkyl, C 8- alkyl, C 12- 4 alkyl, C 1 -18 alkyl, or the like; C 6-36 alkenyl, C 8-2 alkenyl, C ⁇ 2- 4 alkenyl, C12-18 alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8 .
• alkynyl C ⁇ 2-24 alkynyl, C 12-18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or substituted aryl moieties (e.g., phenyl or naphthyl moieties at the end or middle of a chain); polyaromatic hydrocarbon moieties; cycloalkane or substituted alkane moieties with numbers of carbons as described for chains; combinations or mixtures thereof; or the like.
• the alkyl, alkenyl, or alkynyl group can include branching; within chain functionality like an ether group; terminal functionality like alcohol, amide, carboxylate or the like; or the like.
• the linker includes a lipophilic moiety (e.g., a second lipophilic moiety) and a covalent bonding moiety (e.g., a second covalent bonding moiety).
• the linker includes a lipophilic moiety (e.g., a second lipophilic moiety) and a charged moiety (e.g., a second charged moiety).
• the linker preferably forms or can be visualized as forming a covalent bond with an alcohol, phenol, thiol, amine, carbonyl, or like group on the framework.
• the linker can include an alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, ethoxy or propoxy oligomer, a glycoside, or like moiety.
• suitable linkers can include: the functional group participating in or formed by the bond to the framework, the functional group or groups participating in or formed by the reversible interaction with the support or lawn, and a linker backbone moiety.
• the linker backbone moiety can include about 4 to about 48 carbon or heteroatoms, about 8 to about 14 carbon or heteroatoms, about 12 to about 24 carbon or heteroatoms, about 16 to about 18 carbon or heteroatoms, about 4 to about 12 carbon or heteroatoms, about 4 to about 8 carbon or heteroatoms, or the like.
• the linker backbone can include an alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, ethoxy or propoxy oligomer, a glycoside, mixtures thereof, or like moiety.
• the linker includes a lipophilic moiety, the functional group participating in or formed by the bond to the framework, and, optionally, one or more moieties for forming a reversible covalent bond, a hydrogen bond, or an ionic interaction.
• the lipophilic moiety can have about 4 to about 48 carbons, about 8 to about 14 carbons, about 12 to about 24 carbons, about 16 to about 18 carbons, or the like.
• the linker can include about 1 to about 8 reversible bond/interaction moieties or about 2 to about 4 reversible bond/interaction moieties.
• Reagents that form suitable linkers are commercially available and include any of a variety of reagents with orthogonal functionality.
• building blocks can be represented by Formula 2:
• R 2 in which: REi is recognition element 1, RE 2 is recognition element 2, and L is a linker.
• Y is absent, NH, O, CH 2 , or NRCO.
• Y is NH or O.
• Y is NH.
• Z is CH2, O, NH, S, CO, NR, NR 2 ,
• R 2 is H, CH 3 , or another group that confers chirality on the building block and has size similar to or smaller than a methyl group.
• R 3 is CH 2 or CH 2 -phenyl.
• L is the functional group participating in or formed by the bond to the framework (such groups are described herein), the functional group or groups participating in or formed by the reversible interaction with the support or lawn (such groups are described herein), and a linker backbone moiety.
• the linker backbone moiety is about 4 to about 48 carbon or heteroatom alkyl, substituted alkyl, cycloalkyl, heterocyclic, substituted heterocyclic, aryl alkyl, aryl, heteroaryl, heteroaryl alkyl, ethoxy or propoxy oligomer, a glycoside, or mixtures thereof; or about 8 to about 14 carbon or heteroatoms, about 12 to about 24 carbon or heteroatoms, about 16 to about 18 carbon or heteroatoms, about 4 to about 12 carbon or heteroatoms, about 4 to about 8 carbon or heteroatoms.
• Working artificial receptors can be generated to be specific to a given test ligand or specific to a particular part of a given test ligand.
• Heterogeneous and immobilized combinations of building block molecules form the working artificial receptors.
• combinations of 2, 3, 4, or 5 distinct building block molecules immobilized in proximity to one another on a support provide molecular structures that serve as candidate and working artificial receptors.
• the building blocks can be na ⁇ ve to the test ligand. Once a plurality of candidate artificial receptors are generated, they can be tested to determine which are specific or useful for a given ligand.
• the specific or working artificial receptor or receptor complex can then be used in a variety of different methods and systems.
• the receptors can be employed in methods and/or devices for binding or detecting a test ligand.
• the receptors can be employed in methods and/or devices for chemical synthesis.
• Methods and systems for chemical synthesis can include methods and systems for regiospecific and stereospecific chemical synthesis.
• the receptors can also be employed for developing compounds that disrupt or model binding interactions.
• Methods and systems for developing therapeutic agents can include methods and systems for pharmaceutical and vaccine development.
• methods and systems of the present invention can be employed for detecting a plurality of ligands of interest.
• an unknown biological sample can be characterized by the presence of a combination of specific ligands. Such a method can be useful in assays for detecting specific pathogens or disease states.
• such an embodiment can be used for determining the genetic profile of a subject.
• cancerous tissue can be detected or a genetic disposition to cancer can be detected.
• the present artificial receptors can be part of products used in: analyzing a genome and/or proteome (protein isolation and characterization); pharmaceutical development (such as identification of sequence specific small molecule leads, characterization of protein to protein interactions); detectors for a test ligand; drug of abuse diagnostics or therapy (such as clinical or field analysis of cocaine or other drugs of abuse); hazardous waste analysis or remediation; chemical exposure alert or intervention; disease diagnostics or therapy; cancer diagnostics or therapy (such as clinical analysis of prostate specific antigen); biological agent alert or intervention; food chain contamination analysis or remediation and clinical analysis of food contaminants; and the like.
• the invention can include methods and/or devices for binding or detecting a test ligand.
• the present artificial receptors can be used for a variety of assays that presently employ an antibody.
• the present artificial receptors can be specific for a given ligand, such as an antigen or an immunogen.
• the present artificial receptors can be used in formats analogous to enzyme immunoassay, enzyme-linked immunoassay, immunodiffusion, immunoelectrophoresis, latex agglutination, and the like.
• Test ligands that can be detected in such a method include a drug of abuse, a biological agent (such as a hazardous agent), a marker for a biological agent, a marker for a disease state, etc.
• Methods and systems for detection can include methods and systems for clinical chemistry, environmental analysis, and diagnostic assays of all types.
• the artificial receptor can be contacted with a sample including or suspected of including at least one test ligand.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• binding of one or more of the test ligands to the artificial receptors can be detected.
• the binding results can be inte ⁇ reted to provide information about the sample.
• the invention includes a method for detecting a test ligand in a sample including contacting an artificial receptor specific to the test ligand with a sample suspected of containing the test ligand.
• the method can also include detecting or quantitating binding of the test ligand to the artificial receptor.
• an artificial receptor that binds (e.g., tightly) the molecule, cell, or microbe under appropriate conditions can be employed in a format where binding itself is sufficient to indicate presence of the molecule or organism.
• Such a format can also include artificial receptors to be probed with positive and control samples.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand, such as a molecule or cell.
• the method can include making an array of candidate artificial receptors.
• Working artificial receptors can be identified by contacting the array with test ligand and identifying which receptors bind the test ligand.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Such a method can employ a labeled test ligand.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• the method can include employing the array or device for detecting or characterizing the test ligand in a sample, such as a biological, laboratory, or environmental sample.
• Figure 5 schematically illustrates an embodiment of the present method employing an array of candidate artificial receptors.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a test ligand.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to a test ligand, e.g., a molecule or cell.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the molecule or cell can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the molecule or cell.
• a test ligand can be identified by a method employing a single or a plurality of lead or working artificial receptors.
• the plurality of lead or working artificial receptors suitable for identifying a test ligand can be employed in an array format test.
• a single lead or working artificial receptor can be configured on a support as a strip together with positive and/or negative control receptors, which can also be configured as strips.
• the method can include producing or employing the selected working artificial receptor or receptor complex on a substrate.
• the substrate can include working artificial receptors for a single test ligand or working artificial receptors for a plurality of test ligands.
• a method can include contacting the artificial receptors with a sample.
• a substrate including working artificial receptors for a single test ligand can be employed in a method or system for detecting that test ligand. Binding to the working artificial receptors indicates that the sample includes the test ligand.
• a substrate including working artificial receptors for a plurality of test ligands can be employed in a method or system for detecting one, several, or all of the test ligands. Binding to the working artificial receptors for a particular test ligand or ligands indicates that the sample includes such test ligand or ligands.
• the working artificial receptors or receptor complexes can be configured to provide a pattern indicative of the presence of one or more of the test ligands. The method can include detecting the binding pattern of the sample and comparing it with binding patterns from known samples.
• Figure 6 schematically illustrates certain binding patterns on an array of working artificial receptors.
• all artificial receptors for one test ligand can be arranged in a line across the substrate.
• receptors that are specific for IL-2 are in a line 12 on the array 10 of working artificial receptor complexes.
• Working artificial receptors that have bound a test ligand e.g., IL-2
• Working artificial receptors that have not bound a test ligand are illustrated as open circles 26.
• a method employing the illustrated array can include detecting binding on line 12 of working artificial receptors through fluorescence or another means described herein. In the illustrated embodiment, detecting binding on line 12 of working artificial receptors indicates that the sample contains IL-2.
• a method employing such an array can determine whether a sample is a particular type of biological sample or contains a particular type of molecule or cell.
• the device 30 can have spots arranged such that a positive result creates an easily recognizable pattern 36, such as a plus sign. The readily recognizable pattern can thus indicate that a particular test ligand is present in the sample.
• the artificial receptors or spots for a particular target 42 can be arranged randomly on third array 40.
• the invention includes a method for detecting or characterizing a biological sample, a molecule, or cell.
• This embodiment of the method can include selecting an artificial receptor that binds the biological sample, molecule, or cell from an array of artificial receptors, contacting the artificial receptor with a test composition, and detecting binding of the artificial receptor to the test composition.
• binding indicates the presence of the biological sample, molecule, or cell in the test composition.
• the invention includes a method for detecting or characterizing a biological sample, molecule, or cell.
• This embodiment of the method can include contacting an array of artificial receptors with a test composition and detecting binding to the artificial receptors. Binding indicates the presence of the biological sample, molecule, or cell in the test composition.
• the present method can develop or employ a plurality of working receptors specific for a particular test ligand, e.g., biological sample, molecule, or cell. That is, the working receptors can be specific for a particular test ligand, but different receptors can interact with different distinct antigens (e.g., proteins or carbohydrates), ligands, functional groups, or structural features of the test ligand.
• Such a method can provide a robust test for the presence of a test ligand. For example, such a robust test can reduce the chances of a false-positive or false- negative result in comparison with an assay that relies upon a single unique receptor to detect a given test ligand. Further, this embodiment of the method can develop or employ working receptors that demonstrate higher binding affinity due to interaction with multiple antigens or ligands on the same test ligand (e.g., multivalent binding). In an embodiment, the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a polynucleotide, e.g., DNA or RNA.
• a polynucleotide e.g., DNA or RNA.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the polynucleotide, e.g., DNA or RNA.
• the building blocks making up the artificial receptors can be na ⁇ ve to the DNA or RNA.
• the polynucleotide, e.g., DNA or RNA can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the polynucleotide, e.g., DNA or RNA.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a polypeptide or peptide.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the polypeptide or peptide.
• the building blocks making up the artificial receptors can be na ⁇ ve to the polypeptide or peptide.
• the polypeptide or peptide can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the polypeptide or peptide.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a oligo- or polysaccharide.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the oligo- or polysaccharide.
• the building blocks making up the artificial receptors can be na ⁇ ve to the oligo- or polysaccharide.
• the oligo- or polysaccharide can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the oligo- or polysaccharide.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a cell, e.g., a hepatocyte.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the cell, e.g., a hepatocyte.
• the building blocks making up the artificial receptors can be na ⁇ ve to the cell.
• the cell e.g., a hepatocyte
• the cell can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the cell, e.g., a hepatocyte.
• the invention can include methods and/or devices for binding or detecting a drug of abuse.
• Methods and systems for detection can include methods and systems for clinical chemistry, field analysis, and diagnostic assays of all types.
• the artificial receptor can be contacted with a sample including or suspected of including at least one drug of abuse. Then, binding of one or more of the drugs of abuse to the artificial receptors can be detected. Next, the binding results can be inte ⁇ reted to provide information about the sample.
• the invention includes a method for detecting a drug of abuse in a sample including contacting an artificial receptor specific to the drug of abuse with a sample suspected of containing the drug of abuse.
• the method can also include detecting or quantitating binding of the drug of abuse to the artificial receptor.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand. This embodiment of the present method can be employed for detecting a test ligand such as a drug of abuse.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with a drug of abuse and identifying which receptors bind the drug of abuse.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• the method can include employing the array or device for detecting or characterizing the drug of abuse in a sample, such as a biological, laboratory, or evidence sample.
• Figure 5 schematically illustrates an embodiment of the present method employing an array of candidate artificial receptors.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a drug of abuse.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to a drug of abuse.
• the building blocks making up the artificial receptors can be na ⁇ ve to the drug of abuse.
• the drug of abuse can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological or field sample, or characterizing or detecting the drug of abuse.
• the method can include producing or employing the selected working artificial receptor or receptor complex on a substrate.
• the substrate can include working artificial receptors for a single drug of abuse or working artificial receptors for a plurality of drugs of abuse.
• a method can include contacting the artificial receptors with a sample.
• a substrate including working artificial receptors for a single drug of abuse can be employed in a method or system for detecting that drug of abuse. Binding to the working artificial receptors indicates that the sample includes the drug of abuse.
• a substrate including working artificial receptors for a plurality of drugs of abuse can be employed in a method or system for detecting one, several, or all of the drugs of abuse. Binding to the working artificial receptors for a particular drug of abuse or drugs of abuse indicates that the sample includes such a drug of abuse or drugs of abuse.
• the working artificial receptors or receptor complexes can be configured to provide a pattern indicative of the presence of one or more of the drugs of abuse.
• the method can include detecting the binding pattern of the sample and comparing it with binding patterns from known samples.
• Figure 6 schematically illustrates binding patterns on an array of working artificial receptors. Such patterns and schemes can be employed for identifying a variety of test ligands including drugs of abuse.
• the present method can develop or employ a plurality of working receptors specific for a particular drug of abuse or feature on the drug of abuse. That is, the working receptors can be specific for a particular drug of abuse, but different receptors can interact with different distinct ligands, functional groups, or structural features of the drug of abuse.
• Such a method can provide a robust test for the presence of a drug of abuse. For example, such a robust test can reduce the chances of a false-positive or false-negative result in comparison with an assay that relies upon a single unique receptor to detect a given drag of abuse.
• this embodiment of the method can develop or employ working receptors that demonstrate higher binding affinity due to interaction with multiple ligands or features on the same drug of abuse (e.g., multivalent binding).
• Suitable drugs of abuse include cannabinoids (e.g., hashish and marijuana), depressants (e.g., barbiturates, benzodiazepines, gamma-hydroxy butyrate, methaqualone), dissociative anesthetics (e.g., ketamine, PCP, and PCP analogs), hallucinogens (e.g., LSD, mescaline, psilocybin), opiates or opioids (e.g., codeine, fentanyl, fentanyl analogs, heroin, mo ⁇ hine, opium, oxycodone HCL, hydrocodone bitartrate), stimulants (e.g., amphetamine, cocaine, methylenedioxy- methamphetamine, methamphetamine, methylphemdate, nicotine), inhalants (e.g., solvents), and the like.
• cannabinoids e.g., hashish and marijuana
• depressants e
• Suitable drugs of abuse include performance enhancing agents, such as stimulants and beta-blockers, anabolic agents, oxygen carrier enhancers, masking agents, and inhalants.
• Suitable stimulants include caffeine and amphetamines.
• Suitable beta-blockers include salbutamol (used in asthma inhalers) and the like.
• Suitable anabolic agents include steroids (e.g., anabolic steroids), steroid analogs, and growth hormone.
• Suitable oxygen carrier enhancers include erythropoietin and the like.
• the invention can include methods and/or devices for binding or detecting an isomer or isomers of a compound.
• Methods and systems for detection can include methods and systems for clinical chemistry, environmental analysis, and diagnostic assays of all types.
• the artificial receptor can be contacted with a sample including or suspected of including at least one isomer of a compound. Then, binding of one or more of the isomers of a compound to the artificial receptors can be detected. Next, the binding results can be inte ⁇ reted to provide information about the isomers.
• the invention includes a method for detecting an isomer of a compound in a sample including contacting an artificial receptor specific to the isomer with a sample suspected of containing the isomer.
• the method can also include detecting or quantitating binding of the isomer to the artificial receptor.
• the present method can be applied to isomers such as stereoisomers (e.g., geometric isomers or optical isomers), optical isomers (e.g., enantiomers and diastereomers), geometric isomers (e.g., cis- and trans-isomers).
• the present method can be employed to develop working or lead artificial receptors or working artificial complexes that can bind to one or more isomers of a compound (e.g., enantioselective receptor environments).
• the artificial receptor or complex can bind to one stereoisomer of a compound but bind only weakly or not at all another stereoisomer of the compound.
• the artificial receptor or complex can bind one geometric isomer of a compound but bind only weakly or not at all another geometric isomer.
• the artificial receptor or complex can bind one optical isomer of a compound but bind only weakly or not at all another optical isomer.
• the artificial receptor or complex can bind one enantiomer of a compound but bind only weakly or not at all another enantiomer.
• the artificial receptor or complex can bind one diastereomer of a compound but bind only weakly or not at all another diastereomer.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand. This embodiment of the present method can be employed for detecting a test ligand such as an isomer of a compound.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with an isomer and identifying which receptors bind the isomer.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• the method can include employing the array or device for detecting or characterizing the isomer in a sample, such as a biological, laboratory, or clinical sample.
• Figure 5 schematically illustrates an embodiment of the present method employing an array of candidate artificial receptors.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting an isomer.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to an isomer.
• the building blocks making up the artificial receptors can be na ⁇ ve to the isomer.
• the isomer can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological, clinical, or laboratory sample, or characterizing or detecting the isomer.
• the method can include producing or employing the selected working artificial receptor or receptor complex on a substrate.
• the substrate can include working artificial receptors for a single isomer or working artificial receptors for a plurality of isomers.
• a method can include contacting the artificial receptors with a sample.
• a substrate including working artificial receptors for a single isomer can be employed in a method or system for detecting that isomer. Binding to the working artificial receptors indicates that the sample includes the isomer.
• a substrate including working artificial receptors for a plurality of isomers can be employed in a method or system for detecting one, several, or all of the isomers. Binding to the working artificial receptors for a particular isomer or isomers indicates that the sample includes such an isomer or isomers.
• the working artificial receptors or receptor complexes can be configured to provide a pattern indicative of the presence of one or more of the isomers. The method can include detecting the binding pattern of the sample and comparing it with binding patterns from known samples.
• Figure 6 schematically illustrates binding patterns on an array of working artificial receptors. Such patterns and schemes can be employed for identifying a variety of test ligands including isomers.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a stereoisomer.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the stereoisomer.
• the building blocks making up the artificial receptors can be na ⁇ ve to the stereoisomer.
• the stereoisomer can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a lab or clinical sample or characterizing or detecting the stereoisomer.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a geometric isomer (e.g., cis- and trans-isomers).
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the geometric isomer (e.g., cis- and trans-isomers).
• the building blocks making up the artificial receptors can be na ⁇ ve to the geometric isomer.
• the geometric isomer can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a lab or clinical sample or characterizing or detecting the geometric isomer (e.g., cis- and trans-isomers).
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting an optical isomer.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the optical isomer.
• the building blocks making up the artificial receptors can be na ⁇ ve to the optical isomer.
• the optical isomer can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a lab or clinical sample or characterizing or detecting the optical isomer.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting an enantiomer.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the enantiomer.
• the enantiomer can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a lab or clinical sample or characterizing or detecting the enantiomer.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a diastereomer.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the diastereomer.
• the building blocks making up the artificial receptors can be na ⁇ ve to the diastereomer.
• the diastereomer can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a lab or clinical sample or characterizing or detecting the diastereomer.
• the invention can include methods and/or devices for binding or detecting a peptide.
• Methods and systems for detection can include methods and systems for clinical chemistry, environmental analysis, and diagnostic assays of all types.
• the artificial receptor can be contacted with a sample including or suspected of including at least one peptide. Then, binding of one or more of the peptides to the artificial receptors can be detected. Next, the binding results can be inte ⁇ reted to provide information about the sample.
• the invention includes a method for detecting a peptide in a sample including contacting an artificial receptor specific to the peptide with a sample suspected of containing the peptide.
• the method can also include detecting or quantitating binding of the peptide to the artificial receptor.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand. This embodiment of the present method can be employed for detecting a test ligand such as a peptide.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with a peptide and identifying which receptors bind the peptide.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• the method can include employing the array or device for detecting or characterizing the peptide in a sample, such as a biological, laboratory, or clinical sample.
• Figure 5 schematically illustrates an embodiment of the present method employing an array of candidate artificial receptors.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a peptide.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to a peptide.
• the building blocks making up the artificial receptors can be na ⁇ ve to the peptide.
• the peptide can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological or environmental sample, or characterizing or detecting the peptide.
• Figure 7 schematically illustrates an embodiment of a method for developing a method and system for detecting a test ligand, such as a peptide or mixture of peptides.
• This embodiment of the present method includes evaluating a plurality (e.g. array) of candidate artificial receptors for binding to each of a plurality of peptides.
• the building blocks making up the artificial receptors can be na ⁇ ve to one or more of the peptides.
• the plurality of peptides can include the peptides found in a cell or organism.
• the method can include detecting binding of individual peptides to a subset of the plurality or array of candidate artificial receptors.
• the method can include detecting binding of the peptides found in a cell or organism to a subset of or all of the plurality or array of candidate artificial receptors. This can be envisioned as developing a working artificial receptor or artificial receptor complex for each peptide or mixture of peptides.
• each peptide or mixture of peptides can provide a pattern of bound receptors in the plurality or array.
• the pattern of bound receptors can be characteristic of the peptide or mixture of peptides or a sample including the peptide or mixture of peptides.
• the method can include storing a representation of the binding pattern as an image or a data structure.
• the representation of the binding pattern can be evaluated either by an operator or data processing system.
• the method can include such evaluating.
• a binding pattern from an unknown sample that matches the binding pattern for a particular peptide then characterizes the unknown sample as containing that peptide.
• a binding pattern from an unknown sample that matches the binding pattern for a particular mixture of peptides then characterizes the unknown sample as including or being that mixture of peptides or as including or being the organism or cell containing that mixture of peptides.
• a plurality of binding patterns can be stored as a database.
• An embodiment of the illustrated method can include creating an array of artificial receptors.
• This embodiment can also include compiling a database of the binding patterns of a specific peptide or mixture of peptides, for example, by probing the array with a plurality of individual peptides or the peptides found in a cell or organism. Contacting the array with an unidentified peptide or mixture of peptides can create a test binding pattern. The method can then compare the test binding pattern with the binding patterns of known peptides or mixtures of peptides in the database in order to characterize or classify the unidentified peptide, mixture of peptides, or cell or organism.
• the database and the array of receptors has already been constructed and the method involves probing the array with an unknown peptide or mixture of peptides to create a test binding pattern and then comparing this binding pattern with the binding patterns in the database in order to characterize or classify the unidentified peptide, mixture of peptides, or cell or organism.
• An array constructed for distinguishing mixtures of peptides can be contacted with samples from an organism, cell, or tissue of interest.
• Peptides that bind to the array can characterize or detect the organism, cell or tissue; can indicate a disorder caused by the organism or affecting the cell or tissue; can indicate successful therapy of a disorder caused by the organism or affecting the cell or tissue; characterize disease processes; identify therapeutic leads or strategies; or the like.
• the method can include producing or employing the selected working artificial receptor or receptor complex on a substrate.
• the substrate can include working artificial receptors for a single peptide or working artificial receptors for a plurality of peptides.
• a method can include contacting the artificial receptors with a sample.
• a substrate including working artificial receptors for a single peptide can be employed in a method or system for detecting that peptide. Binding to the working artificial receptors indicates that the sample includes the peptide.
• a substrate including working artificial receptors for a plurality of peptides can be employed in a method or system for detecting one, several, or all of the peptides.
• Binding to the working artificial receptors for a particular peptide or peptides indicates that the sample includes such a peptide or peptides.
• the working artificial receptors or receptor complexes can be configured to provide a pattern indicative of the presence of one or more of the peptides.
• the method can include detecting the binding pattern of the sample and comparing it with binding patterns from known samples.
• Figure 6 schematically illustrates binding patterns on an array of working artificial receptors. Such patterns and schemes can be employed for identifying a variety of test ligands including peptides.
• the present method can develop or employ a plurality of working receptors specific for a particular peptide or feature on the peptide.
• the working receptors can be specific for a particular peptide, but different receptors can interact with different distinct ligands, functional groups, or structural features of the peptide.
• Such a method can provide a robust test for the presence of a peptide. For example, such a robust test can reduce the chances of a false-positive or false- negative result in comparison with an assay that relies upon a single unique receptor to detect a given peptide. Further, this embodiment of the method can develop or employ working receptors that demonstrate higher binding affinity due to interaction with multiple ligands or features on the same peptide (e.g., multivalent binding).
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a peptide.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the peptide.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the peptide can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the peptide.
• the present method can include selecting artificial receptors that bind a particular peptide and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) as leads for pharmaceutical development or as active agents for modulating an activity of that peptide.
• the artificial receptor or building blocks making up that artificial receptor can be selected to bind to a portion of a peptide required for its interaction with an other macromolecule (e.g. carbohydrate, protein, or polynucleotide), thus disrupting this interaction.
• the invention can include methods and/or devices for binding or detecting a protein, one or more of a plurality of proteins, or a proteome.
• Methods and systems for detection can include methods and systems for clinical chemistry, environmental analysis, diagnostic assays, and for proteome analysis.
• the artificial receptor can be contacted with a sample including at least one protein or one proteome.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• binding of one or more proteins to the artificial receptors can be detected.
• the binding results can be inte ⁇ reted to provide information about the sample, e.g., the proteome.
• the invention includes a method for detecting a protein in a sample including contacting an artificial receptor specific to the protein with a sample suspected of containing the protein.
• the method can also include detecting or quantitating binding of the protein to the artificial receptor.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand. This embodiment of the present method can be employed for detecting a test ligand such as one or more proteins.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with a protein and identifying which receptors bind the protein.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• the method can include employing the array or device for detecting or characterizing the protein in a sample, such as a biological, laboratory, or environmental sample.
• the method can include producing or employing the selected working artificial receptor or receptor complex on a substrate.
• the substrate can include working artificial receptors for a single protein or working artificial receptors for a plurality of proteins.
• a method can include contacting the artificial receptors with a sample.
• a substrate including working artificial receptors for a single protein can be employed in a method or system for detecting that protein. Binding to the working artificial receptors indicates that the sample includes the protein.
• a substrate including working artificial receptors for a plurality of proteins can be employed in a method or system for detecting one, several, or all of the proteins. Binding to the working artificial receptors for a particular protein or protein indicates that the sample includes such a protein or protein.
• the working artificial receptors or receptor complexes can be configured to provide a pattern indicative of the presence of one or more of the proteins.
• the method can include detecting the binding pattern of the sample and comparing it with binding patterns from known samples.
• Figure 6 schematically illustrates binding patterns on an array of working artificial receptors. Such patterns and schemes can be employed for identifying a variety of test ligands including proteins.
• Figure 7 schematically illustrates an embodiment of a method for developing a method and system for detecting a test ligand, such as a protein or proteome.
• This embodiment of the present method includes evaluating a plurality (e.g. array) of candidate artificial receptors for binding to each of a plurality of test ligands.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the plurality of test ligands can include a plurality of proteins.
• the plurality of test ligands can include the proteins making up the proteome of a cell or organism.
• the method can include detecting binding of individual proteins to a subset of the plurality or array of candidate artificial receptors.
• the method can include detecting binding of proteins making up the proteome to a subset of or all of the plurality or array of candidate artificial receptors. This can be envisioned as developing a working artificial receptor or artificial receptor complex for each protein or for the proteome.
• each protein or proteome can provide a pattern of bound receptors in the plurality or array.
• the pattern of bound receptors can be characteristic of the protein or proteome or a sample including the protein or proteome.
• the method can include storing a representation of the binding pattern as an image or a data structure.
• the representation of the binding pattern can be evaluated either by an operator or data processing system.
• the method can include such evaluating.
• a binding pattern from an unknown sample that matches the binding pattern for a particular protein then characterizes the unknown sample as containing that protein.
• a binding pattern from an unknown sample that matches the binding pattern for a particular proteome then characterizes the unknown sample as including or being that proteome or as including or being the organism or cell having that proteome.
• a binding pattern from an unknown sample can be evaluated against the patterns of a plurality of particular proteins or proteomes and the sample can be characterized as containing one or more of the proteins or proteomes.
• a plurality of binding patterns can be stored as a database.
• An embodiment of the illustrated method can include creating an array of artificial receptors. This embodiment can also include compiling a database of the binding patterns of specific proteins or proteomes, for example, by probing the array with a plurality of individual proteins or proteomes. Contacting the array with unidentified proteins or proteomes can create a test binding pattern.
• the method can then compare the test binding pattern with the binding patterns of known proteins or proteomes in the database in order to characterize or classify the unidentified protein, proteome, or cell or organism.
• the database and the array of receptors has already been constructed and the method involves probing the array with an unknown protein or proteome to create a test binding pattern and then comparing this binding pattern with the binding patterns in the database in order to characterize or classify the unidentified protein, proteome, or cell or organism.
• a proteome array can be contacted with samples from an organism, cell, or tissue of interest.
• Proteins that bind to the proteome array can characterize or detect the organism, cell or tissue; can indicate a disorder caused by the organism or affecting the cell or tissue; can indicate successful therapy of a disorder caused by the organism or affecting the cell or tissue; characterize disease processes; identify therapeutic leads or strategies; or the like.
• the present method can develop or employ a plurality of working receptors specific for a particular protein or feature on the protein. That is, the working receptors can be specific for a particular protein, but different receptors can interact with different distinct ligands, functional groups, or structural features of the protein. Such a method can provide a robust test for the presence of a protein.
• this embodiment of the method can develop or employ working receptors that demonstrate higher binding affinity due to interaction with multiple ligands or features on the same protein (e.g., multivalent binding).
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a protein.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the protein.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the protein can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the protein.
• the present method can include selecting artificial receptors that bind a particular protein and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) as leads for pharmaceutical development or as active agents for modulating an activity of that protein.
• the artificial receptor or building blocks making up that artificial receptor can be selected to bind to or disrupt the activity of the active site of an enzyme or the ligand binding site of a receptor.
• the artificial receptor or building blocks making up that artificial receptor can be selected to bind to a portion of a protein required for its interaction with an other macromolecule (e.g. carbohydrate, protein, or polynucleotide), thus disrupting this interaction.
• the artificial receptor or building blocks making up that artificial receptor can be selected to bind to the binding site of a receptor and act as an agonist of that receptor.
• the present method can include selecting working artificial receptors that bind a preselected protein for use in a system for proteome analysis.
• the working artificial receptors for the preselected protein can be provided on a substrate and the protein bound to the receptors.
• selecting and binding employ a plurality of different working artificial receptors for the preselected protein.
• the plurality of artificial receptors may bind to different features on the preselected protein and leave free different features on the preselected protein.
• This embodiment of the method includes contacting the working receptors with bound preselected protein to at least one candidate binding partner for the preselected protein.
• the method can include detecting binding or absence of binding of the candidate binding partner to the preselected protein.
• a candidate binding partner that binds to the preselected protein can be considered a lead binding partner.
• the method includes contacting the working receptors with bound preselected protein with a proteome of a cell or organism serving as the source of candidate binding partners. The method can then recover from the proteome one or more lead binding partners. This can then characterize the proteome as containing or not a binding partner for the preselected protein.
• the present artificial receptors can be employed in studies of proteomics.
• an array of candidate or working artificial receptors can be contacted with a mixture of peptides, polypeptides, and/or proteins. Each mixture can produce a characteristic finge ⁇ rint of binding to the array.
• identification of a specific receptor environment for a target peptide, polypeptide, and/or protein can be utilized for isolation and analysis of the target. That is, in yet another embodiment, a particular receptor surface can be employed for affinity purification methods, e.g. affinity chromatography.
• the present candidate artificial receptors can be employed to find receptor surfaces that bind proteins in a preferred configuration or orientation. Many proteins (e.g.
• antibodies, enzymes, receptors are stable and/or active in specific environments.
• receptor surfaces can be used to produce binding environments that selectively retain or orient the protein for maximum stability and/or activity.
• the present artificial receptors can be employed to form bioactive surfaces.
• receptor surfaces can be used to specifically bind the active conformation of an antibody or enzyme.
• the present method can include labeling a protein while it remains bound to an artificial receptor. The resulting protein will be labeled on its portions accessible to the labeling reagent but not on those portions bound to the artificial receptor. The method can include releasing the labeled protein from the artificial receptor. Determining the distribution of labels on the protein indicates which portion of the protein was bound to the receptor.
• the present artificial receptors can be employed to distinguish between two conformations of a single protein. Certain proteins exist in two or more stable conformations.
• the present working artificial receptor or complex can bind a first conformation of a protein.
• the present working artificial receptor or complex can bind a second conformation of a protein.
• the present working artificial receptor or complex can bind a first conformation of a protein, but not a second conformation of the same protein.
• the present working artificial receptor or complex can bind a second conformation of a protein, but not a first conformation of the same protein.
• the present working artificial receptor or complex can bind a first or non-infectious conformation of a prion, but not its second or infectious conformation.
• the present working artificial receptor or complex can bind the second or infectious conformation of a prion, but not its first or non-infectious conformation.
• the present working artificial receptor or complex can bind a first or non-plaque-forming conformation of /3-amyloid, but not its second or plaque-forming conformation.
• the present working artificial receptor or complex can bind a second or plaque-forming conformation of /3-amyloid, but not its second or non-plaque-forming conformation.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a desired conformation of a protein.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the desired conformation of the protein.
• the building blocks making up the artificial receptors can be na ⁇ ve to the protein or its 1 desired conformation.
• the desired conformation of the protein can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the desired conformation of the protein.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a first or non-infectious conformation of a prion.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the first or non-infectious conformation of a prion.
• the building blocks making up the artificial receptors can be na ⁇ ve to the prion.
• the first or non-infectious conformation of a prion can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the first or non-infectious conformation of a prion.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a second or infectious conformation of a prion.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the second or infectious conformation of a prion.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the second or infectious conformation of a prion can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the second or infectious conformation of a prion.
• the present method includes developing receptors or a receptor system that can distinguish between the first or non-infectious conformation of a prion and the second or infectious conformation of the prion.
• Such a method can include selecting a working artificial receptor or complex can that bind the first or non-infectious conformation of a prion, but not the second or infectious conformation of the prion.
• This embodiment can include selecting a working artificial receptor or complex can that bind the second or infectious conformation of a prion, but not the first or non-infectious conformation of the prion.
• Employed together, these two sets of working artificial receptors or systems can characterize a biological sample as containing one or both forms of the prion.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a first or non-plaque-forming conformation of a ⁇ - amyloid.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the first or non-plaque- forming conformation of the /3-amyloid.
• the building blocks making up the artificial receptors can be na ⁇ ve to the /3-amyloid.
• the first or non-plaque-forming conformation of the /3-amyloid can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the first or non- plaque-forming conformation of the /3-amyloid.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a second or plaque-forming conformation of a /3-amyloid.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the second or plaque-forming conformation of a /3-amyloid.
• the building blocks making up the artificial receptors can be na ⁇ ve to the /3-amyloid.
• the second or plaque-forming conformation of the /3-amyloid can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the second or plaque-forming conformation of the /3-amyloid.
• the present method includes developing receptors or a receptor system that can distinguish between the first or non-plaque-forming conformation of /3-amyloid and the second or plaque-forming conformation of the ⁇ - amyloid.
• Such a method can include selecting a working artificial receptor or complex can that bind the first or non-plaque-forming conformation of /3-amyloid, but not the second or plaque-forming conformation of the /3-amyloid.
• This embodiment can include selecting a working artificial receptor or complex can that bind the second or plaque-forming conformation of the /3-amyloid, but not the first or non-plaque-forming conformation of /3-amyloid.
• these two sets of working artificial receptors or systems can characterize a biological sample as containing one or both forms of the /3-amyloid.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting cholera toxin.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the cholera toxin.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the cholera toxin can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting cholera toxin.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting at least one protein of a cancer cell.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the cancer cell protein.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the cancer cell protein can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the cancer cell protein.
• the present method can include contacting a working artificial receptor or array with a sample from cells or tissues suspected of being cancerous or including a tumor.
• the sample can be serum. Binding of at least one protein to the working artificial receptor or array can indicate or characterize the presence of the particular cancer or tumor, such as by characterizing the pattern of proteins present.
• Cancers that can be detected or characterized by such a method include, for example, bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, including small cell lung cancer, esophageal cancer, gall-bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, and skin cancer, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibros
• the invention can include methods and/or devices for binding or detecting a microbe, e.g., cell or virus.
• Methods and systems for detection can include methods and systems for clinical chemistry, environmental analysis, and diagnostic assays of all types.
• the artificial receptor can be contacted with a sample including or suspected of including at least one microbe, e.g., cell or virus.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand. Then, binding of one or more of the microbes to the artificial receptors can be detected.
• the invention includes a method for detecting a microbe, e.g., cell or virus, in a sample including contacting an artificial receptor specific to the microbe, e.g., cell or virus, with a sample suspected of containing the microbe, e.g., cell or virus.
• the method can also include detecting or quantitating binding of the microbe, e.g., cell or virus, to the artificial receptor.
• Figure 4 schematically illustrates an embodiment of a method for evaluating candidate artificial receptors for binding to a test ligand. This embodiment of the present method can be employed for detecting a test ligand such as a microbe, e.g., cell or virus.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with a microbe, e.g., cell or virus, and identifying which receptors bind the microbe.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• the method can include employing the array or device for detecting or characterizing the microbe, e.g., cell or virus, in a sample, such as a biological, laboratory, or environmental sample.
• Figure 5 schematically illustrates an embodiment of the present method employing an array of candidate artificial receptors.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a microbe, e.g., cell or virus.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to a microbe, e.g., cell or virus.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the microbe can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the microbe, e.g., cell or virus.
• Figure 7 schematically illustrates an embodiment of a method for developing a method and system for detecting a test ligand, such as a disease causing organism.
• This embodiment of the present method includes evaluating a plurality (e.g. array) of candidate artificial receptors for binding to each of a plurality of test ligands, such as disease causing organisms.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligands.
• the method can include detecting binding of each test ligand (e.g., disease causing organism) to a subset of the plurality or array of candidate artificial receptors. This can be envisioned as developing a working artificial receptor or artificial receptor complex for each of the plurality of test ligands.
• each test ligand e.g., disease causing organism
• the pattern of bound receptors can be characteristic of the test ligand or a sample including the test ligand.
• the method can include storing a representation of the binding pattern as an image or a data structure.
• the representation of the binding pattern can be evaluated either by an operator or data processing system. The method can include such evaluating.
• a binding pattern from an unknown sample that matches the binding pattern for a particular test ligand then characterizes the unknown sample as containing that test ligand.
• a binding pattern from an unknown sample can be evaluated against the patterns of a plurality of particular test ligands and the sample can be characterized as containing one or more of the test ligands.
• a plurality of binding patterns can be stored as a database.
• An embodiment of the illustrated method can include creating an array of artificial receptors. This embodiment can also include compiling a database of the binding patterns of specific disease causing organisms, for example, by probing the array with a plurality of individual organisms. Contacting the array with an unidentified organism can create a test binding pattern.
• the method can then compare the test binding pattern with the binding patterns of known organisms in the database in order to characterize or classify the unidentified organism.
• the database and the array of receptors has already been constructed and the method involves probing the array with an unknown organism to create a test binding pattern and then comparing this binding pattern with the binding patterns in the database in order to characterize or classify the unidentified organism.
• the method can include producing or employing the selected working artificial receptor or receptor complex on a substrate.
• the substrate can include working artificial receptors for a single microbe, e.g., cell or virus, or working artificial receptors for a plurality of microbes, e.g., cells or viruses.
• a method can include contacting the artificial receptors with a sample.
• a substrate including working artificial receptors for a single microbe, e.g., cell or viras, can be employed in a method or system for detecting that microbe. Binding to the working artificial receptors indicates that the sample includes the microbe.
• a substrate including working artificial receptors for a plurality of microbes, e.g., cells or viruses can be employed in a method or system for detecting one, several, or all of the microbes. Binding to the working artificial receptors for a particular microbe or microbes indicates that the sample includes such a microbe or microbes.
• the working artificial receptors or receptor complexes can be configured to provide a pattern indicative of the presence of one or more of the microbes, e.g., cells or viruses.
• the method can include detecting the binding pattern of the sample and comparing it with binding patterns from known samples.
• Figure 6 schematically illustrates binding patterns on an array of working artificial receptors. Such patterns and schemes can be employed for identifying a variety of test ligands including microbes.
• the present method can develop or employ a plurality of working receptors specific for a particular microbe or feature on the microbe. That is, the working receptors can be specific for a particular microbe, but different receptors can interact with different distinct antigens (e.g., proteins or carbohydrates), ligands, or features of the microbe. Such a method can provide a robust test for the presence of a microbe.
• this embodiment of the method can develop or employ working receptors that demonstrate higher binding affinity due to interaction with multiple antigens or ligands on the same microbe (e.g., multivalent binding).
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a bacterium.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the bacterium.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the bacterium can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or characterizing or detecting the bacterium.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a virus particle.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the virus particle.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the virus particle can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample or for characterizing or detecting the virus particle.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a biohazard.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the biohazard.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the biohazard can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the biohazard.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting the Vibrio cholerae.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to V. cholerae.
• the building blocks making up the artificial receptors can be na ⁇ ve to the V. cholerae.
• the V. cholerae can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting V. cholerae.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a microbe.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the microbe.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• One or more artificial receptors that bind the microbe under appropriate conditions can be selected for use on an affinity support that can bind that microbe.
• One or more artificial receptors that bind the microbe or cell sufficiently tightly under appropriate conditions can be selected and its building blocks inco ⁇ orated onto a scaffold molecule.
• An embodiment of the method can employ a support with the one or more artificial receptors or scaffold-receptors on its surface for binding or immobilizing the microbe.
• a support with a plurality of artificial receptors, each binding to a different portion of the microbe, on its surface can be employed for multivalent capture or immobilization of the microbe.
• the present method can include selecting artificial receptors that bind a particular microbe and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) as leads for pharmaceutical development or as active agents for modulating an activity of the microbe or as an antibiotic against that microbe.
• the method can employ an array including a significant number of the present artificial receptors to produce an assay or system for characterizing or detecting a microbe of clinical or environmental interest.
• the method can include evaluating an array including a significant number of candidate artificial receptors for binding to the microbe of clinical or environmental interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the microbe of clinical or environmental interest can exhibit characteristic binding to one or several of the candidate artificial receptors from that array.
• the one or several artificial receptors can be selected as an artificial receptor (e.g., a working artificial receptor or a working artificial receptor complex) that can be employed in methods for characterizing a biological sample, or characterizing or detecting the microbe of clinical or environmental interest.
• Suitable microbes of clinical or environmental interest include bacteria, mycoplasma, fungus, rickettsia, or virus.
• Suitable bacteria or mycoplasma of clinical or environmental interest include Escherichia coli (e.g., E. coli H157:O7), Vibrio cholerae, Acinetobacter caicoaceticus, Haemophilus influenzae, Actinobacillus actinoides, Haemophilus parahaemolyticus, Actinobacillus lignieresii, Haemophilus parainfluenzae, Actinobacillus suis, Legionella pneumophila, Actinomyces bovis, Leptospira interrogans, Actinomyces israelli, Mima polymorpha, Aeromonas hydrophila, Moraxella lacunata, Arachnia propionica, Burkholderia mallei, Burkholderia pseudomallei, Moraxella osioensis, Arizona hinshaw
• Suitable fungus include Absidia, Piedraia hortae, Aspergillus, Prototheca, Candida, Paecilomyces, Cryptococcus neoformans, Cryptosporidium parvum, Phialaphora, Dermatophilus congolensis, Rhizopus, Epidermophyton, Scopulariopsis, Exophiala, Sporothrix schenkii, Fusarium, Trichophyton, Madurella mycetomi, Toxoplasma, Trichosporon, Microsporum, Microsporidia, Wangiella dermatitidis, Mucor, Blastomyces dermatitidis, Giardia lamblia, Entamoeba histolytica, Coccidioides immitis, and Histoplasma capsulatum.
• Suitable rickettsia or viruses of clinical or environmental interest include Coronavirases, Hepatitis virases, Hepatitis A viras, Myxo-Paramyxoviruses (Influenza virases, Measles virus, Mumps virus, Newcastle disease viras),
• Picornavirus (Coxsackie virases, Echoviruses, Poliomyelitis viras), Rickettsia akari, Rochalimaea Quintana, Rochalimaea vinsonii, Norwalk Agent, Adenovirases, Arenavirases (Lymphocytic choriomenigitis, Viscerotrophic strains), He ⁇ esvirus Group (Herpesvirus hominis, Cytomegalovirus, Epstein-Barr viras, Calicivirases, Pseudo-rabies viras, Varicella viras), Human Immunodeficiency Virus,
• Parainfluenza virases (Respiratory syncytial viras, Subsclerosing panencephalitis viras), Picornaviruses (Poliomyelitis virus), Poxvirases Variola, Cowpox viras (Molluscum contagiosum virus, Monkeypox viras, Orf viras, Paravaccinia viras, Tanapox viras, Vaccinia viras, Yabapox viras), Papovavirases (S V 40 virus, B-K- viras), Spongiform Encephalopathy Viruses (Creutzfeld- Jacob agent, Kura agent, BSE), Rhabdoviruses (Rabies virus), Tobaviruses (Rubella virus), Coxiella burnetii, Rickettsia genera, Rickettsia prowazekii, Rickettsia rickettsii, Ricke
• VSV Vesicular Stomatis Viras
• Toga Arena (e.g., LCM, Junin, Lassa, Marchupo, Guanarito, etc.), Bunya (e.g., hantaviras, Rift Valley Fever, etc.), Flaviruses (Dengue), and Filoviruses (e.g., Ebola, Marburg, etc.) of all types, Nipah virus, viral encephalitis agents, LaCrosse, Kyasanur Forest viras, Yellow fever, and West Nile virus.
• Arena e.g., LCM, Junin, Lassa, Marchupo, Guanarito, etc.
• Bunya e.g., hantaviras, Rift Valley Fever, etc.
• Flaviruses Dengue
• Filoviruses e.g., Ebola, Marburg, etc.
• Suitable microbes of clinical or environmental interest include Variola Virases, Congo-Crimean hemorrhagic fever, Tick-bome encephalitis virus complex (Absettarov, Hanzalova, Hypr, Kumlinge, Kyasanur Forest disease, Omsk hemorrhagic fever, and Russian Spring-Summer Encephalitis), Marburg, Ebola, Junin, Lassa, Machupo, He ⁇ esvirus simiae, Bluetongue, Louping III, Rift Valley fever (Zinga), Wesselsbron, Foot and Mouth Disease, Newcastle Disease, African Swine Fever, Vesicular exanthema, Swine vesicular disease, Rinde ⁇ est, African horse sickness, Avian influenza, and Sheep pox.
• Other components of interest include Ricinus communis.
• the present invention can include methods and/or devices for detecting agents that disrupt binding of molecules, for example, macromolecules or a macromolecule and a small molecule.
• Methods and systems for detecting such agents can include methods and systems useful in developing therapeutic agents, in clinical chemistry, in environmental analysis, and in diagnostic assays of all types.
• such a method includes decreasing binding of a test ligand to one or more working artificial receptors with one or more candidate disraptors.
• such a method includes decreasing binding of a binding partner to a test ligand with one or more candidate disraptors, the test ligand being bound to one or more working artificial receptors.
• the present method includes selecting a working artificial receptor or receptor complex that binds a target molecule.
• This embodiment of the method includes binding the target molecule to the working receptor(s).
• the method then includes contacting the receptor with bound target molecule with one or more disruptor candidates. Contacting can occur in a high throughput screening format.
• the method includes selecting one or more disruptor candidates that decreases binding of the target molecule to the working receptor(s) as a lead disraptor(s).
• Any of the general types of test ligands described herein can be a target molecule.
• the target molecule can be one known to participate in a binding interaction with another molecule.
• the target molecule can be on a microbe, and the entire microbe can be employed as a target molecule.
• the target molecule can be a complex of two or more macromolecules, for example, a complex of two proteins.
• the target molecule can be a protein.
• the target molecule can be a polynucleotide.
• the target molecule be on a cell, and the entire cell can be employed as a target molecule.
• the target molecule can be a receptor.
• the lead disruptor can be subjected to further evaluation for example, as a candidate therapeutic agent, candidate vaccine, or candidate antigen.
• a lead disruptor that disrapts binding of a microbe to an artificial receptor of the present invention can be selected for further evaluation as an antibiotic against that microbe, as a candidate immunogen against that microbe, or as a candidate vaccine against that microbe.
• a lead disruptor that disrupts binding of a macromolecule to an artificial receptor of the present invention can be selected for further evaluation as a therapeutic agent, as a candidate immunogen against that macromolecule or an organism including that macromolecule, or as a candidate vaccine against that macromolecule or an organism including that macromolecule.
• Figure 8 schematically illustrates an embodiment of a method for detecting an agent that disrapts a binding interaction of a target molecule. This embodiment of the present method can be employed for detecting an agent that disrapts a binding interaction of a target molecule, such as a macromolecule or a microbe.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with target molecule and identifying which receptors bind the target molecule.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• This method can include producing or employing the selected working artificial receptor or receptor complex on a substrate, such as a slide.
• the substrate can include working artificial receptors for a single target molecule or working artificial receptors for a plurality of target molecules.
• the method includes binding the target molecule(s) to the artificial receptors.
• This illustrated embodiment includes contacting the artificial receptors with bound target molecule with one or more candidate disraptors.
• a substrate including working artificial receptors for a single target molecule can be employed in a method or system for detecting disraptors of binding interactions of that target molecule.
• a substrate including working artificial receptors for a plurality of target molecules can be employed in a method or system for detecting disraptors of binding interactions for one, several, or all of the target molecules.
• the method can include washing unbound or released target molecule from the support.
• the present method includes selecting a working artificial receptor or receptor complex that binds a protein. This embodiment of the method includes binding the protein to the working receptor(s).
• the method then includes contacting the receptor with bound protein with one or more disruptor candidates. Contacting can occur in a high throughput screening format.
• the method includes selecting one or more disruptor candidates that decreases binding of the protein to the working receptor(s) as a lead disruptor(s).
• Such a method can be employed for detecting an agent that disrapts a binding interaction of a protein.
• the method can include making an array of candidate artificial receptors. The building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with protein and identifying which receptors bind the protein.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• This method can include producing or employing the selected working artificial receptor or receptor complex on a substrate, such as a slide.
• the substrate can include working artificial receptors for a single protein or working artificial receptors for a plurality of proteins.
• the method includes binding the protein(s) to the artificial receptors.
• This embodiment of the method includes contacting the artificial receptors with bound protein with one or more candidate disraptors. Release of the protein from the working artificial receptors or decrease in binding of the protein to the artificial receptors indicates that the candidate disraptor is a working or lead disruptor, and can be selected as such.
• the disraptor disrupts a binding interaction of a protein.
• Such a disraptor can be envisioned as a mimic of one or more structural features to which this protein binds, for example on a microbe, tissue, or cell.
• the disraptor can be evaluated for such mimicry.
• the mimic disruptor can then be used as an antigen against the structural feature on the microbe, tissue, or cell.
• the mimic disraptor can be used as an idiotype or anti-idiotype against the structural feature on the microbe, tissue, or cell.
• the present method includes selecting a working artificial receptor or receptor complex that binds a microbe. This embodiment of the method includes binding the microbe to the working receptor(s).
• the method then includes contacting the receptor with bound microbe with one or more disraptor candidates. Contacting can occur in a high throughput screening format.
• the method includes selecting one or more disraptor candidates that decreases binding of the microbe to the working receptor(s) as a lead disraptor(s).
• a method can be employed for detecting an agent that disrupts a binding interaction of a microbe.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with microbe and identifying which receptors bind the microbe.
• the method can include producing an array or device including the working artificial receptor or receptor complex. This method can include producing or employing the selected working artificial receptor or receptor complex on a substrate, such as a slide.
• the substrate can include working artificial receptors for a single microbe or working artificial receptors for a plurality of microbes.
• the method includes binding the microbe(s) to the artificial receptors.
• This embodiment of the method includes contacting the artificial receptors with bound microbe with one or more candidate disraptors. Release of the microbe from the working artificial receptors or decrease in binding of the microbe to the artificial receptors indicates that the candidate disruptor is a working or lead disruptor, and can be selected as such.
• the disraptor disrupts a binding interaction of a microbe.
• Such a disruptor can be envisioned as a mimic of one or more structural features to which this microbe binds, for example on a protein, another microbe, a tissue, or a cell.
• the disraptor can be evaluated for such mimicry.
• the mimic disraptor can then be used as an antigen against the structural feature on the protein, other microbe, tissue, or cell.
• the mimic disruptor can be used as an idiotype or anti- idiotype against the structural feature on the protein, other microbe, tissue, or cell.
• the present method includes selecting a working artificial receptor or receptor complex that binds a cell. This embodiment of the method includes binding the cell to the working receptor(s). The method then includes contacting the receptor with bound cell with one or more disruptor candidates. Contacting can occur in a high throughput screening format. The method includes selecting one or more disraptor candidates that decreases binding of the cell to the working receptor(s) as a lead disruptor(s).
• Such a method can be employed for detecting an agent that disrapts a binding interaction of a cell.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with cell and identifying which receptors bind the cell.
• the method can include producing an array or device including the working artificial receptor or receptor complex.
• This method can include producing or employing the selected working artificial receptor or receptor complex on a substrate, such as a slide.
• the substrate can include working artificial receptors for a single cell or working artificial receptors for a plurality of cells.
• the method includes binding the cell(s) to the artificial receptors.
• This embodiment of the method includes contacting the artificial receptors with bound cell with one or more candidate disraptors. Release of the cell from the working artificial receptors or decrease in binding of the cell to the artificial receptors indicates that the candidate disraptor is a working or lead disraptor, and can be selected as such.
• the disruptor disrupts a binding interaction of a cell.
• a disruptor can be envisioned as a mimic of one or more structural features to which this cell binds, for example on a protein, another cell, a tissue, or a microbe.
• the disraptor can be evaluated for such mimicry.
• the mimic disruptor can then be used as an antigen against the structural feature on the protein, microbe, tissue, or other cell.
• the mimic disraptor can be used as an idiotype or anti-idiotype against the structural feature on the protein, microbe, tissue, or other cell. Any of a variety of compounds can be employed as a candidate disraptor.
• candidate disraptors can include at least one small molecule.
• candidate disraptors can include a library of small molecules.
• candidate disraptors can include at least one peptide.
• candidate disraptors can include a library of peptides.
• the present method includes a method for detecting a disraptor of binding of a binding partner to a test ligand (e.g., target molecule), the test ligand being bound to one or more working artificial receptors.
• the present method includes selecting a working artificial receptor or receptor complex that binds a complex including a target molecule. Such selecting can include evaluating artificial receptors for binding to the target molecule. The building blocks making up the artificial receptors can be na ⁇ ve to the test ligand. From among those artificial receptors that bind the target molecule, the method selects those artificial receptors that can bind the complex.
• the complex including the target molecule can also include one or more binding partners for the target molecule.
• This embodiment of the method includes binding the complex to the selected working receptor(s).
• the method then includes contacting the receptor with bound complex with one or more disraptor candidates. Contacting can occur in a high throughput screening format.
• the method includes selecting one or more disruptor candidates that decrease binding of at least one binding partner to the complex as a lead disruptor(s).
• Figure 9 schematically illustrates an embodiment of a method for detecting an agent that disrapts a binding interaction of a complex including a target molecule.
• This embodiment of the present method can be employed for detecting an agent that disrupts a binding interaction of a complex, such as a protein: small molecule complex, a proteimprotein complex, a proteimpoiynucleotide complex, a protein:polysaccharide complex, a proteimmicrobe complex, or a protei cell complex.
• the method can include making an array of candidate artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Working artificial receptors can be identified by contacting the array with target molecule and identifying which receptors bind the target molecule.
• the identified working artificial receptors can be contacted with the complex including the target molecule and the receptors that bind the complex can be selected.
• the method can include producing an array or device including the selected working artificial receptor or receptor complex.
• This method can include producing or employing the selected working artificial receptor or receptor complex on a substrate, such as a slide.
• the method includes binding the complex to the artificial receptors.
• This illustrated embodiment includes contacting the artificial receptors with bound complex with one or more candidate disraptors. Release of the binding partner portion of the complex from the working artificial receptors but retaining the target molecule on the receptors indicates that the candidate disraptor is a working or lead complex disruptor, and can be selected as such. Decrease in binding of the binding partner portion of the complex to the artificial receptors but retaining the target molecule on the receptors indicates that the candidate disraptor is a working or lead complex disraptor, and can be selected as such.
• the working or lead complex disruptor can, in an embodiment, be selected as a lead for developing a therapeutic agent for a disorder mediated by the complex.
• the method can include washing unbound or released binding partner from the support.
• the complex disraptor disrupts a complex including at least two proteins, a first protein and a second protein.
• Figure 10 schematically illustrates a candidate disraptor disrupting a proteimprotein complex.
• one protein component remains bound to the receptor and the other dissociates and leaves the receptor.
• An embodiment of such a disruptor can be envisioned as a mimic of one or more structural features of the binding portion of one of the proteins included in the complex. The disruptor can be evaluated for such mimicry.
• the disraptor can mimic a structural feature of the first protein that interacts with the second protein.
• the mimic disraptor can then be used as an antigen against that feature of the first protein.
• the mimic disraptor can be used as an idiotype or anti-idiotype against the structural feature on the first protein.
• a working artificial receptor or receptor complex can be employed to produce or as an affinity support for any of the test ligands described herein.
• the present method can include a method for producing an affinity support for a test ligand.
• This method can include selecting a working artificial receptor or receptor complex that binds to the test ligand.
• This method can also include coupling the working artificial receptor or receptor complex to a support.
• Figure 11 schematically illustrates an embodiment of such a method.
• the support can be suitable for use as an affinity support for, for example, chromatography, membrane filtration, electrophoresis (e.g., 1 or 2 dimensional electrophoresis), or the like.
• the present method can include selecting artificial receptors that bind a particular test ligand and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for isolation or analysis of a particular test ligand.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the artificial receptor can be employed as a receptor surface that can bind the test ligand and remove (e.g., purify) it from a mixture or biological sample.
• Such a method can include contacting one or more candidate artificial receptors with a test ligand of interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the method can include selecting one or more of the candidate artificial receptors that bind the test ligand as working artificial receptor(s).
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a significant quantity of the test ligand of interest.
• the support can be a chromatography support or medium.
• the support can be a plate, tube, or membrane.
• binding of the test ligand of interest to the support can be followed by eluting the test ligand of interest from the support.
• Eluting can employ a wash with a pH, buffer, solvent, salt concentration, or ligand concentration effective to elute the test ligand of interest from the support.
• Figure 12 schematically illustrates evaluating an array of candidate artificial receptors for binding of a test ligand and selecting one or more working artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Figure 12 illustrates that a receptor surface employing such a working artificial receptor can be employed for binding a protein, immobilizing an antibody, binding a single enantiomer, or protecting a structural feature (e.g., a functional group) on a compound.
• the receptor surface can bind more than one structural feature on the protein.
• the working artificial receptor can be selected to bind the constant portion, rather than the variable portions, of an antibody.
• the receptor surface can include a catalytic moiety that can catalyze a reaction of a functional group of the bound test ligand.
• a catalytic moiety can be a building block, for example, an organometallic building block.
• the present method can include selecting artificial receptors that bind a particular isomer of a compound and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for isolation or analysis of a particular isomer.
• the artificial receptor can be employed as a receptor surface that can bind the isomer and remove (e.g., purify) it from a mixture or biological sample.
• Such a method can include contacting one or more candidate artificial receptors with an isomer of interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the method can include selecting one or more of the candidate artificial receptors that bind the isomer as working artificial receptor(s).
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a significant quantity of the isomer of interest.
• the support can be a chromatography support or medium.
• the support can be a plate, tube, or membrane.
• binding of the isomer of interest to the support can be followed by eluting the isomer of interest from the support.
• Eluting can employ a wash with a pH, buffer, solvent, salt concentration, or ligand concentration effective to elute the isomer of interest from the support.
• the present method can include selecting artificial receptors that bind or protect a particular structural feature of a compound and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for isolation or analysis of the compound including the structural feature.
• the artificial receptor can be employed as a receptor surface that can bind or protect the stractural feature of the compound. Binding of the stractural feature can be determined by lack of binding of an analogous compound the lacking the stractural feature. Protection of the stractural feature can be evaluated by that stractural feature being unavailable to a, for example, solution phase reactive species when the compound is bound to the receptor surface.
• Such a method can include contacting one or more candidate artificial receptors with a compound of interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the method can include selecting one or more of the candidate artificial receptors that bind the structural feature of the compound as lead artificial receptor(s).
• the lead artificial receptor can be evaluated for protecting the structural feature.
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a significant quantity of the compound of interest.
• binding of the compound of interest to the support can be followed by reacting a portion of the compound that is not the bound or protected structure feature.
• the present method can include selecting artificial receptors that bind a particular peptide or protein and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for isolation or analysis of a particular peptide or protein.
• the artificial receptor can be employed as a receptor surface that can bind the peptide or protein and remove (e.g., purify) it from a mixture or biological sample.
• Such a method can include contacting one or more candidate artificial receptors with a peptide or protein of interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the method can include selecting one or more of the candidate artificial receptors that bind the peptide or protein as working artificial receptor(s).
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a significant quantity of the peptide or protein of interest.
• the support can be a chromatography support or medium.
• the support can be a plate, tube, or membrane.
• binding of the peptide or protein of interest to the support can be followed by eluting the peptide or protein of interest from the support.
• Eluting can employ a wash with a pH, buffer, salt concentration, or ligand concentration effective to elute the peptide or protein of interest from the support.
• the present artificial receptors can be employed to form selective membranes.
• Such a selective membrane can be based on a molecular gate including an artificial receptor surface.
• an artificial receptor surface can line the walls of pores in the membrane and either allow or block a target molecule from passing through the pores.
• an artificial receptor surface can line the walls of pores in the membrane and act as "gatekeepers" on e.g. micro cantilevers/molecular cantilevers to allow gate opening or closing on binding of the target.
• the artificial receptors to be used in the selective membranes can be identified by exposing the target molecule to a plurality of distinct artificial receptors and then determining which ones it binds to. For example, the binding can be detected through any of the techniques described herein, including fluorescence.
• the method can include producing one or more receptor surfaces, each receptor surface including building blocks from a working receptor for a particular test ligand.
• Such a method can include employing the receptor surface for chromatography of the test ligand. Chromatographing the test ligand against a plurality of such receptor surfaces can rank the affinity of the surfaces for the test ligand. Under a given set of conditions, the receptor surface that retains the chromatographed test ligand the longest exhibits the greatest affinity for the test ligand.
• the method can include selecting the receptor surface with suitable (e.g., the greatest) affinity for use as an affinity support for the test ligand. Any of a variety of supports can be employed as the affinity support.
• the affinity support can be a dish, a tube, a well, a bead, a chromatography support, a microchannel, or the like.
• the artificial receptor affinity support can be used in various applications, such as chromatography, microchannel devices, as an immunoassay support, or the like.
• a microchannel with the artificial receptor on its surface can be employed as an analytical device.
• the present artificial receptors can be employed to form bioactive surfaces.
• receptor surfaces can be used to specifically bind antibodies or enzymes.
• the present method can include a method for producing a reaction support for at least one test ligand.
• This method can include selecting a working artificial receptor or receptor complex that binds to the test ligand under conditions suitable for a desired reaction with that test ligand.
• This method can also include coupling the working artificial receptor or receptor complex to a support.
• Figure 11 schematically illustrates an embodiment of such a method.
• the support can be suitable for use as a reaction support for, for example, oxidation, reduction, substitution, or displacement reactions.
• the present method can include selecting artificial receptors that bind a particular test ligand and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for reaction of a particular test ligand.
• the artificial receptor can be employed as a receptor surface that can bind the test ligand and position it for reaction at a particular prochiral group, functional group, or orientation.
• a method can include contacting one or more candidate artificial receptors with a test ligand of interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the method can include selecting one or more of the candidate artificial receptors that bind the test ligand as working artificial receptor(s).
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a desired quantity of the test ligand of interest.
• the support can be a chromatography support or medium.
• the , support can be a plate, bead, tube, or membrane.
• the method also includes contacting the support including bound test ligand with a reactant for the desired reaction. Suitable reactants include reducing agent, oxidizing agent, nucleophile, electrophile, solvent (e.g., aqueous or organic solvent), or the like.
• the method can include contacting with one or more reactants and selecting reactant or reactants suitable for participating in the desired reaction.
• This embodiment of the method includes reacting the test ligand with the reactant. In an embodiment, reacting can be followed by washing the reactant or side products from the support.
• reacting can be followed by eluting the product (e.g., reacted test ligand) from the support.
• Eluting can employ a wash with a pH, buffer, solvent, salt concentration, or ligand concentration effective to elute the product from the support.
• Figure 12 schematically illustrates evaluating an array of candidate artificial receptors for binding of a test ligand and selecting one or more working artificial receptors. The building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Figure 12 illustrates that a receptor surface employing such a working artificial receptor can be employed for binding a test ligand.
• the test ligand can be bound in an orientation that leaves a reactive moiety available for reaction with a reactant placed into contact with the receptor surface.
• the test ligand can be bound in an orientation that occludes or protects a second reactive moiety from reacting with the reactant.
• This embodiment includes reacting the test ligand and release of the reacted test ligand from the receptor surface.
• the illustration shows the reduction of an aldehyde with sodium borohydride to produce an alcohol.
• the receptor surface can include a catalytic moiety that can catalyze a reaction of a functional group of the bound to test ligand the catalytic reaction can also employ the reactant.
• a catalytic moiety can be a building block, for example, an organometallic building block.
• the present method can include selecting artificial receptors that bind or protect a particular stractural feature of a compound and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for reacting the compound including the stractural feature.
• the artificial receptor can be employed as a receptor surface that can bind and protect the structural feature of the compound while another feature of the compound reacts with a reactant. Protection of the stractural feature can be evaluated by that structural feature not reacting with the reactant.
• a substrate e.g. a steroid
• a first side of a molecule (or a functional group) is bound to a receptor surface while a second side is left exposed. Then a reagent is added that could react with either side (or group) but is hindered from reacting with the first side of the molecule since it is bound to the receptor surface, accordingly the reagent reacts with the second side of the molecule only.
• Such a method can include contacting one or more candidate artificial receptors with a compound of interest. The method can include selecting one or more of the candidate artificial receptors that bind the stractural feature of the compound as lead artificial receptor(s). The lead artificial receptor can be evaluated for protecting the structural feature. The method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a desired quantity of the compound of interest.
• binding of the compound of interest to the support can be followed by reacting a portion of the compound that is not the bound or protected structure feature.
• Conventional synthesis of a chiral compound generally requires complicated procedures, hi an embodiment, the present candidate artificial receptors can be employed to find receptor surfaces that provide a spatially oriented binding surface for a stereospecific reaction. For example, an artificial receptor surface can bind a small molecule so that particular functional groups are exposed to the environment, and others are obscured by the receptor. In this manner, the stereospecificity of the reaction can be controlled.
• an artificial receptor surface can be employed in synthesis including chiral induction.
• regiospecificity can also be controlled using receptors of the present invention.
• the present method can include selecting artificial receptors that bind a first reaction ligand and a second reaction ligand or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for a reaction including the first and second reaction ligands.
• the artificial receptor can be employed as a receptor surface that can bind the first reaction ligand and the second reaction ligand at a distance or orientation at which these ligands can react with one another.
• the reaction can optionally include one or more reactants not bound to the receptor surface.
• Such a method can include contacting one or more candidate artificial receptors with a first reaction ligand and a second reaction ligand.
• the building blocks making up the artificial receptors can be na ⁇ ve to the ligands.
• the method can include selecting one or more of the candidate artificial receptors that bind both of the reaction ligands as working artificial receptor(s).
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a desired quantity of the first and second reaction ligands.
• the support can be a chromatography support or medium.
• the support can be a plate, bead, tube, or membrane.
• the first and second reaction ligands can be bound to the support at one or several molar ratios, the reaction evaluated, and a molar ratio selected for conducting the reaction.
• the method can also include contacting the support including bound reaction ligands with a reactant for the desired reaction. Suitable reactants include reducing agent, oxidizing agent, nucleophile, electrophile, or the like.
• This embodiment of the method includes reacting the test ligand with the reactant. In an embodiment, reacting can be followed by washing the reactant or side products from the support. In an embodiment, the first and second reaction ligands react without the reactant. In an embodiment, reacting can be followed by eluting the product (e.g., reacted test ligand) from the support.
• Eluting can employ a wash with a pH, buffer, solvent, salt concentration, or ligand concentration effective to elute the product from the support.
• the present candidate artificial receptors can be employed to find receptor surfaces that provide a spatially oriented binding surface for a stereospecific reaction.
• an artificial receptor surface can bind a small molecule with particular functional groups exposed to the environment, and others obscured by the receptor.
• Such an artificial receptor surface can be employed in synthesis including chiral induction.
• a substrate e.g. a steroid
• a substrate can be stereospecifically bound to the artificial receptor and present a particular moiety/sub-structure/"face" for reaction with a reagent in solution.
• the artificial receptor surface can act as a protecting group where a reactive moiety of a molecule is "protected" by binding to the receptor surface so that a different moiety with similar reactivity can be transformed.
• the one or more working artificial receptors that bind a plurality (e.g., 2) of the reactants can be produced on a substrate and the reactants bound.
• Each receptor with a plurality of bound reactants can then be screened against one or more reagents or conditions (e.g., various molar ratios of the reactants or various solvents).
• the artificial receptor allowing or promoting reaction between the two or more reactants can be identified.
• the artificial receptor can then be produced on a substrate to provide a reactor for the reaction of interest.
• the reaction support can be a dish, a tube, a well, a bead, a chromatography support, a microchannel, or the like.
• the artificial receptor reaction support can be used in various applications, such as a microchannel device. A microchannel with the artificial receptor on its surface can be employed as a reactor.
• a working artificial receptor or receptor complex can be employed to produce or as a supported catalyst for any of the test ligands described herein.
• the present method can include a method for producing a supported catalyst for at least one test ligand. This method can include selecting a working artificial receptor or receptor complex that binds to the test ligand under conditions suitable for catalyzing a reaction with that test ligand. This method can also include coupling the working artificial receptor or receptor complex to a support.
• Figure 11 schematically illustrates an embodiment of such a method.
• the support can be suitable for use as a supported catalyst for any of a variety of catalytic moieties or building blocks, such as an organometallic moiety, a coenzyme, a redox active moiety, a nucleophilic moiety, an acid moiety, a base moiety, or the like.
• the present method can include selecting artificial receptors that bind and catalyze a reaction of a particular test ligand and/or the building blocks making up these receptors (e.g., bound to a scaffold molecule) for catalyzing a reaction of a particular test ligand.
• the artificial receptor can be employed as a receptor surface that can bind the test ligand and position it for reaction with the catalytic moiety at a particular prochiral group, functional group, or orientation.
• a method can include contacting one or more candidate artificial receptors with a test ligand of interest.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• the method can include selecting one or more of the candidate artificial receptors that bind and catalyze a desired reaction of the test ligand as working artificial receptor(s).
• the method can then include employing the working artificial receptor(s) to make a receptor surface.
• Making a receptor surface can include coupling the building blocks making up the working artificial receptor(s) to a support.
• the support can have sufficient area to bind a desired quantity of the test ligand of interest.
• the support can be a chromatography support or medium.
• the support can be a plate, bead, tube, or membrane.
• the method also includes contacting the support including bound test ligand with a reactant or cofactor for the desired reaction. Suitable reactants include reducing agent, oxidizing agent, nucleophile, electrophile, solvent (e.g., aqueous or organic solvent), or the like.
• the method can include contacting with one or more selecting reactants and selecting reactant or reactants suitable for participating in the desired reaction.
• This embodiment of the method includes reacting the test ligand with the reactant. hi an embodiment, reacting can be followed by washing the reactant or side products from the support.
• reacting can be followed by eluting the product (e.g., reacted test ligand) from the support.
• Eluting can employ a wash with a pH, buffer, solvent, salt concentration, or ligand concentration effective to elute the product from the support.
• Figure 12 schematically illustrates evaluating an array of candidate artificial receptors for binding and catalysis of a reaction of a test ligand and selecting one or more working artificial receptors.
• the building blocks making up the artificial receptors can be na ⁇ ve to the test ligand.
• Figure 12 illustrates that a receptor surface employing such a working artificial receptor can be employed for binding and catalysis of a reaction of a test ligand.
• the test ligand can be bound in an orientation that leaves a reactive moiety available for reaction with a the catalytic moiety of the receptor.
• the test ligand can be bound in an orientation that occludes or protects a second reactive moiety from reacting with the catalytic moiety.
• This embodiment includes reacting the test ligand and release of the reacted test ligand from the receptor surface.
• the illustration shows the reduction of an aldehyde with a catalytic moiety (MC) on the catalytic support to produce an alcohol.
• the receptor surface can include a catalytic moiety that can catalyze a reaction of a functional group of the bound to test ligand the catalytic reaction can also employ the reactant.
• Such a catalytic moiety can be a building block, for example, an organometallic building block.
• the invention includes a method for identifying a catalyst including binding a first reaction ligand to an artificial receptor array, contacting the array with a reactant, and identifying those artificial receptors that have promoted the reaction.
• the array can be screened for those artificial receptors that produce (e.g., catalyze conversion of the reactant to) a desired product.
• Any of a variety of supports can be employed as the catalytic support.
• the catalytic support can be a dish, a tube, a well, a bead, a chromatography support, a microchannel, or the like.
• the artificial receptor reaction support can be used in various applications, such as a microchannel device. A microchannel with the artificial receptor on its surface can be employed as a reactor.
• the invention can include methods and/or devices for not binding a test ligand. Methods and systems for not binding a test ligand can be employed in systems useful in clinical chemistry, environmental analysis, and diagnostic assays of all types.
• the invention includes a method for making a substrate that does not bind a test ligand. The method can include contacting at least one candidate artificial receptor with the test ligand, detecting binding or lack of binding of the test ligand to one or more of the artificial receptors, and selecting an artificial receptor that does not bind the test ligand as a working non-binding surface.
• the artificial receptor or receptors that do not bind a first test ligand can be tested against one or more additional test ligands.
• the non-binding artificial receptors can be screened for those artificial receptors that do not bind any of a plurality of test ligands.
• a surface covered with the building blocks making up such non-binding artificial receptors can then be employed as a working non-binding surface.
• the present method can employ an array of candidate artificial receptors. This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce one or more working artificial receptors or non-binding surfaces for one or more test ligands.
• the method can include evaluating an array including a significant number of candidate artificial receptors for not binding to at least one test ligand. Those candidate artificial receptors that do not bind to any of one or more test ligands can be selected as a non-binding surface for those one or more test ligands.
• the present method can evaluate an array of candidate artificial receptors to develop a surface that does not bind one or more proteins (e.g., plasma proteins).
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce one or more working artificial receptors or non-binding surfaces for one or more proteins (e.g., plasma proteins).
• the method can include evaluating an array including a significant number of candidate artificial receptors for not binding to at least one protein (e.g., plasma protein). Those candidate artificial receptors that do not bind to any of one or more proteins (e.g., plasma proteins) can be selected as a non-binding surface for those proteins. Such a surface can be employed on an implantable medical device.
• the present method can evaluate an anay of candidate artificial receptors to develop a surface that does not bind one or more cells.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce one or more working artificial receptors or non-binding surfaces for one or more cells.
• the method can include evaluating an array including a significant number of candidate artificial receptors for not binding to at least one cell.
• Those candidate artificial receptors that do not bind to any of one or more cells can be selected as a non-binding surface for those cells.
• a surface can be employed on an implantable medical device.
• the present method can evaluate an array of candidate artificial receptors to develop a surface that does not bind one or more microbes.
• This embodiment of the method can employ an array including a significant number of the present artificial receptors to produce one or more working artificial receptors or non-binding surfaces for one or more microbes.
• the method can include evaluating an array including a significant number of candidate artificial receptors for not binding to at least one microbe.
• Those candidate artificial receptors that do not bind to any of one or more microbes can be selected as a non-binding surface for those microbes.
• Such a surface can be employed on an implantable medical device.
• Such a surface can be employed in a system otherwise subject to biofouling, such as water piping, reservoirs or flumes in a food processing plant, cooling towers, ship bottom
• Methods for Detecting Contacting an array including a plurality of artificial receptors with a test ligand can identify one or more lead or working artificial receptors. Binding of the test ligand to the lead or working artificial receptor or complex can produce a detectable signal.
• the detectable signal can be produced, for example, through mechanisms and properties such as scattering, absorbing or emitting light, producing or quenching fluorescence or luminescence, producing or quenching an electrical signal, and the like.
• Spectroscopic detection methods include use of labels or enzymes to produce light for detection by optical sensors or optical sensor arrays.
• the light can be ultraviolet, visible, or infrared light, which can be produced and/or detected through fluorescence, fluorescence polarization, chemiluminescence, bioluminescence, or chemibioluminescence.
• Systems and methods for detecting electrical conduction, and changes in electrical conduction include ellipsometry, surface plasmon resonance, capacitance, conductometry, surface acoustic wave, quartz crystal microbalance, Love-wave, infrared evanescent wave, enzyme labels with electrochemical detection, nanowire field effect transistors, MOSFETS - metal oxide semiconductor field effect transistors, CHEMFETS - organic membrane metal oxide semiconductor field effect transistors, ICP - intrinsically conducting polymers, FRET - fluorescence resonance energy transfer.
• the working artificial receptor or complex can be configured on the surface of an optical fiber, for example, as a series of discrete areas, spots, zones, or the like.
• the working artificial receptor or complex can be contacted with the test ligand or sample suspected of containing the test ligand.
• the test ligand sample can be in the form of a stream of air, an aerosol, or liquid (e.g., a solution or suspension).
• a detectable colorimetric, fluorometric, or like signal can be produced by a label inco ⁇ orated into the optic fiber surface.
• the colorimetric or fluorogenic signal can be intrinsic to the ligand or can be produced upon binding of the ligand to the working artificial receptors.
• Apparatus that can detect such binding to or signal from a working artificial receptor or complex includes UV, visible, or infrared spectrometer, fluorescence or luminescence spectrometer, surface plasmon resonance, surface acoustic wave or quartz crystal microbalance detectors, pH, voltammetry or amperometry meters, radioisotope detector, or the like.
• a working artificial receptor or complex can be positioned on an optic fiber to provide a detectable signal, such as an increase or decrease in transmitted light, reflected light, fluorescence, luminescence, or the like.
• the detectable signal can originate from, for example, a signaling moiety inco ⁇ orated into the working artificial receptor or complex or a signaling moiety added to the working artificial receptor.
• the signal can also be intrinsic to the working artificial receptor or to the test ligand.
• the signal can come from, for example, the interaction of the test ligand with the working artificial receptor, the interaction of the test ligand with a signaling moiety that has been inco ⁇ orated into the working artificial receptor, into the optic fiber or onto the optic fiber.
• the present method can include selecting an artificial receptor for which binding induces a change in the signal from the signaling moiety, e.g., a fluorescent moiety. Such a change can signal binding to the artificial receptor.
• the working artificial receptor can be on a support such as a surface of a test tube, microwell, capillary, microchannel, or the like.
• the test ligand or a sample suspected of containing the test ligand can be contacted with the working artificial receptor or complex by addition of a solution containing the test ligand or a sample suspected of containing the test ligand.
• a detectable signal can be produced by a labeled compound or conjugate of the test ligand. This labeled moiety can be reacted with the working artificial receptor or complex in competition with the solution containing the test ligand or the sample suspected of containing the test ligand.
• the working artificial receptor is on a support such as the surface of a surface acoustic wave or quartz crystal microbalance or surface plasmon resonance detector.
• test ligand or a sample suspected of containing the test ligand can be brought into contact with the working artificial receptor or complex by exposure to a stream of air, to an aerosol, or to a solution containing the test ligand or a sample suspected of containing the test ligand.
• a detectable electrical signal can be produced by the interaction of the test ligand with the working artificial receptor or complex on the active surface of the surface acoustic wave or quartz crystal microbalance or surface plasmon resonance detector.
• more than one working artificial receptor, arranged as regions or spots in an array, on a support, such as a glass or plastic surface can be inco ⁇ orated onto the signaling surfaces of one or more surface plasmon resonance detectors.
• the ligands of interest or a sample suspected of containing the ligands of interest is brought into contact with the working artificial receptors or array. Contacting can be accomplished by addition of a solution of the ligands of interest or a sample suspected of containing the ligands of interest.
• Detectable electrical signals can be produced by binding of the ligands of interest to the working artificial receptors array on the surface of the surface plasmon resonance detectors. Such detectors produce a signal for each working artificial receptor in the array, which produces a pattern of signal response, which is characteristic of the composition of the sample of interest.
• the present artificial receptors can be part of products used in: analyzing a genome and/or proteome; pharmaceutical development; detectors for any of the test ligands; drag of abuse diagnostics or therapy; hazardous waste analysis or remediation; chemical warfare alert or intervention; disease diagnostics or therapy; cancer diagnostics or therapy; biowarfare alert or intervention; food chain contamination analysis or remediation; and the like.
• the present artificial receptors can be used in products for identification of sequence specific small molecule leads; protein isolation and identification; identification of protein to protein interactions; detecting contaminants in food or food products; clinical analysis of food contaminants; clinical analysis of prostate specific antigen; clinical and field or clinical analysis of cocaine; clinical and field or clinical analysis of other drags of abuse; other clinical analysis systems, home test systems, or field analysis systems; monitors or alert systems for bioterrorism or chemical warfare agents; and the like.
• Methods of Making an Artificial Receptor The present invention relates to a method of making an artificial receptor or a candidate artificial receptor. In an embodiment, this method includes preparing a spot or region on a support, the spot or region including a plurality of building blocks immobilized on the support.
• the method can include forming a plurality of spots on a solid support, each spot including a plurality of building blocks, and immobilizing (e.g., reversibly) a plurality of building blocks on the solid support in each spot.
• an array of such spots is referred to as a heterogeneous building block array.
• the method can include mixing a plurality of building blocks and employing the mixture in forming the spot(s).
• the method can include spotting individual building blocks on the support.
• Coupling building blocks to the support can employ covalent bonding or noncovalent interactions. Suitable noncovalent interactions include interactions between ions, hydrogen bonding, van der Waals interactions, and the like.
• the support can be functionahzed with moieties that can engage in covalent bonding or noncovalent interactions.
• Forming spots can yield a microarray of spots of heterogeneous combinations of building blocks, each of which can be a candidate artificial receptor.
• the method can apply or spot building blocks onto a support in combinations of 2, 3, 4, or more building blocks.
• the present method can be employed to produce a solid support having on its surface a plurality of regions or spots, each region or spot including a plurality of building blocks.
• the method can include spotting a glass slide with a plurality of spots, each spot including a plurality of building blocks. Such a spot can be referred to as including heterogeneous building blocks.
• a plurality of spots of building blocks can be referred to as an array of spots.
• the present method includes making a receptor surface.
• Making a receptor surface can include forming a region on a solid support, the region including a plurality of building blocks, and immobilizing (e.g., reversibly) the plurality of building blocks to the solid support in the region.
• the method can include mixing a plurality of building blocks and employing the mixture in forming the region or regions.
• the method can include applying individual building blocks in a region on the support. Forming a region on a support can be accomplished, for example, by soaking a portion of the support with the building block solution.
• the resulting coating including building blocks can be referred to as including heterogeneous building blocks.
• a region including a plurality of building blocks can be independent and distinct from other regions including a plurality of building blocks.
• one or more regions including a plurality of building blocks can overlap to produce a region including the combined pluralities of building blocks.
• two or more regions including a single building block can overlap to form one or more regions each including a plurality of building blocks.
• the overlapping regions can be envisioned, for example, as portions of overlap in a Ven diagram, or as portions of overlap in a pattern like a plaid or tweed.
• the method produces a spot or surface with a density of building blocks sufficient to provide interactions of more than one building block with a ligand. That is, the building blocks can be in proximity to one another.
• Proximity of different building blocks can be detected by determining different (e.g., greater) binding of a test ligand to a spot or surface including a plurality of building blocks compared to a spot or surface including only one of the building blocks.
• the method includes forming an array of heterogeneous spots made from combinations of a subset of the total building blocks and/or smaller groups of the building blocks in each spot. That is, the method forms spots including only, for example, 2 or 3 building blocks, rather than 4 or 5.
• the method can form spots from combinations of a full set of building blocks (e.g. 81 of a set of 81) in groups of 2 and/or 3.
• the method can form spots from combinations of a subset of the building blocks (e.g., 25 of the set of 81) in groups of 4 or 5.
• the method can form spots from combinations of a subset of the building blocks (e.g., 25 of a set of 81) in groups of 2 or 3.
• the method can include forming additional arrays inco ⁇ orating building blocks, lead artificial receptors, or structurally similar building blocks.
• the method includes forming an array including one or more spots that function as controls for validating or evaluating binding to artificial receptors of the present invention, h an embodiment, the method includes forming one or more regions, tubes, or wells that function as controls for validating or evaluating binding to artificial receptors of the present invention.
• Such a control spot, region, tube, or well can include no building block, only a single building block, only functionalized lawn, or combinations thereof.
• the method can immobilize (e.g., reversibly) building blocks on supports using known methods for immobilizing compounds of the types employed as building blocks.
• Coupling building blocks to the support can employ covalent bonding or noncovalent interactions. Suitable noncovalent interactions include interactions between ions, hydrogen bonding, van der Waals interactions, and the like.
• the support can be functionalized with moieties that can engage in reversible covalent bonding, moieties that can engage in noncovalent interactions, a mixture of these moieties, or the like.
• the support can be functionalized with moieties that can engage in covalent bonding, e.g., reversible covalent bonding.
• the present invention can employ any of a variety of the numerous known functional groups, reagents, and reactions for forming reversible covalent bonds. Suitable reagents for forming reversible covalent bonds include those described in Green, TW; Wuts, PGM (1999), Protective Groups in Organic Synthesis Third Edition. Wiley- Interscience, New York, 779 pp.
• the support can include functional groups such as a carbonyl group, a carboxyl group, a silane group, boric acid or ester, an amine group (e.g., a primary, secondary, or tertiary amine, a hydroxylamine, a hydrazine, or the like), a thiol group, an alcohol group (e.g., primary, secondary, or tertiary alcohol), a diol group (e.g., a 1,2 diol or a 1,3 diol), a phenol group, a catechol group, or the like.
• functional groups such as a carbonyl group, a carboxyl group, a silane group, boric acid or ester, an amine group (e.g., a primary, secondary, or tertiary amine, a hydroxylamine, a hydrazine, or the like), a thiol group, an alcohol group (e.g., primary, secondary, or tert
• These functional groups can form groups with reversible covalent bonds, such as ether (e.g., alkyl ether, silyl ether, thioether, or the like), ester (e.g., alkyl ester, phenol ester, cyclic ester, thioester, or the like), acetal (e.g., cyclic acetal), ketal (e.g., cyclic ketal), silyl derivative (e.g., silyl ether), boronate (e.g., cyclic boronate), amide, hydrazide, imine, carbamate, or the like.
• ether e.g., alkyl ether, silyl ether, thioether, or the like
• ester e.g., alkyl ester, phenol ester, cyclic ester, thioester, or the like
• acetal e.g., cyclic acetal
• Such a functional group can be referred to as a covalent bonding moiety, e.g., a first covalent bonding moiety.
• a carbonyl group on the support and an amine group on a building block can form an imine or Schiff s base. The same is true of an amine group on the support and a carbonyl group on a building block.
• a carbonyl group on the support and an alcohol group on a building block can form an acetal or ketal. The same is true of an alcohol group on the support and a carbonyl group on a building block.
• a thiol (e.g., a first thiol) on the support and a thiol (e.g., a second thiol) on the building block can form a disulfide.
• a carboxyl group on the support and an alcohol group on a building block can form an ester. The same is true of an alcohol group on the support and a carboxyl group on a building block. Any of a variety of alcohols and carboxylic acids can form esters that provide covalent bonding that can be reversed in the context of the present invention.
• reversible ester linkages can be formed from alcohols such as phenols with electron withdrawing groups on the aryl ring, other alcohols with electron withdrawing groups acting on the hydroxyl- bearing carbon, other alcohols, or the like; and/or carboxyl groups such as those with electron withdrawing groups acting on the acyl carbon (e.g., nitrobenzylic acid, R- CF 2 -COOH, R-CCl 2 -COOH, and the like), other carboxylic acids, or the like.
• the support, matrix, or lawn can be functionalized with moieties that can engage in noncovalent interactions.
• the support can include functional groups such as an ionic group, a group that can hydrogen bond, or a group that can engage in van der Waals or other hydrophobic interactions.
• Such functional groups can include cationic groups, anionic groups, lipophilic groups, amphiphilic groups, and the like.
• the support, matrix, or lawn includes a charged moiety
• Suitable charged moieties include positively charged moieties and negatively charged moieties.
• Suitable positively charged moieties include amines, quaternary ammonium moieties, ferrocene, or the like.
• Suitable negatively charged moieties include carboxylates, phenols substituted with strongly electron withdrawing groups (e.g., tetrachlorophenols), phosphates, phosphonates, phosphinates, sulphates, sulphonates, thiocarboxylates, hydroxamic acids, or the like.
• the support, matrix, or lawn includes groups that can hydrogen bond (e.g., a first hydrogen bonding group), either as donors or acceptors.
• the support, matrix, or lawn can include a surface or region with groups that can hydrogen bond.
• the support, matrix, or lawn can include a surface or region including one or more carboxyl groups, amine groups, hydroxyl groups, carbonyl groups, or the like. Ionic groups can also participate in hydrogen bonding.
• the support, matrix, or lawn includes a lipophilic moiety (e.g., a first lipophilic moiety).
• Suitable lipophilic moieties include branched or straight chain C 6-36 alkyl, C 8-24 alkyl, C 12-24 alkyl, C 12 -i 8 alkyl, or the like; C -36 alkenyl, C 8-24 alkenyl, C 12-2 alkenyl, C 12-18 alkenyl, or the like, with, for example, 1 to 4 double bonds; C 6-36 alkynyl, C 8-24 alkynyl, C 1 - 4 alkynyl, C 12-18 alkynyl, or the like, with, for example, 1 to 4 triple bonds; chains with 1-4 double or triple bonds; chains including aryl or substituted aryl moieties (e.g., phenyl or naphthyl moieties at the end or middle of a chain); polyaromatic hydrocarbon moieties; cycloalkane or substituted alkane moieties with numbers of carbons as described for chains; combinations or mixtures thereof; or the like.
• the alkyl, alkenyl, or alkynyl group can include branching; within chain functionality like an ether group; tem inal functionality like alcohol, amide, carboxylate or the like; or the like.
• a lipophilic moiety like a quaternary ammonium lipophilic moiety can also include a positive charge.
• a candidate artificial receptor, a lead artificial receptor, or a working artificial receptor includes combination of building blocks immobilized (e.g., reversibly) on, for example, a support.
• An individual artificial receptor can be a heterogeneous building block spot on a slide or a plurality of building blocks coated on a slide, tube, or well.
• the building blocks can be immobilized through any of a variety of interactions, such as covalent, electrostatic, or hydrophobic interactions.
• the building block and support or lawn can each include one or more functional groups or moieties that can form covalent, electrostatic, hydrogen bonding, van der Waals, or like interactions.
• An array of candidate artificial receptors can be a commercial product sold to parties interested in using the candidate artificial receptors as implements in developing receptors for test ligands of interest.
• a useful array of candidate artificial receptors includes at least one glass slide, the at least one glass slide including spots of a predetermined number of combinations of members of a set of building blocks, each combination including a predetermined number of building blocks.
• One or more lead artificial receptors can be developed from a plurality of candidate artificial receptors.
• a lead artificial receptor includes a combination of building blocks and binds detectable quantities of test ligand upon exposure to, for example, several picomoles of test ligand at a concentration of 1, 0.1, or 0.01 ⁇ g/ml, or at 1, 0.1, or 0.01 ng/ml test ligand; at a concentration of 0.01 ⁇ g/ml, or at 1, 0.1, or 0.01 ng/ml test ligand; or a concentration of 1, 0.1, or 0.01 ng/ml test ligand.
• Artificial receptors, particularly candidate or lead artificial receptors can be in the form of an array of artificial receptors.
• Such an array can include, for example, 1.66 million spots, each spot including one combination of 4 building blocks from a set of 81 building blocks. Such an array can include, for example, 28,000 spots, each spot including one combination of 2, 3, or 4 building blocks from a set of 29 building blocks. Each spot is a candidate artificial receptor and a combination of building blocks.
• the array can also be constructed to include lead artificial receptors. For example, the array of artificial receptors can include combinations of fewer building blocks and/or a subset of the building blocks.
• an array of candidate artificial receptors includes building blocks of general Formula 2 (shown hereinbelow), with REi being Bl, B2, B3, B3a, B4, B5, B6, B7, B8, or B9 (shown hereinbelow) and with RE 2 being Al, A2, A3, A3a, A4, A5, A6, A7, A8, or A9 (shown hereinbelow).
• the framework is tyrosine.
• One or more working artificial receptors can be developed from one or more lead artificial receptors.
• a working artificial receptor includes a combination of building blocks and binds categorizing or identifying quantities of test ligand upon exposure to, for example, several picomoles of test ligand at a concentration of 100, 10, 1, 0.1, 0.01, or 0.001 ng/ml test ligand; at a concentration of 10, 1, 0.1, 0.01, or 0.001 ng/ml test ligand; or a concentration of 1, 0.1, 0.01, or 0.001 ng/ml test ligand.
• the artificial receptor of the invention includes a plurality of building blocks coupled to a support.
• the plurality of building blocks can include or be building blocks of Formula 2.
• a candidate artificial receptor can include combinations of building blocks of formula TyrAlBl, TyrA2B2, TyrA2B4, TyrA2B6, TyrA2B8, TyrA3B3, TyrA4B2, TyrA4B4, TyrA4B6, TyrA4B8, TyrA5B5, TyrA6B2, TyrA6B4, TyrA6B6, TyrA6B8, TyrA7B7, TyrA8B2, TyrA8B4, TyrA8B6, or TyrA8B8.
• the present artificial receptors can employ any of a variety of supports to which building blocks or other array materials can be coupled.
• the support can be glass or plastic; a slide, a tube, or a well; an optical fiber; a nanotube or a buckyball, a nanodevice; a dendrimer, or a scaffold; or the like
• the present invention includes a method of using artificial receptors.
• the present invention includes a method of screening candidate artificial receptors to find lead artificial receptors that bind a particular test ligand. Detecting test ligand bound to a candidate artificial receptor can be accomplished using known methods for detecting binding to arrays on a slide or to coated tubes or wells.
• the method can employ test ligand labeled with a detectable label, such as a fluorophore or an enzyme that produces a detectable product.
• the method can employ an antibody (or other binding agent) specific for the test ligand and including a detectable label.
• One or more of the spots that are labeled by the test ligand or that are more or most intensely labeled with the test ligand are selected as lead artificial receptors.
• the degree of labeling can be evaluated by evaluating the signal strength from the label.
• the amount of signal can be directly proportional to the amount of label and binding.
• Figure 13 provides a schematic illustration of an embodiment of this process.
• screening candidate artificial receptors against a test ligand can yield one or more lead artificial receptors.
• One or more lead artificial receptors can be a working artificial receptor. That is, the one or more lead artificial receptors can be useful for detecting the ligand of interest as is.
• the method can then employ the one or more artificial receptors as a working artificial receptor for monitoring or detecting the test ligand.
• the one or more lead artificial receptors can be employed in the method for developing a working artificial receptor.
• the one or more lead artificial receptors can provide stractural or other information useful for designing or screening for an improved lead artificial receptor or a working artificial receptor.
• Such designing or screening can include making and testing additional candidate artificial receptors including combinations of a subset of building blocks, a different set of building blocks, or a different number of building blocks.
• the present invention includes a method of screening candidate artificial receptors to find lead artificial receptors that bind a particular test ligand. The method can include allowing movement of the building blocks that make up the artificial receptors.
• Movement of building blocks can include mobilizing the building block to move along or on the support and/or to leave the support and enter a fluid (e.g., liquid) phase separate from the support or lawn.
• building blocks can be mobilized to move along or on the support (translate or shuffle).
• Such translation can be employed, for example, to allow building blocks aheady bound to a test ligand to rearrange into a lower energy or tighter binding configuration still bound to the test ligand.
• Such translation can be employed, for example, to allow the ligand access to building blocks that are on the support but not bound to the ligand. These building blocks can translate into proximity with and bind to a test ligand.
• Building blocks can be induced to move along or on the support or to be reversibly immobilized on the support through any of a variety of mechanisms.
• inducing mobility of building blocks can include altering the conditions of the support or lawn. That is, altering the conditions can reverse the immobilization of the building blocks, thus mobilizing them.
• Reversibly immobilizing the building blocks after they have moved can include, for example, returning to the previous conditions.
• Suitable alterations of conditions include changing pH, changing temperature, changing polarity or hydrophobicity, changing ionic strength, changing nucleophilicity or electrophilicity (e.g. of solvent or solute), and the like.
• a building block reversibly immobilized by hydrophobic interactions can be mobilized by increasing the temperature, by exposing the surface, lawn, or building block to a more hydrophobic solvent (e.g., an organic solvent or a surfactant), or by reducing ionic strength around the building block.
• a more hydrophobic solvent e.g., an organic solvent or a surfactant
• the organic solvent includes acetonitrile, acetic acid, an alcohol, tetrahydrofuran (THF), dimethylformamide (DMF), hydrocarbons such as hexane or octane, acetone, chloroform, methylene chloride, or the like, or mixture thereof.
• the surfactant includes a nonionic surfactant, such as a nonylphenol ethoxylate, or the like.
• a building block that is mobile on a support can be reversibly immobilized by hydrophobic interactions, for example, by decreasing the temperature, exposing the surface, lawn, or building block to a more hydrophilic solvent (e.g., an aqueous solvent) or increased ionic strength.
• a building block reversibly immobilized by hydrogen bonding can be mobilized by increasing the ionic strength, concentration of hydrophilic solvent, or concentration of a competing hydrogen bonder in the environs of the building block.
• a building block that is mobile on a support can be reversibly immobilized through an electrostatic interaction by decreasing ionic strength of the hydrophilic solvent, or the like.
• a building block reversibly immobilized by an electrostatic interaction can be mobilized by increasing the ionic strength in the environs of the building block. Increasing ionic strength can disrupt electrostatic interactions.
• a building block that is mobile on a support can be reversibly immobilized through an electrostatic interaction by decreasing ionic strength.
• a building block reversibly immobilized by an imine, acetal, or ketal bond can be mobilized by decreasing the pH or increasing concentration of a nucleophihc catalyst in the environs of the building block.
• the pH is about 1 I to about 4. lhiines, acetals, and ketals undergo acid catalyzed hydrolysis.
• a building block that is mobile on a support can be reversibly immobilized by a reversible covalent interaction, such as by forming an imine, acetal, or ketal bond, by increasing the pH.
• building blocks can be mobilized to leave the support and enter a fluid (e.g., liquid) phase separate from the support or lawn (exchange).
• a fluid e.g., liquid
• building blocks can be exchanged onto and/or off of the support.
• Exchange can be employed, for example, to allow building blocks on a support but not bound to a test ligand to be removed from the support.
• Exchange can be employed, for example, to add additional building blocks to the support.
• the added building blocks can have structures selected based on knowledge of the structures of the building blocks in artificial receptors that bind the test ligand.
• the added building blocks can have structures selected to provide additional structural diversity.
• the added building blocks can include all of the building blocks.
• a building block reversibly immobilized by hydrophobic interactions can be released from the support by, for example, raising the temperature, e.g., of the support and/or artificial receptor.
• the hydrophobic interactions e.g., the hydrophobic group on the support or lawn and on the building block
• the hydrophobic interactions can be selected to provide immobilized building block at about room temperature or below and release can be accomplished at a temperature above room temperature.
• the hydrophobic interactions can be selected to provide immobilized building block at about refrigerator temperature (e.g., 4 °C) or below and release can be accomplished at a temperature of, for example, room temperature or above.
• a building block can be reversibly immobilized by hydrophobic interactions, for example, by contacting the surface or artificial receptor with a fluid containing the building block and that is at or below room temperature.
• a building block reversibly immobilized by hydrophobic interactions can be released from the support by, for example, contacting the artificial receptor with a sufficiently hydrophobic fluid (e.g., an organic solvent or a surfactant).
• a sufficiently hydrophobic fluid e.g., an organic solvent or a surfactant.
• the organic solvent includes acetonitrile, acetic acid, an alcohol, tetrahydrofuran (THF), dimethylformamide (DMF), hydrocarbons such as hexane or octane, acetone, chloroform, methylene chloride, or the like, or mixture thereof.
• the surfactant includes a nonionic surfactant, such as a nonylphenol ethoxylate, or the like.
• a nonionic surfactant such as a nonylphenol ethoxylate, or the like.
• Such reversible immobilization can also be effected by contacting the surface or artificial receptor with a hydrophilic solvent and allowing the somewhat lipophilic building block to partition on to the hydrophobic surface or lawn.
• a building block reversibly immobilized by an imine, acetal, or ketal bond can be released from the support by, for example, contacting the artificial receptor with fluid having an acid pH or including a nucleophihc catalyst.
• the pH is about 1 to about 4.
• a building block can be reversibly immobilized by a reversible covalent interaction, such as by forming an imine, acetal, or ketal bond, by contacting the surface or artificial receptor with fluid having a neutral or basic pH.
• a building block reversibly immobilized by an electrostatic interaction can be released by, for example, contacting the artificial receptor with fluid having sufficiently high ionic strength to disrupt the electrostatic interaction.
• a building block can be reversibly immobilized through an electrostatic interaction by contacting the surface or artificial receptor with fluid having ionic strength that promotes electrostatic interaction between the building block and the support and/or lawn.
• Test Ligands The test ligand can be any ligand for which binding to an array or surface can be detected.
• the test ligand can be a pure compound, a mixture, or a "dirty" mixture containing a natural product or pollutant. Such dirty mixtures can be tissue homogenate, biological fluid, soil sample, water sample, or the like.
• Test ligands include prostate specific antigen, other cancer markers, insulin, warfarin, other anti-coagulants, cocaine, other drags-of-abuse, markers for E.
• test ligand can be at least one of small organic molecules, inorganic/organic complexes, metal ion, mixture of proteins, protein, nucleic acid, mixture of nucleic acids, mixtures thereof, and the like.
• Suitable test ligands include any compound or category of compounds described elsewhere in this document as being a test ligand, including, for example, the microbes, proteins, cancer cells, drugs of abuse, and the like described above.
• Example 1 Synthesis of Building Blocks Selected building blocks representative of the alkyl-aromatic-polar span of the an embodiment of the building blocks were synthesized and demonstrated effectiveness of these building blocks for making candidate artificial receptors. These building blocks were made on a framework that can be represented by tyrosine and included numerous recognition element pairs. These recognition element pairs include enough of the range from alkyl, to aromatic, to polar to represent a significant degree of the interactions and functional groups of the full set of 81 such building blocks.
• Example 2 Preparation and Evaluation of Microarrays of Candidate Artificial Receptors
• Microarrays of candidate artificial receptors were made and evaluated for binding several protein ligands. The results obtained demonstrate the 1) the simplicity with which microarrays of candidate artificial receptors can be prepared, 2) binding affinity and binding pattern reproducibility, 3) significantly improved binding for building block heterogeneous receptor environments when compared to the respective homogeneous controls, and 4) ligand distinctive binding patterns (e.g., working receptor complexes).
• Example 1 Materials and Methods Building blocks were synthesized and activated as described in Example 1.
• the building blocks employed in this example were TyrAlBl [1-1], TyrA2B2, TyrA2B4, TyrA2B6, TyrA4B2, TyrA4B4, TyrA4B6, TyrA6B2, TyrA6B4, and TyrA6B6.
• the abbreviation for the building block including a linker, a tyrosine framework, and recognition elements AxBy is TyrAxBy.
• n is the number of different building blocks employed in a receptor environment.
• Amine modified (amine "lawn”; SuperAmine Microarray plates) microarray plates were purchased from Telechem Inc., Sunnyvale, CA (www.arrayit.com). These plates were manufactured specifically for microarray preparation and had a nominal amine load of 2-4 amines per square nm according to the manufacturer.
• the CAM microarrays were prepared using a pin microarray spotter instrument from Telechem Inc. (SpotBotTM Arrayer) typically with 200 um diameter spotting pins from Telechem Inc. (Stealth Micro Spotting Pins, SMP6) and 400-420 um spot spacing.
• the 9 building blocks were activated in aqueous dimethylformamide (DMF) solution as described above.
• DMF dimethylformamide
• the activated building block solutions were diluted 10-fold with a solution of DMF/H 2 O/PEG400 (90/10/10, v/v/v; PEG400 is polyethylene glycol nominal 400 FW, Aldrich Chemical Co., Milwaukee, Wl). These stock solutions were aliquotted (10 ⁇ l per aliquot) into the wells of a 384-well microwell plate (Telechem Inc.). A separate series of controls were prepared by aliquotting 10 ⁇ l of building block with either 10 ⁇ l or 20 ⁇ l of the activated [1-1] solution.
• the plate was covered with aluminum foil and placed on the bed of a rotary shaker for 15 minutes at 1,000 RPM. This master plate was stored covered with aluminum foil at -20°C when not in use.
• a well-to-well transfer e.g. A-l to A-l, A-2 to A-2, etc.
• This plate was stored tightly covered with aluminum foil at -20°C when not in use.
• the SpotBotTM was used to prepare up to 13 microarray plates per run using the 4 ⁇ l microwell plate.
• the SpotBotTM was programmed to spot from each microwell in quadruplicate.
• the wash station on the SpotBotTM used a wash solution of EtOH/H2O (20/80, v/v). This wash solution was also used to rinse the microarrays on completion of the SpotBotTM printing run.
• the plates were given a final rinse with deionized (DI) water, dried using a stream of compressed air, and stored at room temperature.
• DI deionized
• Certain of the microarrays were further modified by reacting the remaining amines with succinic anhydride to form a carboxylate lawn in place of the amine lawn.
• the following test ligands and labels were used in these experiments: 1) r-Phycoerythrin, a commercially available and intrinsically fluorescent protein with a FW of 2,000,000.
• HRP Horseradish peroxidase
• Fluorescence detection of these HRP conjugates was based on the Alexa 647-tyramide kit available from Molecular Probes, Eugene, OR. 5) Cholera toxin labeled with the AlexaTM fluorophore (Molecular Probes Inc., Eugene, OR).
• Microarray incubation and analysis was conducted as follows: For test ligand incubation with the microarrays, solutions (e.g. 500 ⁇ l) of the target proteins in PBS-T (PBS with 20 ⁇ l/L of Tween-20) at typical concentrations of 10, 1.0 and 0.1 ⁇ g/ml were placed onto the surface of a microarray and allowed to react for, e.g., 30 minutes.
• the microarray was rinsed with PBS-T and DI water and dried using a stream of compressed air.
• the incubated microarray was scanned using an Axon Model 4200A Fluorescence Microarray Scanner (Axon Instruments, Union City, CA).
• the Axon scanner and its associated software produce a false color 16-bit image of the fluorescence intensity of the plate.
• This 16-bit data is integrated using the Axon software to give a Fluorescence Units value (range 0 - 65,536) for each spot on the microarray.
• This data is then exported into an Excel file (Microsoft) for further analysis including mean, standard deviation and coefficient of variation calculations.
• the CARATM Combinatorial Artificial Receptor ArrayTM concept has been demonstrated using a microarray format.
• a CARA microarray based on N 9 building blocks was prepared and evaluated for binding to several protein and substituted protein ligands.
• Reading the Arrays A typical false color/gray scale image of a microarray that was incubated with 2.0 ⁇ g/ml r-phycoerythrin is shown in Figure 14. This image illustrates that the processes of both preparing the microarray and probing it with a protein test ligand produced the expected range of binding as seen in the visual range of relative fluorescence from dark to bright spots.
• the starting point in analysis of the data was to take the integrated fluorescence units data for the array of spots and normalize to the observed value for the [1-1] building block control. Subsequent analysis included mean, standard deviation and coefficient of variation calculations. Additionally, control values for homogeneous building blocks were obtained from the building block plus [1-1] data.
• the following protein ligands were evaluated for binding to the candidate artificial receptors in the microarray.
• the resulting Fluorescence Units versus candidate receptor environment data is presented in both a 2D format where the candidate receptors are placed along the X-axis and the Fluorescence Units are shown on the Y-axis and a 3D format where the Candidate Receptors are placed in an X-Y format and the Fluorescence Units are shown on the Z-axis.
• a key for the composition of each spot was developed (not shown).
• a key for the building blocks in each of the 2D and 3D representations of the results was also developed (not shown).
• the data presented are for 1-2 ⁇ g/ml protein concentrations.
• Figures 15 and 16 illustrate binding data for r-phycoerythrin (intrinsic fluorescence).
• Figures 17 and 18 illustrate binding data for ovalbumin (commercially available with fluorescence label).
• Figures 19 and 20 illustrate binding data for bovine serum albumin (labeled with rhodamine).
• Figures 21 and 22 illustrate binding data for HRP-NH-Ac (fluorescent tyramide read-out).
• Figures 23 and 24 illustrate binding data for HRP-NH-TCDD (fluorescent tyramide read-out).
• High target affinity is useful for specific target binding, isolation, etc. while binding diversity can provide multiplexed target detection systems.
• This example employed a relatively small number of building blocks to produce ca. 120 binding environments.
• the following analysis of the present data clearly demonstrates that even a relatively small number of binding environments can produce diverse and useful artificial receptors.
• the target binding experiments performed for this study used protein concentrations including 0.1 to 10 ⁇ g/ml.
• BSA data As representative, it is clear that some of the receptor environments readily bound 1.0 ug/ml BSA concentrations near the saturation values for fluorescence units (see, e.g., Figure 20). Based on these data and the formula weight of 68,000 for BSA, several of the receptor environments readily bind BSA at ca.
• One goal of artificial receptor development is the specific recognition of a particular target.
• Figure 30 compares the observed binding for r-phycoerythrin and BSA. Comparison of the overall binding pattern indicates some general similarities. However, comparison of specific features of binding for each receptor environment demonstrates that the two targets have distinctive recognition features as indicated by the (*) in Figure 30.
• One goal of artificial receptor development is to develop receptors which can be used for the multiplexed detection of specific targets.
• Example 3 Preparation and Evaluation of Microarrays of Candidate Artificial Receptors Including Reversibly Immobilized Building Blocks
• Microarrays of candidate artificial receptors including building blocks immobilized through van der Waals interactions were made and evaluated for binding of a protein ligand. The evaluation was conducted at several temperatures, above and below a phase transition temperature for the lawn (vide infra).
• Amino lawn microarray plates were modified to produce the C18 lawn by reaction of stearoyl chloride (Aldrich Chemical Co.) in A) dimethylformamide / PEG 400 solution (90:10, v/v, PEG 400 is polyethylene glycol average MW 400 (Aldrich Chemical Co.) or B) methylene chloride / TEA solution (100 ml methylene chloride, 200 ⁇ l triethylamine) using the lawn modification procedures generally described in Example 2.
• the C18 lawn plates where printed using the SpotBot standard procedure as described in Example 2.
• the building blocks were in printing solutions prepared by solution of ca. 10 mg of each building block in 300 ⁇ l of methylene chloride and 100 ⁇ l methanol.
• the selected microarray was incubated with a 1.0 ⁇ g/ml solution of the test ligand, cholera toxin subunit B labeled with the AlexaTM fluorophore (Molecular Probes Inc., Eugene, OR), using the following variables: 1) the microarray was washed with methylene chloride, ethanol and water to create a control plate; and 2) the microarray was incubated at 4 °C, 23 °C, or 44 °C. After incubation, the plate(s) were rinsed with water, dried and scanned (AXON 4100A). Data analysis was as described in Example 2.
• FIG. 35-37 illustrate fluorescence signals from arrays printed identically, but incubated with cholera toxin at 4 °C, 23 °C, or 44 °C, respectively. Spots of fluorescence can be seen in each array, with very pronounced spots produced by incubation at 44 °C. The fluorescence values for the spots in each of these three arrays are shown in Figures 38-40. Fluorescence signal generally increases with temperature, with many nearly equally large signals observed after incubation at 44 °C. Linear increases with temperature can reflect expected improvements in binding with temperature.
• Nonlinear increases reflect rearrangement of the building blocks on the surface to achieve improved binding, which occurred above the phase transition for the lipid surface (vide infra).
• Figure 41 can be compared to Figure 39.
• the fluorescence signals plotted in Figure 39 resulted from binding to reversibly immobilized building blocks on a support at 23 °C.
• the fluorescence signals plotted in Figure 41 resulted from binding to covalently immobilized building blocks on a support at 23 °C.
• Figure 42 illustrates the changes in fluorescence signal from individual combinations of covalently immobilized building blocks at 4 °C, 23 °C, or 44 °C. Binding increased modestly with temperature. The mean increase in binding was 1.3 -fold. A plot of the fluorescence signal for each of the covalently immobilized artificial receptors at 23 °C against its signal at 44 °C (not shown) yields a linear correlation with a correlation coefficient of 0.75. This linear correlation indicates that the mean 1.3 -fold increase in binding is a thermodynamic effect and not optimization of binding.
• Figure 43 illustrates the changes in fluorescence signal from individual combinations of reversibly immobilized building blocks at 4 °C, 23 °C, or 44 °C.
• This graph illustrates that at least one combination of building blocks (candidate artificial receptor) exhibited a signal that remained constant as temperature increased. At least one candidate artificial receptor exhibited an approximately linear increase in signal as temperature increased. Such a linear increase indicates normal temperature effects on binding.
• the candidate artificial receptor with the lowest binding signal at 4 °C became one of the best binders at 44 °C. This indicates that rearrangement of the building blocks of this receptor above the phase transition for the lawn, which increases the building blocks' mobility, produced increased binding.
• FIG 44 illustrates the data presented in Figure 42 (lines marked A) and the data presented in Figure 43 (lines marked B).
• the increases in binding observed with the reversibly immobilized building blocks are significantly greater than the increases observed with covalently bound building blocks.
• Binding to reversibly immobilized building blocks increased from 23 °C and 44 °C by a median value of 6.1 -fold and a mean value of 24-fold. This confirms that movement of the reversibly immobilized building blocks within the receptors increased binding (i.e., the receptor underwent dynamic affinity optimization).
• a plot of the fluorescence signal for each of the reversibly immobilized artificial receptors at 23 °C against its signal at 44 °C (not shown) yields no correlation (correlation coefficient of 0.004).
• a plot of the fluorescence signal for each of the reversibly immobilized artificial receptors at 44 °C against the signal for the corresponding covalently immobilized receptor (not shown) also yields no correlation (correlation coefficient 0.004). This lack of correlation provides further evidence that movement of the reversibly immobilized building blocks within the receptors increased binding.
• Figure 45 illustrates a graph of the fluorescence signal at 44 °C divided by the signal at 23 °C against the fluorescence signal obtained from binding at 23 °C for the artificial receptors with reversibly immobilized receptors. This comparison indicates that the binding enhancement is independent of the initial affinity of the receptor for the test ligand.
• Table 1 identifies the reversibly immobilized building blocks making up each of the artificial receptors, lists the fluorescence signal (binding strength) at 44 °C and 23 °C, and the ratios of the observed binding at these two temperatures. These data illustrate that each artificial receptor reflects a unique attribute for each combination of building blocks relative to the role of each individual building block.
• Example 4 The Oligosaccharide Portion of GMl Competes With Artificial Receptors for Binding to Cholera Toxin
• Microarrays of candidate artificial receptors were made and evaluated for binding of cholera toxin.
• the arrays were also evaluated for disrupting that binding. Disrupting of binding employed a compound that binds to cholera toxin, the oligosaccharide moiety from GMl (GMl OS).
• the results obtained demonstrate that a ligand of a protein specifically disrupted binding of the protein to the microarray.
• the building blocks employed in this example were TyrAlBl [1-1], TyrA2B2, TyrA2B4, TyrA2B6, TyrA2B8, TyrA3B3, TyrA3B5, TyrA3B7, TyrA4B2, TyrA4B4, TyrA4B6, TyrA4B8, TyrA5B3, TyrA5B5, TyrA5B7, TyrA6B2, TyrA6B4, TyrA6B6, TyrA6B8, TyrA7B3, TyrA7B5, TyrA7B7, TyrA8B2, TyrA8B4, TyrA8B6, and TyrA8B8.
• the abbreviation for the building block including a linker, a tyrosine framework, and recognition elements AxBy is TyrAxBy.
• the microarrays were prepared using a pin microarray spotter instrument from Telechem Inc. (SpotBotTM Arrayer) typically with 200 ⁇ m diameter spotting pins from Telechem Inc. (Stealth Micro Spotting Pins, SMP6) and 400-420 ⁇ m spot spacing.
• the 19 building blocks were activated in aqueous dimethylformamide (DMF) solution as described above. For preparing the 384-well feed plate, the activated building block solutions were diluted 10-fold with a solution of
• DMF/H 2 O/PEG400 (90/10/10, v/v/v; PEG400 is polyethylene glycol nominal 400 FW, Aldrich Chemical Co., Milwaukee, Wl).
• These stock solutions were aliquotted (10 ⁇ l per aliquot) into the wells of a 384-well microwell plate (Telechem Inc.). Control spots included the building block [1-1].
• the plate was covered with aluminum foil and placed on the bed of a rotary shaker for 15 minutes at 1 ,000
• This master plate was stored covered with aluminum foil at -20°C when not in use.
• a well-to-well transfer (e.g. A-l to A-l, A-2 to A-2, etc.) from the feed plate to a second 384-well plate was performed using a 4 ⁇ l transfer pipette.
• This plate was stored tightly covered with aluminum foil at -20°C when not in use.
• the SpotBotTM was used to prepare up to 13 microarray plates per run using the 4 ⁇ l microwell plate.
• the SpotBotTM was programmed to spot from each microwell in quadruplicate.
• the wash station on the SpotBotTM used a wash solution of EtOH/H2O (20/80, v/v).
• This wash solution was adjusted to pH 4 with 1 M HCI and used to rinse the microarrays on completion of the SpotBotTM printing ran.
• the plates were given a final rinse with deionized (DI) water, dried using a stream of compressed air, and stored at room temperature.
• DI deionized
• the microarrays were further modified by reacting the remaining amines with acetic anhydride to form an acetamide lawn in place of the amine lawn.
• the test ligand employed in these experiments was cholera toxin labeled with the AlexaTM fluorophore (Molecular Probes Inc., Eugene, OR).
• the candidate disraptor employed in these experiments was GMl OS (GMl oligosaccharide), a known ligand for cholera toxin.
• Microarray incubation and analysis was conducted as follows: For control incubations with the microarrays, solutions (e.g. 500 ⁇ l) of the cholera toxin in PBS- T (PBS with 20 ⁇ l/L of Tween-20) at a concentrations of 1.7 pmol/ml (0.1 ⁇ g/ml) was placed onto the surface of a microarray and allowed to react for 30 minutes. For disraptor incubations with the microarrays, solutions (e.g.
• GMl OS was added at 0.34 and at 5.1 ⁇ M in separate experiments. After either of these incubations, the microarray was rinsed with PBS-T and DI water and dried using a stream of compressed air. The incubated microarray was scanned using an Axon Model 4200A Fluorescence Microarray Scanner (Axon Instruments, Union City, CA).
• the Axon scanner and its associated software produce a false color 16-bit image of the fluorescence intensity of the plate.
• This 16-bit data is integrated using the Axon software to give a Fluorescence Units value (range 0 - 65,536) for each spot on the microarray.
• This data is then exported into an Excel file (Microsoft) for further analysis including mean, standard deviation and coefficient of variation calculations.
• Table 2 identifies the building blocks in each of the first 150 receptor environments. TABLE 2
• Figure 46 illustrates binding of cholera toxin to the microarray of candidate artificial receptors followed by washing with buffer produced fluorescence signals. These fluorescence signals demonstrate that the cholera toxin bound strongly to certain receptor environments, weakly to others, and undetectably to some. Comparison to experiments including those reported in Example 2 indicates that cholera toxin binding was reproducible from array to array and from month to month. Binding of cholera toxin was also conducted with competition from GMl OS (0.34 ⁇ M). Figure 47 illustrates the fluorescence signals due to cholera toxin binding that were detected after this competition. Notably, many of the signals illustrated in Figure 47 are significantly smaller than the corresponding signals recorded in Figure 46.
• the small signals observed in Figure 47 represent less cholera toxin bound to the array.
• GMl OS significantly disrapted binding of cholera toxin to many of the receptor environments.
• the disruption in cholera toxin binding caused by GMl OS can be visualized as the ratio of the amount bound in the absence of GMl OS to the amount bound in competition with GMl OS. This ratio is illustrated in Figure 48.
• the ratio can be as large as about 30.
• the ratios are independent of the quantity bound in the control.
• FIG 49 High Concentration of GMl OS Binding of cholera toxin to the microarray of candidate artificial receptors followed by washing with buffer produced fluorescence signals illustrated in Figure 49.
• cholera toxin was reproducible and it bound strongly to certain receptor environments, weakly to others, and undetectably to some.
• Figure 50 illustrates the fluorescence signals detected due to cholera toxin binding that were detected upon competition with GMl OS at 5.1 ⁇ M.
• GMl OS significantly disrapted binding of cholera toxin to many of the receptor environments. This disruption is presented as the ratio of the amount bound in the absence of GMl OS to the amount bound after contacting with GMl OS in Figure 51. The ratios range up to about 18 and are independent of the quantity bound in the control.
• test ligand binding of a test ligand to an artificial receptor of the present invention can be diminished (e.g., competed) by a candidate disraptor molecule.
• the test ligand was the protein cholera toxin and the candidate disraptor was a compound known to bind to cholera toxin, GMl OS.
• the degree to which binding of the test ligand was disrapted was independent of the degree to which the test ligand bound to the artificial receptor.
• Example 5 - GMl Competes With Artificial Receptors for Binding to Cholera Toxin
• Microarrays of candidate artificial receptors were made and evaluated for binding of cholera toxin.
• the arrays were also evaluated for disrupting that binding.
• Disrupting of binding employed a compound that binds to cholera toxin, the liposaccharide GMl .
• the results obtained demonstrate that a ligand of a protein specifically disrapts binding of the protein to the microarray.
• Building blocks were synthesized and activated as described in Example 1.
• the building blocks employed in this example were TyrAlBl [1-1], TyrA2B2, TyrA2B4, TyrA2B6, TyrA4B2, TyrA4B4, TyrA4B6, TyrA6B2, TyrA6B4, and
• TyrA6B6 in groups of 4 building blocks per artificial receptor.
• the abbreviation for the building block including a linker, a tyrosine framework, and recognition elements AxBy is TyrAxBy.
• the test ligand employed in these experiments was cholera toxin labeled with the AlexaTM fluorophore (Molecular Probes Inc., Eugene, OR). Cholera toxin was employed at 5.3 nM in both the control and the competition experiments.
• the candidate disruptor employed in these experiments was GMl, a known ligand for cholera toxin, which competed at concentrations of 0.042, 0.42, and 8.4 ⁇ M.
• Microarray incubation and analysis was conducted as described for Example 4. Table 3 identifies the building blocks in each receptor enviromnent. TABLE 3
• Results Figure 52 illustrates the fluorescence signals produced by binding of cholera toxin to the microarray of candidate artificial receptors alone and in competition with each of the three concentrations of GMl .
• the magnitude of the fluorescence signal decreases steadily with increasing concentration of GMl.
• the amount of decrease is not quantitatively identical for all of the receptors, but each receptor experienced decreased binding of cholera toxin.
• These decreases indicate that GMl competed with the artificial receptor for binding to the cholera toxin.
• the decreases show a pattern of relative competition for the binding site on cholera toxin. This can be demonstrated through graphs of fluorescence signal obtained at a particular concentration of GMl against fluorescence signal in the absence of GMl (not shown).
• Certain of the receptors appear at similar relative positions on these plots as concentration of GMl increases.
• the disruption in cholera toxin binding caused by GMl can be visualized as the ratio of the amount bound in the absence of GMl OS to the amount bound upon competition with GMl. This ratio is illustrated in Figure 53.
• the larger the ratio the more cholera toxin remained bound to the artificial receptor upon competition with GMl.
• the ratio can be as large as about 14.
• the ratios are independent of the quantity bound in the control. Interestingly, in several instances minor changes in structure to the artificial receptor caused significant changes in the ratio.
• the artificial receptor including building blocks 24, 26, 46, and 66 differs from that including 24, 42, 46, and 66 by only substitution of a single building block, (xy indicates building block TyrAxBy.)
• the substitution of building block 42 for 26 increased binding in the presence of GMl by about 14-fold.
• the artificial receptor including building blocks 22, 24, 46, and 64 differs from that including 22, 46, 62, and 64 by only substitution of a single building block.
• the substitution of building block 24 for 62 increased binding in the presence of GMl by about 3-fold. Even substitution of a single recognition element affected binding.
• the artificial receptor including building blocks 22, 24, 42, and 44 differs from that including 22, 24, 42, and 46 by only substitution of a single recognition element.
• the substitution of building block 44 for 46 (a change of recognition element B6 to B4) increased binding in the presence of GMl by about 3 -fold.
• test ligand binding of a test ligand to an artificial receptor of the present invention can be diminished (e.g., competed) by a candidate disraptor molecule.
• test ligand was the protein cholera toxin and the candidate disruptor was a compound known to bind to cholera toxin, GMl . Minor changes in structure of the building blocks making up the artificial receptor caused significant changes in the competition.
• Example 6 GMl Employed as a Building Block Alters Binding of Cholera Toxin to the Present Artificial Receptors
• Microarrays of candidate artificial receptors were made, GMl was bound to the arrays, and they were evaluated for binding of cholera toxin. The results obtained demonstrate that adding GMl as a building block in an array of artificial receptors can increase binding to certain of the receptors.
• Materials and Methods Building blocks were synthesized and activated as described in Example 1. The building blocks employed in this example were those described in Example 4.
• the test ligand employed in these experiments was cholera toxin labeled with the AlexaTM fluorophore (Molecular Probes Inc., Eugene, OR). Cholera toxin was employed at 0.01 ug/ml ( 0.17 pM) or 0.1 ug/ml (1.7 pM) in both the control and the competition experiments.
• GMl was employed as a test ligand for the artificial receptors and became a building block for receptors used to bind cholera toxin.
• the arrays were contacted with GMl at either 100 ⁇ g/ml, 10 ⁇ g/ml, or 1 ⁇ g/ml as described above for cholera toxin and then rinsed with deionized water. The arrays were then contacted with cholera toxin under the conditions described above. Microanay analysis was conducted as described for Example 4. Table 2 identifies the building blocks in each receptor environment.
• Results Figure 54 illustrates the fluorescence signals produced by binding of cholera toxin to the microarray of candidate artificial receptors without pretreatment with GMl. Binding of GMl to the microarray of candidate artificial receptors followed by binding of cholera toxin produced fluorescence signals illustrated in Figures 55, 56, and 57 (100 ⁇ g/ml, 10 ⁇ g/ml, and 1 ⁇ g/ml GMl, respectively). The enhancement of cholera toxin binding caused by pretreatment with GMl can be visualized as the ratio of the amount bound in the presence of GMl to the amount bound in the absence of GMl. This ratio is illustrated in Figure 58 for 1 ⁇ g/ml GMl .
• the ratio can be as large as about 16.
• minor changes in structure to the artificial receptor caused significant changes in the ratio.
• the artificial receptor including building blocks 46 and 48 differs from that including 46 and 88 by only substitution of a single recognition element on a single building block, (xy indicates building block TyrAxBy.)
• the substitution of building block 48 for 88 increased the ratio representing increased binding the presence of GMl building block from about 0.5 to about 16.
• the artificial receptor including building blocks 42 and 77 differs from that including 24 and 77 by only substitution of a single building block.
• Cholera Toxin B sub-unit binds to GMl on the cell surface.
• GMl binding interaction binding site
• GMl binding interaction can utilize both a sugar and an alkyl/aromatic functionality (Pickens, et al., Chemistry and Biology, vol. 9, pp 215- 224 (2002)).
• fluorescently labeled Cholera Toxin B sub-unit binds to arrays of the present artificial receptors to give a defined binding pattern which reflects cholera toxin B's surface topology.
• an affinity support/membrane mimic could be prepared by pre-incubating an array of artificial receptors with GMl which would then bind/capture cholera toxin in a binding pattern which could be used to select a working artificial receptor(s) for, for example, the high-throughput screen of lead compounds which will disrupt the "cholera:membrane ⁇ GMl mimic".
• the GMl pre-incubation studies clearly demonstrated that several of the working artificial receptors which were poor cholera binders significantly increased their cholera binding, presumably through an affinity interaction between the cholera toxin and both the immobilized GMl pentasaccharide moiety and the working artificial receptor building block environment.

Landscapes

• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Nanotechnology (AREA)
• Organic Chemistry (AREA)
• Crystallography & Structural Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Physics & Mathematics (AREA)
• Medicinal Chemistry (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Immunology (AREA)
• Biotechnology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Urology & Nephrology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Hematology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cell Biology (AREA)
• Biomedical Technology (AREA)
• General Physics & Mathematics (AREA)
• Composite Materials (AREA)
• General Engineering & Computer Science (AREA)
• Analytical Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Computational Biology (AREA)
• Food Science & Technology (AREA)
• Microbiology (AREA)
• Condensed Matter Physics & Semiconductors (AREA)
• Materials Engineering (AREA)
• Pathology (AREA)
• Medical Informatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Toxicology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Genetics & Genomics (AREA)
• Mathematical Physics (AREA)

Applications Claiming Priority (9)

Publications (1)

Family

ID=43027551

Family Applications (1)

Country Status (4)

Family Cites Families (7)

• 2004
  • 2004-09-03 JP JP2006526234A patent/JP4716991B2/ja not_active Expired - Fee Related
  • 2004-09-03 CA CA002537264A patent/CA2537264A1/en not_active Abandoned
  • 2004-09-03 WO PCT/US2004/029121 patent/WO2005024433A2/en active Application Filing
  • 2004-09-03 EP EP04788611A patent/EP1664792A2/en not_active Ceased

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events